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the case definitions they were using at the meeting. Our group was conducting a clinical trial 
of TB-IRIS treatment at the time. We therefore had developed detailed clinical case 
definitions for TB-IRIS and had experience of using them in a prospective clinical study. 
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ABSTRACT 
 
PhD candidate: Graeme Ayton Meintjes 
 
Title: Diagnosis, treatment and immunopathogenesis of the HIV-associated tuberculosis 
immune reconstitution inflammatory syndrome 
 
Date: 8 August 2011 
 
Background 
The paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-
IRIS) is a frequent complication of antiretroviral therapy (ART) among patients who start 
ART while on treatment for tuberculosis (TB). The condition manifests with new, worsening 
or recurrent inflammatory features of TB due to immunopathology attendant on rapidly 
recovering immune function. 
 
Methods 
We screened consecutive patients referred with suspected paradoxical TB-IRIS using 
standard TB-IRIS case definitions and excluded alternative causes for clinical deterioration. 
A randomized placebo-controlled clinical trial of prednisone for the treatment of paradoxical 
TB-IRIS was conducted. Participants received prednisone (n = 55) or placebo (n = 55) for 4 
weeks. Immunology studies were conducted, exploring the role of mycobacterial-specific 
IFNγ-producing T cells and regulatory T cells in pathogenesis and the effect of prednisone on 
the immune response in TB-IRIS. The TB-IRIS case definitions we developed formed the 
framework for consensus case definitions developed by the International Network for the 
Study of HIV-associated IRIS. 
 
Results 
Among patients presenting with suspected paradoxical TB-IRIS, 10.1% (95% confidence 
interval = 3.9 – 16.4%) were found to have undiagnosed rifampicin-resistant TB once those 
with known rifampicin resistance and alternative diagnoses were excluded. In the clinical 
trial, the combined primary endpoint of days hospitalised and outpatient therapeutic 
procedures (counted as an additional day) was more frequent in the placebo than the 
prednisone arm (median 3 days versus 0 days, p=0.04). Prednisone also resulted in more 
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rapid improvements in symptoms, quality of life and chest radiology. In serum, significant 
decreases in IL-6, IL-10, IL-12p40, TNFα, IFNγ and IP-10 concentrations during prednisone, 
but not placebo, treatment were observed. Paradoxical TB-IRIS cases had higher median 
ELISpot responses to several mycobacterial antigens in cross-sectional analysis compared 
with non-IRIS controls, but responses were heterogenous and dynamic in both cases and 
controls in longitudinal analysis. No association with regulatory T cell numbers was 
demonstrated.  
 
Conclusions 
Drug resistant TB should be excluded in all patients presenting with suspected paradoxical 
TB-IRIS. Prednisone reduced morbidity in paradoxical TB-IRIS and resulted in more rapid 
symptom and radiographic improvement. This appears to be mediated through reductions in 
concentrations of pro-inflammatory cytokines. Although T cell responses likely contribute to 
TB-IRIS pathogenesis they do not appear to be causal. 
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CHAPTER 1 
 
Introduction     
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Context 
 
Antiretroviral therapy (ART) for HIV infection has dramatically altered the natural history of 
the disease. As a consequence of immune restoration on ART, HIV-infected patients are 
protected from opportunistic infections and experience improved quality of life and 
prolonged survival. However, ART is accompanied by a number of potential complications. 
The immune reconstitution inflammatory syndrome (IRIS) is an important and frequent early 
complication of ART, particularly in patients who start ART with advanced 
immunosuppression and co-existent opportunistic infections. IRIS occurs during initial rapid 
immune recovery on ART and manifests with clinical deterioration accompanied by features 
of an inflammatory process, which is the consequence of an immunopathological reaction to 
the antigens of an opportunistic infection. Tuberculosis-associated IRIS (TB-IRIS) is the 
most common form of IRIS worldwide. 
 
Over the last two decades South Africa has experienced an upsurge of the dual epidemics of 
HIV and TB. The HIV epidemic has undermined the TB control programme and fuelled the 
incidence of TB in the country, and TB is the major cause of morbidity and mortality among 
HIV-infected Africans (1). In 2006, South Africa reported the fourth highest number of TB 
cases globally (2). TB case notification rates have risen nearly four-fold from 1986 to 2006 
(from 163 per 100 000 population in 1986 to 628 per 100 000 population in 2006) (2). The 
country is the worst affected in the world by the co-epidemic of HIV and TB. While it is 
estimated that 0.7% of the world’s population lives in South Africa, approximately one-
quarter of all global cases of HIV-associated TB occur in the country (3). Since 2004 there 
has been a massive scale-up of ART in public sector clinics in South Africa. It is estimated 
that approximately 1.4 million peoples have accessed ART in the South African public sector 
to date (4). 
 
Many patients learn their HIV status when they are diagnosed with active TB and require the 
initiation of ART soon after starting TB treatment because of a low CD4+ T-lymphocyte 
count. In ART clinics in Cape Town up to 42% of patients starting ART are concurrently on 
TB treatment (5), reflecting that the diagnosis of TB is frequently the entry point into HIV 
care in this setting (6). Patients starting ART following a recent diagnosis of active TB are at 
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risk for paradoxical TB-IRIS, which typically occurs in the first weeks of ART and manifests 
with new, recurrent or worsening symptoms, signs and/or radiographic manifestations of TB.  
 
Whilst many cases are self-limiting, paradoxical TB-IRIS results in considerable morbidity 
and places considerable burden on the health services. Patients frequently require 
hospitalization, diagnostic and therapeutic procedures. In South Africa, given the large 
numbers of HIV-TB co-infected patients with advanced immunosuppression and the rapidly 
expanding availability of ART in the public sector to effectively treat these patients, 
paradoxical TB-IRIS has become a frequent reason for presentation at primary care and 
higher referral levels of the health care system. There is no confirmatory diagnostic test and 
the diagnosis is made on the basis of characteristic clinical features after excluding alternative 
diagnoses that could otherwise explain the symptomatic deterioration. This condition poses 
considerable challenges for clinicians. A major reason for this is that our evidence base 
regarding the diagnosis, treatment and pathogenesis of this condition is limited.  
 
The studies reported in this thesis aimed to establish an evidence-based approach to the 
diagnostic work-up of patients presenting with paradoxical TB-IRIS, define the role of 
prednisone in the treatment of paradoxical TB-IRIS in a randomized-controlled clinical trial 
and investigate the immunopathogenesis of the condition. A better understanding of the 
immunopathogenesis of TB-IRIS may allow for predictive and diagnostic markers to be 
discovered and more targeted and rational therapies for the condition.   
 
Key research questions 
 
The key research questions addressed in this thesis are developed to address gaps in 
knowledge that were identified when the research work was initiated. They are: 
 
1) When assessing patients with suspected paradoxical TB-IRIS what are the important 
alternative diagnoses to exclude? 
2) What are the common clinical features in patients with paradoxical TB-IRIS? 
3) What is the immunopathogenesis of TB-IRIS, with a focus on the role of 
mycobacterial-specific interferon-γ-producing T cells and regulatory T cells? 
14
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4) Do the clinical benefits of prednisone used to treat paradoxical TB-IRIS outweigh 
potential risks in these patients who have advanced HIV? 
5) Given that prednisone did provide clinical benefit, what is its effect on the mediators 
of inflammation in paradoxical TB-IRIS? 
 
Setting  
 
These studies were conducted in Cape Town in the Western Cape Province of South Africa. 
The randomised controlled trial was conducted at GF Jooste Hospital. This is a public sector 
referral hospital located in Manenberg on the Cape Flats, which during the period of the 
studies served as the adult referral hospital for a population of approximately 1.3 million 
people. The communities served by this hospital included Khayelitsha, Gugulethu, Nyanga 
and Mitchells Plain. The antenatal HIV seroprevalence in Khayelitsha was 33% and TB 
annual notification rate 1612 / 100 000 during the study. There were 16 public sector TB 
clinics and 10 ART clinics in the referral area of the hospital during the study. All patients 
attending these clinics who require specialist level investigations or opinion or hospital 
admission are referred to the hospital. During the clinical trial primary care clinicians were 
also educated about the study and asked to refer all suspected paradoxical TB-IRIS cases to 
GF Jooste Hospital for assessment by the study team even if they did not fulfill the usual 
referral criteria. GF Jooste Hospital runs an Infectious Diseases Referral Unit that supports 
these TB and ART clinics by providing a service to which patients experiencing 
complications in primary care or with problems that cannot be adequately investigated or 
managed in primary care can be referred and rapidly assessed. Until 2008, a primary care 
ART clinic was also run within the outpatient department of GF Jooste Hospital. By June 
2009, there were 16 828 adults receiving ART at the primary care ART clinics in the referral 
area of the hospital. 
 
The largest of these clinics is the Ubuntu TB-HIV clinic in Site B Khayelitsha. The 
longitudinal study described in Chapter 5 was conducted at this facility. A pilot ART clinic 
was started at this facility in 2001, a collaboration between Medecins sans Frontieres and the 
Provincial Government of the Western Cape prior to the national public sector ART roll-out 
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(7). Currently over 5000 adults receive ART at this facility. The HIV and TB clinics have 
been integrated at this facility.  
 
The laboratory studies described in Chapter 5 and Chapter 7 were conducted in the laboratory 
of Professor Robert J. Wilkinson at the Institute of Infectious Diseases and Molecular 
Medicine at the Faculty of Health Sciences of the University of Cape Town 
 
Chronology of studies 
 
The randomised controlled trial was designed in 2004 and a funding application to the 
Medical Research Council was successful that year. The trial recruited patients from June 
2005 until December 2007.  During the course of this trial 287 patients with suspected 
paradoxical TB-IRIS were screened and 110 participants were enrolled in the clinical trial. 
Pre-defined case definitions for TB-IRIS were used to screen patients for the clinical trial and 
during the work-up for the trial patients were investigated for drug resistant TB and 
alternative diagnoses. The first 100 patients screened in this way formed the basis for the 
study reported in Chapter 4 which reports the important differential diagnoses and clinical 
features of patients with paradoxical TB-IRIS with the most important finding that 10% of 
patients were found to have had previously undiagnosed rifampicin-resistant TB during 
work-up. 
 
A further prospective cohort study enrolled 63 patients starting ART at Ubuntu TB-HIV 
clinic between January 2006 and September 2007. The main purpose of this study was to 
obtain blood samples for the longitudinal immunology study described in Chapter 5. 
Furthermore, blood samples were taken from patients seen at GF Jooste Hospital with TB-
IRIS prior to enrollment in the clinical trial (included in the cross-sectional study described in 
Chapter 5) and during the clinical trial (included in the study described in Chapter 7 that 
assesses the effect of prednisone on mediators of inflammation). 
 
In 2004-5, prior to commencing the clinical trial, we developed clinical case definitions for 
paradoxical TB-IRIS. These case definitions incorporated aspects of previous case definitions 
(8, 9), but were designed to be useful in a busy clinical setting utilizing no more than routine 
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laboratory tests. In November 2006, a meeting of IRIS researchers from around the world 
was held in Kampala, Uganda, and at this meeting the International Network for the Study of 
HIV-associated IRIS (INSHI) was formed. The major output of this meeting was the 
development of consensus case definitions for TB-IRIS (both the unmasking and paradoxical 
forms). The paradoxical TB-IRIS case definitions drew heavily from our case definitions and 
our experience of using these in our studies, and also incorporated aspects of other groups’ 
case definitions. I was asked to be the head of the writing committee and lead author 
responsible for consolidating the consensus case definitions and preparing a paper for 
publication. The consensus case definitions were published in 2008 (10) and are described in 
Chapter 3. 
 
Outline of the thesis 
 
In Chapter 2 (Background and literature review) background regarding the dual epidemic of 
HIV and TB in South Africa, antiretroviral therapy and its effect on the CD4 T cell recovery, 
the ART programme in South Africa and the Western Cape Province, issues related to the co-
treatment of HIV and TB and the timing of ART in HIV-TB patients is presented. Thereafter 
the literature on three topics is reviewed in detail: clinical studies of TB-IRIS, immunological 
studies of TB-IRIS and studies that report the use of corticosteroids in the treatment of TB.   
 
In Chapter 3 the consensus case definitions developed at the 2006 INSHI meeting are 
presented. Consensus case definitions for the following conditions were developed: 
paradoxical TB-associated IRIS, ART-associated TB and unmasking TB-associated IRIS. 
The process of the development of consensus around these case definitions is discussed.  
 
In Chapter 4 the prospective clinical study in which clinical case definitions for paradoxical 
TB-IRIS were assessed among 100 patients with suspected paradoxical TB-IRIS referred to 
the Infectious Diseases Referral Unit or medical wards at GF Jooste Hospital is presented. 
The aim of this study was to ascertain the major differential diagnoses for paradoxical TB-
IRIS in HIV-TB patients presenting with deteriorating TB after starting ART. The clinical 
features of the cases of paradoxical TB-IRIS are also described. 
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Chapter 5 reports two related studies that investigated the immunopathogenesis of 
paradoxical TB-IRIS: one a cross-sectional study of patients who presented with paradoxical 
TB-IRIS at GF Jooste Hospital and the other a longitudinal study of patients with HIV-
associated TB starting ART at Ubuntu TB-HIV Clinic in Khayelitsha. In the cross-sectional 
study samples of 35 patients at the time of presentation with TB-IRIS were compared with 
two groups of controls. The first control group (n=29) was patients on TB treatment and ART 
who did not develop TB-IRIS (sampled at 2 weeks on ART) and the second control group 
(n=31) was HIV-associated TB patients prior to starting treatment for TB or ART. In the 
longitudinal study, samples were taken at 0, 2 and 4 weeks on ART and the serial samples of 
10 cases who developed paradoxical TB-IRIS were compared with 29 controls who did not. 
 
The hypothesis of these studies was that paradoxical TB-IRIS was associated with 
expansions of Th1 lymphocytes that had distinct Mycobacterium tuberculosis antigen 
specificity and that TB-IRIS was associated with greater expansions of Th1 lymphocytes, but 
reduced expansion of T-regulatory cells (CD4+ expressing FoxP3) in response to 
Mycobacterium tuberculosis antigen stimulation in vitro. 
 
Experiments that we performed in these two studies to test these hypotheses were: 1) 
Interferon-gamma enzyme-linked immunospot (ELISpot) assays using the following 
antigens: PPD, ESAT-6, α-crystallin 1 and 2 and 38kDa cell wall antigen; and 2) flow 
cytometry on culture supernatants following stimulation with heat-killed MTB, staining for 
CD4, FoxP3 and the T cell activation markers HLA-DR and CD71. 
 
Chapter 6 reports the randomized placebo-controlled clinical trial of prednisone for the 
treatment of paradoxical TB-IRIS. This was the first clinical trial of treatment for TB-IRIS 
Prior to this there were anecdotal reports of response to corticosteroid therapy (11, 12). 
However, corticosteroids are potentially harmful in patients with advanced HIV, having been 
associated with herpes virus infection reactivations and Kaposi’s sarcoma development and 
exacerbation (13-15). Given this equipoise, a clinical trial of corticosteroids to treat 
paradoxical TB-IRIS was warranted. The central hypothesis of this clinical trial was that a 4-
week course of prednisone would reduce morbidity without an excess of corticosteroid side 
effects or infections in patients presenting with non-life threatening paradoxical TB-IRIS. 
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In Chapter 7 an immunological study that arose out of the clinical trial is presented. In this 
study the effects of prednisone on mediators of inflammation in TB-IRIS was explored. The 
hypothesis of this study was that the clinically beneficial effect of corticosteroid treatment in 
TB-IRIS is mediated through effects on specific immune mediators. Our aim in this study 
was to define the effects that prednisone has on RNA expression, concentrations of specific 
cytokines and chemokines, and T cell expansions in vitro in response to mycobacterial 
antigens. In addition unstimulated serum was assayed for cytokine/chemokine concentrations. 
During the clinical trial samples were collected at 0, 2 and 4 weeks of the trial from 31 
prednisone-treated patients and 27 placebo-treated patients. We performed three sets of 
experiments to explore the role of prednisone (with patients who were treated with placebo 
the controls in each experiment). The following experiments were performed: 1) ELISpot 
assays using the following antigenic stimuli: ESAT 6, α-crystallin 1 and 2, heat-killed 
H37Rv, 37kDa antigen and PPD; 2) real-time PCR on culture supernatants of samples 
cultured with heat-killed MTB to determine the RNA expression levels of the genes of 18 
cytokines/chemokines longitudinally; and 3) assay of the protein levels of 17 of these 
cytokines/chemokines in the same tissue culture supernatants using multiplex cytokine 
fluorescent bead-based immunoassay as well as 12 cytokines/chemokines in unstimulated 
serum. 
 
In Chapter 8 the findings of the studies are summarized and conclusions from across all the 
studies are presented. The implications of the research for the field in general are discussed 
and priorities for future TB-IRIS research are identified. 
 
Coherence of the thesis 
 
The coherence of this body of work is underpinned by four common themes. Firstly, I 
(Graeme Meintjes) was the first author on all five of the papers included and was the lead 
investigator on all the studies. Secondly, all these studies have been undertaken under the 
joint supervision of Professors Robert J. Wilkinson and Gary Maartens (my PhD supervisors) 
while I have been based at the Institute of Infectious Diseases and Molecular Medicine at 
UCT and GF Jooste Hospital over the past 6 years. Thirdly, all of the research investigates 
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the same clinical condition (paradoxical TB-IRIS) within the same geographical and clinical 
setting. Finally, the work presented represents an evolution of investigation into this 
condition from clinical diagnosis, to immunopathogenesis, to treatment and finally an 
investigation of the immune mechanisms of effective treatment.    
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CHAPTER 2 
 
Background and literature review  
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The dual epidemic of HIV and tuberculosis in South Africa 
 
South Africa is the country most severely affected by the global HIV epidemic. It is 
estimated that 5.5 million people live with HIV infection in SA (10.9% of the 
population over 2 years of age are HIV-infected according to the 2008 Human 
Sciences Research Council (HSRC) household survey (1)). While the South African 
population accounts for 0.7% of the world’s population it accounts for 17% of all HIV 
infections worldwide (2). 
 
The first case of AIDS was documented in South Africa in 1982. Through the 1980’s 
the epidemic was largely concentrated among men who have sex with men and 
haemophiliacs who had received infected blood transfusions. The circulating virus 
was subtype B, which is the dominant strain in high-income countries (3, 4). There 
was little evidence of HIV spread in the general population. The early 1990’s 
represented the initiation of a generalized subtype C epidemic (2, 3). Subtype C is the 
dominant strain in sub-Saharan Africa. The predominant modes of transmission 
shifted to heterosexual and mother to child transmission. The doubling time of the 
HIV epidemic was just over one year during the early 1990’s (3). Through the late 
1990’s there was continued rapid spread through the general population. Data from 
government antenatal clinics demonstrate an increase in HIV seroprevalence among 
pregnant women from 0.8% in 1990 to 20.5% by 2000 (2). After 2000 the incidence 
of AIDS in the general population rose sharply with increasing numbers of people 
dying. By 2006 it was estimated that there were 345 640 deaths annually due to HIV 
(2). Life expectancy has fallen by almost 20 years and mean life expectancy is 48.4 
years for men and 51.6 years for women according to 2008 estimates from Statistics 
South Africa (2). The most severely affected sector of the population is young women 
with an HIV prevalence of 32.7% among women aged 25-29 years documented in the 
2008 HSRC survey. In men HIV prevalence peaks in the 30-34 year age group at 
25.8% (Figure 1) (1).The response of the South African government until 2008 was 
characterized by denial, lack of political will and inefficiencies in implementation of 
policies (2).  The HIV epidemic has profoundly impacted the economy of South 
Africa both at a macro-economic level and at the level of households from loss 
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Figure 1: HIV prevalence, by sex and age, South Africa 2008. 
From the Human Sciences Research Council South African National HIV Prevalence, 
Incidence, Behaviour and Communication Survey 2008 (reproduced from reference 
(1))  
26
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
 
of breadwinners and growing numbers of HIV orphans (5). 
 
HIV impairs cell-mediated immunity that plays a critical role in containment of 
tuberculosis (TB). Patients with HIV, and particularly those with advanced HIV, are 
thus at heightened risk of reactivation of latent TB and progression from infection or 
re-infection to active disease. In South African individuals with advanced HIV the 
annual risk of active TB is as high as 30% (6). However, even in the first year of HIV 
infection the risk of active TB doubled compared with those who remained HIV 
negative in a study done on the South African gold mines (7). Thereafter, during the 
chronic phase of HIV infection, TB incidence steadily increased and by 11 years 
nearly half these men had developed active TB (8). In patients with advanced HIV 
and CD4 counts < 200 cells/mm3 the risk of active TB increases exponentially (6, 9). 
The HIV epidemic is undermining TB control efforts in many regions of the world 
(10, 11). Sub-Saharan Africa is now most severely impacted by the dual epidemic of 
HIV and TB, with TB incidence rates increasing by up to five-fold in many countries 
in the region over the last two decades (10). In South Africa annual TB case 
notification rose from 163 per 100 000 population in 1986 to 628 per 100 000 
population in 2006 (2). The actual incidence of TB is greater given that not all cases 
are detected. In 2009, according to World Health Organization (WHO) estimates, 
74% of cases were detected giving an estimated incidence of TB of 971 / 100 000 
population for that year (2). In 2009, there were a total of 405 982 cases of TB 
notified in South Africa and 58% of those patients tested were HIV seropositive (2).  
However, other estimates suggest that up to 70% of TB cases are HIV co-infected (2). 
Certain communities are more severely affected, such as Khayelitsha in Cape Town 
where the TB case notification rate was 1612 / 100 000 in 2005 (City of Cape Town 
data (12)). The South African population is 0.7% of the world’s population, but the 
country accounted for 28% of the global burden of HIV-associated TB in 2006 (8).  
  
TB patients with HIV co-infection have a substantially higher case-fatality rate and 
TB is the leading cause of death in HIV-infected patients in developing world 
countries (13, 14). The WHO estimates that in 2007 there were 456 000 HIV-
associated TB deaths globally accounting for a quarter of the estimated 2 million 
27
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
HIV-related deaths that year (8). It is estimated that there were 105 000 TB deaths in 
South Africa in 2006 (2), the majority among HIV co-infected individuals. 
 
The HIV epidemic has also coincided with an increase in the prevalence of drug-
resistant TB in South Africa (15). The HIV epidemic has overwhelmed TB services 
undermining programme performance and has probably indirectly led to the 
emergence of drug resistant TB in this way. In addition, in congregate settings such as 
hospital wards and outpatient clinics transmission of drug resistant TB to patients with 
advanced HIV may result in outbreaks. HIV infection was associated with 
institutional outbreaks of multi-drug resistant (MDR) TB in the United States, Italy, 
Spain and Argentina in the 1980’s and 1990’s (15). These outbreaks mainly occurred 
in hospital settings where infection control practices were poor and patients with 
infectious TB and advanced HIV were in close proximity. The mortality rate was high 
(generally > 70%) with delay to the diagnosis of MDR a major factor contributing to 
this (15). The outbreak of extremely drug resistant (XDR) TB in Tugela Ferry in 
Kwazulu-Natal from 2005 onward could also be traced largely to hospital acquisition 
(16) and was initially associated with 98% mortality and all patients tested were HIV 
seropositive (17).  The strain causing this outbreak was identified as F15/LAM4/KZN 
(18). Despite these associations with drug resistant TB outbreaks, HIV does not 
appear to be an independent risk factor for drug resistant TB in a community setting: 
people with HIV infection are at heightened and similar risk of both drug susceptible 
and resistant TB (15). In a cross-sectional survey among adult TB clinic attendees 
conducted in Khayelitsha in 2008 MDR was diagnosed among 3.3% of new TB cases 
and 7.7% of retreatment cases. There was not a significant association between 
rifampicin resistance and HIV infection in multivariate analysis (19). In South Africa 
as a whole, the number of MDR cases confirmed in the laboratory annually tripled 
between 2005 and 2007 from 2000 to 7350 and 5.6% of MDR cases were confirmed 
to have XDR between 2004-7 (20). 
 
Antiretroviral therapy and immune recovery 
 
Antiretroviral therapy (ART) first became available with the discovery that the 
nucleoside reverse transcriptase inhibitor zidovudine (AZT) had activity against HIV. 
However, it soon became apparent that the benefits of AZT were short lived due to 
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the development of drug resistance (21). This was followed by an era of dual therapy 
with nucleoside reverse transcriptase inhibitors, but with similar disappointing long-
term results (22, 23). The discovery of the protease inhibitor class of drugs, which, 
when used with dual nucleoside reverse transcriptase inhibitors, made sustained 
suppression of HIV replication possible with durable long-term clinical benefit (24, 
25). Since the mid-1990’s combined antiretroviral therapy, usually with a 
combination of 3 drugs, has made it possible to achieve sustained suppression of HIV 
viral load in plasma to below 50 copies/ml. This allows for both quantitative and 
qualitative reversal of the immune suppression caused by HIV. After initiation of 
ART the majority of patients achieve a CD4 count greater 200 cells/mm3 (26). 
However, about a third of patients fail to achieve a CD4 count greater than 500 
cells/mm3 despite viral suppression after 5 years. In the Swiss HIV Cohort 36% did 
not achieve a CD4 count above 500 cells/mm3 after 5 years despite continuous 
suppression of viral load below 1000 copies/ml (27). However, in a select group of 
patients on continuous ART for 10 years without a detectable viral load at any time 
point, CD4 counts continue to rise and reach normal levels regardless of the nadir 
CD4 count (28). Full restoration of the CD4 T cell compartment is thus possible on 
ART provided HIV replication remains suppressed and immune activation is 
efficiently controlled for a prolonged period (29).  
 
This recovery of immune function has resulted in dramatic declines in AIDS-related 
morbidity and mortality (30, 31). Several studies have now demonstrated that with 
currently available ART options decades of life expectancy can be added for an HIV-
infected person (32-34). There has been a dramatic and sustained reduction in the 
incidence of AIDS-related opportunistic infections in developed world countries since 
the mid 1990’s when triple drug ART became available (35). Across studies 
performed in high and low TB burden settings ART use is associated with a 67% 
(95% confidence interval = 61-73%) reduction in TB incidence rates among HIV-
infected people (36).  
 
Autran and collegues (37) demonstrated soon after the introduction of triple drug 
ART that there are three phases of T cell reconstitution. There is an early rise of 
memory CD4 T cells. This is thought to reflect recirculation of cells previously 
recruited into productively infected tissues once viral replication is suppressed 
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representing recovery from inflammatory responses to the HIV infection. There is 
little de novo production of immune cells in the first 2-3 months of ART (29). The 
second phase is characterized by a reduction in T cell activation with improved CD4+ 
T cell reactivity to recall antigens. There is a later rise of naïve CD4 T cells while 
CD8 T cells decline (37). The regeneration of naïve CD4 T cells is accompanied by 
restoration in the diversity of the CD4 T cell receptor repertoire (38). 
 
Reconstitution of mycobacterial-specific CD4 T cell immune responses was explored 
using flow cytometry after PPD stimulation of peripheral blood mononuclear cells 
(PBMC) in a cohort of 19 HIV-infected patients with latent TB starting ART in South 
Africa (39). The first cells to proportionally expand were central memory CD4+ T 
cells by 12 weeks, representing the strongest correlate of ART mediated immunity. 
This was followed by expansion of naïve CD4 T cells by 36 weeks. Terminally 
differentiated effector cells proportionately decreased by 12 weeks, however the 
absolute number of PPD-specific IFN-γ producing cells determined by ELISpot 
increased during this period.  
 
CD4+ CCR5+ T-lymphocytes are almost completely depleted in the gut-associated 
lymphoid tissue during the first weeks of acute HIV infection and this depletion is 
sustained through chronic HIV infection. Despite reconstitution of systemic CD4 T 
cells, CD4 T cell reconstitution in the small intestine mucosa has been demonstrated 
to be poor and occurs much more slowly than in peripheral blood. It is hypothesized 
that this is related to ongoing low level HIV replication in the gut mucosa and fibrotic 
damage to the Peyer’s patches, which impairs their ability to support CD4+ T cell 
reconstitution in the gut (40). 
 
Predictors of poor reconstitution of systemic CD4 T cell counts on ART include: 
older age (27, 41, 42), longer duration of HIV infection prior to ART (27), lower CD4 
T cell count at ART initiation (43, 44), lower number of naïve CD4 T cells (45), 
higher levels of immune activation (46) and intermittent viral replication during ART 
(47). Even if there is adequate CD4 T cell count recovery on ART, restoration of 
functional immunity on ART may be incomplete as reflected in studies that have 
assessed immune responses to vaccination. One study showed that despite 
reconstitution of CD4 T cell numbers on ART memory B and T cell responses to 
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tetanus and diphtheria toxoid were impaired in patients with low nadir CD4 T cell 
counts and not related to current CD4 T cell count on ART (48). 
 
ART programme in South Africa and the Western Cape Province 
 
ART was available in the South African private sector from the 1990’s initially as 
dual therapy for cost reasons. Because of the prohibitive costs of the ART drugs at the 
time and the skepticism towards ART from the national government of the time, no  
ART was available in the public sector in South Africa until 2004. However, through 
partnerships between non-governmental organizations and the Provincial Government 
of the Western Cape, ART was made available to public sector patients at three 
clinics in Khayelitsha and one in Gugulethu in Cape Town from 2001 (49, 50). In the 
programme initiated at the 3 Khayelitsha clinics by Medecins sans Frontieres the 
annual enrolment in the ART programme increased from 80 patients in 2001 to 2087 
by 2006 (51). Data on patients starting and maintained on ART in the Western Cape 
province is prospectively captured into facility-based registers from which monthly 
cross-sectional activity and quarterly cohort reports are aggregated (52). Data from 
this reporting system show that by the end of February 2011, 88 100 adults and 6432 
children were receiving ART in the Western Cape province public-sector programme 
and it is estimated that 1.4 million people have accessed ART nationally. 
 
The South African public sector ART programme has followed a public health 
approach with standardized criteria for initiating, monitoring and switching ART. The 
first line and second line regimens are also standardized with substitutions allowed in 
the event of drug toxicities. The initial first line regimen used in the national 
programme was stavudine (D4T), lamivudine (3TC) and a non-nucleoside reverse 
transcriptase inhibitor (nevirapine or efavirenz). Efavirenz is advised in patients who 
are on rifampicin-based TB treatment when starting ART. In April 2010, tenofovir 
was substituted for stavudine in the first line regimen due to the toxicity issues related 
to stavudine (53-55). 
 
Five-year outcome data from the Khayelitsha clinics (n=7323) shows that 9.8% of 
people were lost to follow-up for at least 6 months of whom one-third had died. 
Corrected mortality at 5 years was 20.9%, but mortality fell over time as patients 
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accessed ART with higher CD4 counts (the median CD4 count in patients starting 
ART was 43 cells/mm3 in 2001 and 131 cells/mm3 in 2006). By 5 years 14% of 
patients had failed first line ART virologically (51). 
 
Co-treatment of HIV and TB 
 
In patients who are diagnosed with active TB and require the initiation of ART there 
are a number of complexities to co-treatment of both conditions. These include shared 
drug toxicities, drug interactions, high pill burden (which potentially impacts 
adherence) and the paradoxical TB-associated immune reconstitution inflammatory 
syndrome (TB-IRIS). 
 
Shared drug toxicities include drug-induced liver injury (which may be caused by 
rifampicin, isoniazid, pyrazinamide and the non-nucleoside reverse transcriptase 
inhibitors (NNRTI’s) and protease inhibitors (PI’s)), drug rashes (which may be 
caused by many of the TB drugs and the NNRTI’s), peripheral neuropathy (which 
may be caused by stavudine, didanosine and isoniazid), renal impairment (related to 
tenofovir or aminoglycosides used to treat TB) and gastro-intestinal intolerance 
(related to many of the TB and ART drugs) (56). When severe drug toxicity occurs in 
a patient on treatment for both TB and HIV, treatment often needs to be interrupted 
and a complex rechallenge process follows. Such interruptions may contribute to 
morbidity and mortality due to inadequate therapy and the emergence of drug 
resistance.  
 
Pharmacokinetic drug interactions are mainly related to rifampicin being a potent 
inducer of cytochrome P450 enzymes, particularly isoenzyme 3A4/5, and the drug 
transporter p-glycoprotein. The effect of rifampicin is to moderately reduce the levels 
of efavirenz (although standard doses are sufficient), but more significantly reduce 
nevirapine concentrations (with an effect on virological outcomes) (57-59). 
Rifampicin causes very substantial reduction in the concentrations of all PI’s and if 
used with PI’s such as lopinavir and saquinavir then additional boosting with ritonavir 
is required (56). 
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Because of these clinical challenges the optimal timing of ART in HIV-infected TB 
patients has been an important research issue internationally. 
 
The timing of ART in TB patients 
 
The timing of ART in HIV-infected TB patients with low CD4 counts needs to 
balance the potential complexities of co-treatment with the high risk of HIV disease 
progression with associated mortality in such patients. ART has been shown to 
decrease mortality in HIV-infected TB patients by 64-95% (60). To answer the 
question of when the optimal time to start ART in such patients is, a number of 
randomized strategy trials have compared different timing of ART initiation during 
TB treatment.  
 
The CAMELIA study (61) conducted in Cambodia among patients with smear 
positive TB and CD4 ≤ 200 cells/mm3 compared starting ART 2 weeks versus 8 
weeks after starting TB treatment. Patients in this trial had very advanced HIV with 
median CD4 count of 25 cells/mm3 and body mass index of 17. There was a 34% 
reduction in mortality in those who started at 2 weeks. The ACTG 5221 STRIDE 
study (62) was a multi-country study that enrolled patients with confirmed or 
suspected TB that had a CD count < 250 cells/mm3. ART was started 2 weeks after 
TB treatment in the one arm and between 8-12 weeks in the other. There was no 
difference in the combined endpoint of AIDS progression and death between the two 
arms. However, in a sub-analysis of only those with CD4 counts ≤ 50 cells/mm3 
AIDS progression and death was reduced by 42% among those who started at 2 
weeks. 
 
Similar findings were demonstrated in the SAPiT study (63) conducted in Durban. 
This study enrolled patients with smear-positive PTB and CD4 counts < 500 
cells/mm3. The most recent report from this study, presented at the 18th Conference on 
Retroviruses and Opportunistic Infections (64), compared outcomes in the two 
integrated arms of the study: one arm started ART within 4 weeks of starting TB 
treatment and the other within 4 weeks of the completion of intensive phase of TB 
treatment. There was no difference in the combined endpoint of AIDS progression or 
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death comparing the two arms, but again in a sub-analysis of those with CD4 < 50 
cells/mm3, earlier ART (at a median of 8 days) reduced AIDS progression or death by 
68% (marginally significant, p=0.06). In all three of these studies, the incidence of 
paradoxical TB-IRIS was approximately 2 to 3 fold higher among those starting ART 
in the earlier arm.  
 
Finally, in a study of ART timing in patients with TB meningitis conducted in 
Vietnam (65) there was no difference in survival among patients starting ART 
immediately or deferring 2 months. Mortality at 9 months was around 60% in both 
arms. Patients in this study were treated with adjunctive high dose dexamethasone for 
the first 6-8 weeks of TB treatment. Grade 4 adverse events occurred more frequently 
in patients who started immediately. 
 
In summary, these studies demonstrate that TB patients with a CD4 < 50 cells/mm3 
benefit from starting ART within 2 weeks of starting TB treatment with one study 
showing this reduced mortality and two demonstrating a reduction in a combined 
endpoint of AIDS progression and death among these patients, despite a higher 
incidence of paradoxical TB-IRIS. Among those with higher CD4 counts deferring 
ART up to 2 months may reduce the risk of TB-IRIS without compromising outcome. 
In TB meningitis mortality is extremely high and unaffected by the exact timing of 
ART within the first 2 months of TB treatment and deferring ART a few weeks may 
reduce risk of severe adverse events. 
 
Immune reconstitution inflammatory syndrome: history and spectrum 
 
The immune reconstitution inflammatory syndrome (IRIS) was first described among 
Australian patients in the early 1990’s. After commencing AZT monotherapy a 
localized form of Mycobacterium avium intracellulare (MAI) infection occurred 
concurrently with restoration of cutaneous delayed-type hypersensitivity responses to 
mycobacterial antigens. This was characterized by lymphadenitis and fevers 1-2 
weeks after commencing AZT, and differed in clinical presentation to the MAI 
infections that had been previously encountered in patients with advanced HIV which 
typically presented with wasting, fevers, gastro-intestinal symptoms and cytopaenias. 
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The atypical presentations were thought to result from the restoration of cellular 
immunity (66). 
 
Since then a wide range of IRIS conditions has been described in association with 
viral infections (eg. cytomegalovirus immune recovery uveitis), fungi (eg. 
cryptococcal IRIS), other mycobacteria (eg. TB-IRIS), parasites (eg. schistosomiasis 
IRIS), tumours (eg. Kaposi’s sarcoma IRIS), auto-immune conditions (eg. Grave’s 
disease of the thyroid) and other inflammatory conditions such as sarcoidosis (67). 
IRIS may occur in the context of treated or untreated infections and has been most 
frequently described in association with mycobacterial, fungal and herpesvirus 
infections (68). IRIS associated with HIV itself has also been described in patients 
with HIV encephalopathy who deteriorate neurologically after starting ART due to 
encephalitis which has been shown on brain histology to be related to CD8+ T-
lymphocyte infiltration (69). Synonymous terms used to describe IRIS that have been 
used in the literature are immune restoration disease (IRD) and immune reconstitution 
syndrome (IRS). 
 
IRIS has also been described in HIV-negative patients recovering from iatrogenic 
immunosuppression (70, 71). The most common situations in which this is described 
is with recovery of neutrophil counts following engraftment of bone marrow 
transplants and in patients where iatrogenic immunosuppression is withdrawn. An 
example of the latter is patients on tumour necrosis factor α (TNFα) receptor 
inhibitors who are diagnosed with TB, started on TB treatment and thereafter the TNF 
α receptor inhibitor is withdrawn. A life threatening paradoxical reaction involving 
the lungs has been described in such a patient (72). 
 
Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-
IRIS) and unmasking of tuberculosis by antiretroviral therapy 
 
It was well recognized prior to the HIV era that the immune response to TB 
contributes to pathology as well as protection. Paradoxical TB reactions (discussed 
below) and the basal exudate complicated by endarteritis that may develop in TB 
meningitis are examples of this immunopathology. During the early period of rapid 
immune recovery on ART, immunopathology in the form of IRIS has emerged as an 
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important clinical entity altering the clinical presentation and course of TB infection. 
TB-IRIS is thought to result from dysregulated recovering immune responses driving 
exaggerated inflammation directed towards the antigens of Mycobacterium 
tuberculosis resulting in clinical deterioration in patients experiencing immune 
recovery during early ART (67, 73). 
 
TB-IRIS is a frequent early complication of ART, especially in countries where TB is 
prevalent. Two forms of TB-IRIS are recognized: paradoxical and unmasking. 
Paradoxical TB-IRIS manifests with new or recurrent TB symptoms or signs in 
patients being treated for TB during early ART and unmasking TB-IRIS is 
characterized by an exaggerated, unusually inflammatory initial presentation of TB 
following initiation of ART (74). 
 
The diagnosis of TB is a common reason for HIV testing and entry into HIV care in 
sub-Saharan Africa. ART dramatically improves survival in HIV-infected people (75) 
and reduces TB risk by 70-90% (76-79), but very high TB incidence rates have been 
noted in the first 3 months of ART in developing countries (80-82). A substantial 
proportion of patients starting ART in sub-Saharan Africa are on treatment for active 
TB (up to 42% (51)) or have undiagnosed active TB (81), and are therefore at risk of 
TB-IRIS.  
 
Paradoxical TB reactions in patients not on ART 
 
Paradoxical reactions during TB treatment (new or recurrent TB symptoms or signs 
occurring after initial response to treatment) are recognized to occur in HIV-
uninfected patients and HIV-infected patients not on ART. Up to 25% of patients with 
TB lymphadenitis will experience a paradoxical reaction usually manifesting as 
enlargement of the lymph nodes (83, 84). Other manifestations include recurrent 
fevers, worsening pulmonary infiltrates, enlarging pleural effusions, the development 
of tuberculous meningitis (TBM), new or enlarging tuberculomas or tuberculous 
lesions developing at other anatomical sites (85-87). In a South African case series, 
reported prior to widespread ART availability, 23% of TBM in HIV-infected patients 
was diagnosed in patients already on TB treatment, so-called “breakthrough” TBM 
(88).  
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These paradoxical reactions are thought to reflect an immunologically-mediated 
deterioration rather than TB treatment failure. The pathogenesis has variably been 
attributed to a combination of the following factors: persistence of lipid rich insoluble 
cell wall antigen in infected tissue (84), exposure and release of new antigen targets 
during mycobacterial killing (89), hypersensitivity to such antigens (89) and 
exaggerated immune restoration (following TB-induced immunosuppression) 
occurring on TB treatment (86). The development of paradoxical reactions in patients 
not infected with HIV is associated with greater increases in total lymphocyte count 
on TB treatment (86).  
 
Paradoxical TB-IRIS: clinical aspects 
 
Paradoxical TB-IRIS is a form of paradoxical TB reaction that occurs during early 
ART-mediated immune recovery and which is often more severe and more frequently 
involves multiple organ systems than paradoxical reactions seen in patients not on 
ART. Paradoxical reactions are also far more frequent in the period after ART 
initiation than in HIV negative patients and HIV-infected patients not on ART (36% 
vs 7% vs 2% respectively in one study (90)).  
 
Paradoxical TB-IRIS occurs in 8-46% of patients starting ART while on TB treatment 
(Table 1). In a meta-analysis of studies reporting the incidence of paradoxical TB-
IRIS the pooled cumulative incidence was 15.7% (95% credibility interval calculated 
using Bayesian methods = 9.7 – 24.5%) (91). In the same meta-analysis the mortality 
risk associated with the development of TB-IRIS was reported as 3.2% (95% 
credibility interval = 0.7 – 9.2%). Death due to paradoxical TB-IRIS is infrequent 
apart from when the central nervous system is affected (discussed below) and certain 
of the deaths occurring in TB-IRIS patients are not due to TB-IRIS but due to other 
infections (92). In cohort studies the mortality rate in patients who develop 
paradoxical TB-IRIS has been no different to TB patients starting ART who do not 
develop paradoxical TB-IRIS (93, 94). In contrast, the mortality risk associated with 
cryptococcal IRIS is much higher: the estimate was 20.8% (95% credibility interval = 
5.0 - 52.7%) in the same meta-analysis (91).  
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TABLE 1: Cohort studies reporting the incidence, treatment and outcome of 
paradoxical tuberculosis-associated immune reconstitution inflammatory 
syndrome (TB-IRIS) in adult patients a 
First author 
(Country and year of 
publication) 
Incidence of 
paradoxical 
TB-IRIS 
Treatment of IRIS 
episode 
Duration 
symptom onset 
to resolution of 
IRIS episode 
Number of 
deaths 
(% of IRIS 
cases) 
Narita (90) 
(United States, 1998) 
12/33 (36%) Corticosteroids (2) 
ART interruption (1) 
NR NR 
Breen (95) 
(UK, 2004) 
8/28 (29%) Prednisone (8 of 14)b 
 
NR NR 
Breton (96) 
(France, 2004) 
16/37 (43%) Corticosteroids (6) 
NSAIDs (2) 
ART interruption (7) 
Surgery (1) 
NR NR 
Kumarasamy (97) 
(India, 2004) 
11/144 (8%) Corticosteroids (6) 
NSAIDs (5) 
Aspiration (1) 
NR 0 (0%) 
Michailidis (98) 
(UK, 2005) 
9/28 (32%) Corticosteroids (11) 
IL-2 and GM-CSF (1) 
Aspiration (10)c 
Median 2.5 
months  
(range 0.5-15 
months)c 
NR 
Manosuthi (94) 
(Thailand, 2006) 
21/167 (13%) Corticosteroids (11) NR 2 (10%) 
Lawn (93) 
(South Africa, 2007) 
19/160 (12%) Corticosteroids (2) 
Laporotomy (1) 
NR 2 (11%) 
Burman (99) 
(United States, 2007) 
19/109 (17%) Corticosteroids (4) 
Aspirations (11) 
Surgical drainage (6)d 
Median 60 days 
(range 11-442 
days)d 
1 (5%) 
Tansuphasawadikul 
(100) (Thailand, 2007) 
15/101 (15%) Corticosteroids (6) NR 0 (0%) 
Serra (101) 
(Brazil, 2007) 
10/84 (12%)e Prednisone (8) 
NSAIDs (2) 
Mean 91 days +/- 
30 days 
0 (0%) 
Baalwa (102) 
(Uganda, 2008) 
13/45 (29%) NR NR NR 
Manosuthi (103) 
(Thailand, 2009) 
22/126 (18%) NR NR 0 (0%) 
Elliott (104) 
(Cambodia, 2009) 
15/75 (20%) NR NR 0 (0%) 
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Bourgarit (105) 
(France, 2009) 
11/24 (46%) NR NR NR 
Sharma (106) 
(India, 2010) 
18/237 (8%) Corticosteroids (2) 
Surgical drainage (1) 
NSAIDs or paracetamol 
(15) 
NR 0 (0%) 
Eshun-Wilson (107) 
(South Africa, 2010) 
35/333 (11%) Corticosteroids (13) NR 1 (2%) 
Worodria (92) 
(Uganda, 2011) 
61/258 (24%) NR NR 6 (10%) 
Haddow (108) 
(South Africa, 2011) 
14/102 (14%) NR NR NR 
 
Legend for Table 1 
a This table is restricted to cohort studies that assessed the incidence and outcomes of 
paradoxical TB-IRIS in adult patients starting ART while on TB treatment and where 
8 or more cases of TB-IRIS were documented. Cohorts in which all-cause IRIS was 
assessed are not included. 
b This study reported 14 paradoxical reactions in HIV-infected patients, 8 of them in 
patients who started ART after TB treatment (paradoxical TB-IRIS). Among all 14, 8 
were treated with corticosteroids. 
c This study reported 14 cases of paradoxical reaction, 9 of which were paradoxical 
TB-IRIS. Data regarding treatment and duration relate to all 14 patients. 
d Burman et al reported 25 cases of paradoxical reaction in HIV-infected patients, 19 
of which were in patients starting ART after TB treatment. Data regarding treatment 
and duration are for all 25 cases. 
e Of these 10 patients who had paradoxical reactions, 9 were on ART when the 
paradoxical reaction occurred and 1 was not. 
 
NR = Not reported 
NSAIDs = Non-steroidal anti-inflammatory drugs 
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The median interval from ART initiation to onset of paradoxical TB IRIS is typically 
2-4 weeks (90, 93-96, 101), but cases may occur within a few days and rarely onset 
may be months after ART is started (109). The median duration of symptoms is 
reported to be 2-3 months (98, 99, 109). A minority of cases have manifestations that 
last for more than a year (99, 109, 110) and recurrent episodes are described up to 4 
years after ART initiation (111).  
 
The most frequent clinical features of TB-IRIS are recurrent symptoms, fever, 
enlarging inflammatory lymph nodes (Figure 1) and new or enlarging serous 
effusions. In addition, worsening of radiographic pulmonary infiltrates (Figure 2) is 
seen in up to 45% of TB patients starting ART and patterns observed include 
consolidation, cavitation, miliary infiltrates and cystic changes (112, 113). 
Subcutaneous and deep tissue abscesses may form (99, 110). Common manifestations 
are listed in Table 2. There are case reports of other rare manifestations such as 
hypercalcaemia (attributed to TB-IRIS granulomas increasing production 1,25 
dihydroxy-Vitamin D3) (114, 115), choroidal granuloma enlargement and retinal 
detachment (116) and chylothorax (117). 
 
Abdominal manifestations of TB-IRIS are frequent, but not widely reported. Hepatic 
and splenic involvement may occur together with intestinal lesions, peritonitis, 
ascites, enlargement of intra-abdominal lymphadenopathy (Figure 3) and formation of 
abscesses including psoas abscesses (118, 119).  Abdominal symptoms reported 
include abdominal pain, nausea, vomiting and diarrhea (94, 118). Hepatic 
involvement, which occurs in between 21-56% of TB-IRIS cases, can be difficult to 
differentiate from drug-induced hepatitis (118, 120). Hepatic TB-IRIS manifests with 
tender liver enlargement, cholestatic liver function derangement with or without 
jaundice and frequently there is evidence of TB-IRIS at other sites. A granulomatous 
hepatitis is found on liver biopsy (120). Such patients may have had subclinical 
abdominal involvement at the time of TB diagnosis and only manifest with abdominal 
features at the time of IRIS. 
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Table 2: Common manifestations of paradoxical TB-IRIS 
Worsening or recurrence of TB symptoms 
Weight loss 
Fever 
Systemic inflammatory syndrome 
Lymph node enlargement  
Cold abscess formation   
Respiratory manifestations 
Progressive pulmonary infiltrates on chest radiography (several patterns 
described, including miliary infiltrates and alveolitis) 
 Pleural effusions  
 Lymph node compression of airways 
Abdominal manifestations 
 Hepatic enlargement and abscesses 
 Splenic enlargement, rupture and abscesses 
 Intestinal involvement, eg. ileo-caecal perforation 
 Peritonitis 
Ascites 
 Psoas and intra-abdominal abscesses 
Central nervous system manifestations 
 Tuberculoma enlargement 
 Meningitis  
Myeloradiculitis 
Genito-urinary tract manifestations 
 Renal involvement with acute renal failure 
 Ureteric compression  
Epipidymo-orchitis 
Other system involvement 
Arthritis and osteitis 
Pericardial effusion 
Bone marrow involvement 
(Originally produced for reference (121)) 
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Figure 1: Supraclavicular lymphadenitis due to TB-IRIS 
This 23 year-old HIV-infected woman with a CD4 count of 143 cells/mm3 was 
diagnosed with pulmonary TB on the basis of a sputum culture that grew 
Mycobacterium tuberculosis susceptible to isoniazid and rifampicin. At the time of 
TB diagnosis she had small cervical lymph nodes. She reported initial symptom 
response on TB treatment and started ART 3 weeks later. Three weeks after starting 
ART she developed painful right supraclavicular lymphadenitis that enlarged to a 
nodal mass measuring 15 x 8 cm with overlying erythema and tenderness 
characteristic of TB-IRIS lymphadenitis. 
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Figure 2: Worsening pulmonary infiltrate and new pleural effusion  
A 49-year old HIV-infected man with CD4 of 29 cells/mm3 was diagnosed with drug-
susceptible pulmonary TB (chest radiograph A). He started ART 2 weeks after TB 
treatment. Two weeks later he developed recurrent TB symptoms, worsening of 
pulmonary infiltrate and new pleural effusion due to paradoxical TB-IRIS (chest 
radiograph B). The TB sputum culture and pleural aspirate TB culture were negative 
at the time of TB-IRIS. 
 
 
 
A                                                              B
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Figure 3: Abdominal lymphadenitis due to TB-IRIS 
A 21-year old HIV-infected woman with a CD4 count of 77 cells/mm3  was diagnosed 
with pulmonary TB (Mycobacterium tuberculosis isolated from sputum was 
susceptible to rifampicin and isoniazid). She commenced ART (stavudine, lamivudine 
and efavirenz) five weeks after starting 5-drug antitubercular therapy that she was 
taking as an inpatient. After two weeks on ART she developed progressively 
worsening abdominal pain and severe vomiting. The pain required opiate analgesia. A 
contrasted CT scan of her abdomen revealed mesenteric and retroperitoneal rim-
enhancing, coalescent lymph nodes with necrotic centres (arrowed), that were thought 
to be the cause of her symptoms and the consequence of paradoxical TB-IRIS. A 
percutaneous aspirate of one of these nodes grew drug-susceptible Mycobacterium 
tuberculosis. 
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Figure 4: Fatal enlargement of intracerebral tuberculoma due to TB-IRIS 
A 34-year old HIV-infected woman with a CD4 count of 26 cells/mm3 was diagnosed 
with TB meningitis after presenting with headaches and neck stiffness. Lumbar 
puncture demonstrated lymphocytic meningitis, CSF cryptococcal antigen test was 
negative and chest radiograph was compatible with pulmonary TB. She started TB 
treatment and prednisone and improved significantly. She was able to self-care after 
discharge and started ART 6 weeks after TB treatment. Two weeks after starting ART 
she was admitted following several generalized convulsions and had a depressed level 
of consciousness and right hemiparesis. CT scan showed a large left fronto-parietal 
ring-enhancing lesion with extensive surrounding oedema and mid-line shift. ART 
was stopped, she was commenced on high dose dexamethasone and anitconvulsants, 
but deteriorated and died 2 days later. 
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Neurological deterioration has been reported as 12% of paradoxical TB-IRIS cases 
(122). Manifestations include new or recurrent meningitis, enlarging tuberculomas 
(Figure 4) and radiculomyelopathy. In the case series (n=23) of neurologic TB-IRIS 
reported by Pepper et al (122), only 70% of patients were known to be alive at 6 
months; and of the survivors 6 of 16 had long term neurologic disability. Other life 
threatening manifestations of paradoxical TB-IRIS include pericardial tamponade 
(123), acute renal failure (124), splenic rupture (96, 125), intestinal perforation (126), 
airway compromise due to compression by enlarging nodes (96) and respiratory 
failure. As stated above overall reported deaths from paradoxical TB-IRIS are rare 
(Table 1), although this may represent publication bias. There is one study that has 
reported a high mortality rate among paradoxical TB-IRIS cases from Ethiopia (5 of 
11 (45%) of cases died), but the causes of these deaths was not reported (127). Whilst 
many cases are self-limiting, paradoxical TB-IRIS results in considerable morbidity 
and places considerable burden on the health services. Patients frequently require 
hospitalization, diagnostic and therapeutic procedures. 
 
The risk factors for paradoxical TB-IRIS most consistently identified are: 
disseminated TB, low CD4 count prior to ART and shorter interval from TB treatment 
to ART (93-96, 98, 99, 128). Should ART therefore be delayed in order to reduce the 
risk of TB-IRIS? This consideration needs to be counterbalanced by the risk that 
delaying ART confers in terms of increased HIV disease progression and the 
additional opportunistic infections and mortality associated with this. A further 
complication is that patients at highest risk for TB-IRIS are those with low CD4 
counts who are most at risk of HIV complications if ART is delayed. In addition, 
delaying ART until after 2 months of TB treatment does not necessarily prevent 
paradoxical TB-IRIS. In a Ugandan study, 22% of patients starting ART within 2 
months developed TB-IRIS whereas 31% of those starting after 2 months developed 
TB-IRIS (102). As discussed above, several randomized clinical trials have now 
demonstrated that mortality (or the combined endpoint of mortality and AIDS 
progression) is reduced if ART is started within 2 weeks of having started TB 
treatment in patients with low CD4 counts (CD4 < 50 cells/mm3). This survival 
benefit of early ART in such patients clearly takes precedence over concerns of a 
higher incidence of paradoxical TB-IRIS. 
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Paradoxical TB-IRIS is diagnosed on the basis of a characteristic clinical presentation, 
temporal relationship to the initiation of ART and exclusion of alternative 
explanations for clinical deterioration. It is important to investigate for other 
opportunistic infections and malignancies, TB treatment failure (due to non-
adherence, TB drug resistance or malabsorption of TB drugs) or drug reaction. In 
addition, paradoxical TB-IRIS may develop in patients with undiagnosed rifampicin 
resistance, clinically indistinguishable from TB-IRIS that occurs in patients with 
drug-susceptible disease (data in this regard is presented in Chapter 4)(118). Where 
possible drug susceptibility testing, preferably using a rapid diagnostic assay, should 
be performed in all patients presenting with paradoxical TB-IRIS. Other 
investigations in a particular case will depend on the nature of the clinical 
presentation. Consensus case definitions for use in resource limited settings have been 
developed (presented in Chapter 3)(110). 
  
Mild cases require reassurance and symptomatic treatment. In cases with more 
significant symptoms non-steroidal anti-inflammatory drugs and corticosteroids have 
been used. Corticosteroid therapy will exacerbate other untreated infections or drug-
resistant TB, so should only be considered for paradoxical TB-IRIS when alternative 
diagnoses have been excluded. Breen reported 8 HIV-infected patients with 
paradoxical reactions or paradoxical TB-IRIS who all responded to prednisone at a 
range of doses (10-80mg/day)(95). Our randomized placebo-controlled trial of 
prednisone for the treatment of paradoxical-TB IRIS (presented in Chapter 6) 
demonstrated a significant reduction in a combined endpoint of days hospitalized plus 
outpatient therapeutic procedures in prednisone-treated cases. Significant benefit was 
also demonstrated for symptom improvement. Patients received prednisone or placebo 
at a dose of 1.5mg/kg for 2 weeks followed by 0.75mg/kg for 2 weeks. Cases with 
immediately life-threatening manifestations were excluded from this trial (129). 
Corticosteroid use is associated with risks such as reactivations of herpes virus 
infections, Kaposi’s sarcoma and metabolic side effects (130-132). Some patients 
require corticosteroids for several months (133) where side effects are likely to be 
greater. There is a case report of successful treatment with the TNFα receptor 
antagonist infliximab of a TB paradoxical reaction involving the central nervous 
system (134) and the role of these agents in life-threatening TB-IRIS warrants further 
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investigation. Needle aspiration to provide symptom relief and for aesthetic reasons 
for suppurative lymphadenitis or cold abscesses may be required (99). ART 
interruption may rarely be considered in life-threatening cases, for example those with 
depressed level of consciousness due to neurological involvement.   
 
Immunopathogenesis of paradoxical TB-IRIS 
 
IRIS occurs during the initial weeks to months of effective ART during a period of 
rapid recovery in immune function. While IRIS is characterized by exaggerated 
inflammatory responses clinically, driven by this rapid recovery in immunity, the 
precise pathogenic mechanisms are incompletely understood. Inflammatory features 
are heterogenous: mycobacterial and fungal IRIS are characterized by delayed type 
hypersensitivity responses, granuloma formation and in some cases suppuration 
whereas in viral conditions CD8+ T-lymphocyte responses predominate (67, 119, 
135).  
 
The pathogenesis of TB-IRIS is related to recovery of MTB-specific immunity but the 
relative contribution of various components and cells of the immune system is a field 
of intense and ongoing study (Figure 5). The first report to suggest that mycobacterial 
IRIS coincided with recovery of mycobacterial-specific immune responses was in 
patients who developed a localized form of Mycobacterium avium complex (MAC) 
disease, such as lymphadenitis, after starting AZT monotherapy in the early 1990’s. 
Reversion of tuberculin or MAC purified protein derivative (PPD) skin tests from 
anergic to positive was demonstrated (66). This was later also reported in patients 
with anergic PPD skin tests who developed paradoxical TB-IRIS who developed 
strongly positive skin tests around the time of IRIS (90). These studies implicate 
recovery of delayed type hypersensitivity responses in pathogenesis. Certain patients 
with TB-IRIS in the latter study (90) had not had a CD4 count rise at the time of IRIS, 
suggesting that at a tissue level IRIS may occur prior to CD4 count recovery in 
peripheral blood. This has also been observed in patients with MAC IRIS (136). 
 
The association between increases in mycobacterial-specific T cells in peripheral 
blood and paradoxical TB-IRIS has been investigated using enzyme-linked 
immunospot (ELISpot) assays, whole blood interferon-gamma release assays and 
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flow cytometry (104, 105, 137-140). Bourgarit et al (137) showed that TB-IRIS was 
associated with large expansions of PPD-specific interferon-γ producing T cells. 
Expansions were not seen in the TB-IRIS patients when CMV antigens or ESAT-6 
were used as antigen stimuli. Similar findings have been reproduced in other studies 
(104, 139). Bourgarit et al (105) subsequently reported that these PPD-specific T cells 
are multifunctional (IFN-γ+ TNF-α+ IL2-), of the CD4+ effector memory phenotype 
and highly activated. In contrast, our study presented in Chapter 5 showed that while 
TB-IRIS patients had greater median IFN-γ-producing T cell expansions in response 
to a number of mycobacterial antigens in cross-sectional analysis, the responses in 
both cases and controls were heterogenous, and in longitudinal analysis responses 
were highly variable and dynamic (with expansions and contractions occurring in 
both cases and controls).  That these expansions are the cause of TB-IRIS is 
questioned (138).  In addition, a Thai study found no significant differences in 
cytokine assays for T helper 1 cytokines (IL-2, IL-12, and IFN-γ) following PPD and 
RD1 antigen stimulation between patients who developed TB-IRIS and controls prior 
to ART or at time of IRIS (140).  
 
Bourgarit et al (105) also observed that TB-IRIS patients had high levels of γδ T cells 
not expressing KIR (killer Ig-related receptor) at baseline and at TB-IRIS, suggesting 
a role for these cells in the pathogenesis of TB-IRIS and that they may be deficiently 
regulated. γδ T cells respond to mycobacterial phospho-antigens and produce large 
amounts of IFN-γ. 
 
It has been suggested that paradoxical TB-IRIS is precipitated by a “cytokine storm” 
(141). TB-IRIS was accompanied by elevations in a range of Th1 and inflammatory 
cytokines and chemokines, but not Th2 cytokines in one study (137). In a South 
African study (142) cytokine concentrations were studied in patients who developed 
TB-IRIS and compared to controls (patients with HIV-associated TB who did not 
develop TB-IRIS on ART) at 2 weeks on ART. A broad range of cytokines and 
chemokines were elevated after in vitro re-stimulation but the most consistently 
elevated cytokines and those significantly elevated in unstimulated serum after 
correction for multiple comparisons were TNF-α, IFN-γ and IL-6. Oliver et al (143) 
demonstrated that TB-IRIS was associated with higher concentrations of CXCL10 
and IL-18 and lower levels of CCL2 in unstimulated samples and suggest therefore 
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that pertubations of the innate immune responses may contribute to pathogenesis. 
CXCL10 (also known as IFN-γ inducible protein-10 (IP-10)) is chemotactic for 
effector T cells. IL-18 is a macrophage-derived inducer of IFN-γ that contributes to 
protective responses to TB. The results were interpreted to indicate that production of 
IL-18 and CXCL10 augment effector T cell responses to MTB antigens in TB-IRIS 
(144). Another study that analysed IFN-γ and IL-5 concentrations in whole blood 
mitogen-stimulated cultures demonstrated no differences in concentrations when 
comparing TB-IRIS cases and controls and the levels of these two cytokines 
correlated with each other in both patient groups. The interpretation of this data was 
that TB-IRIS is not caused by an imbalance of Th1- and Th2-polarised T cells (145).   
 
In a nested case-control study conducted in Durban, South Africa, 9 patients with 
paradoxical TB-IRIS were compared with 12 controls with TB who started ART and 
developed non-IRIS clinical events. At the time of the clinical event, which was 
similar in time from ART initiation in cases and controls, TB-IRIS patients had lower 
IL-10 and MCP-1 (monocyte chemotactic protein-1 also known as CCL2) 
concentrations, higher C-reactive protein:IL-10 ratio when compared with controls 
and undetectable IL-12p70 and GM-CSF. It was concluded that this reflected lower 
monocyte and regulatory T cell activity and higher pro-inflammatory activity (108). 
 
It has been hypothesized that paradoxical TB-IRIS may reflect a relative delay in 
recovery of regulatory T cell numbers and function compared with pro-inflammatory 
responses (141, 146). Two studies (one presented in Chapter 5) have demonstrated no 
deficiency of regulatory T cells in TB-IRIS patients (138, 139). Seddiki et al (147) 
demonstrated expansions of CD127lo Foxp3+ CD25+ T regulatory cells and a higher 
ratio of T regulatory to effector/memory subsets in TB-IRIS patients. In this same 
study (147) in vitro suppression assays demonstrated reduced functional capacity of 
and reduced IL-10 secretion from suppressor cells in TB-IRIS patients, suggesting 
that while T regulatory cells numbers are increased their ability to downregulate 
aberrant immune responses is impaired. Another study of two patients with 
mycobacterial IRIS demonstrated impaired IL-10 and increased IFN-γ production. 
The authors suggested that an imbalance of regulatory and effector cytokine responses 
may be the cause of IRIS (146). As discussed above, low pre-ART levels of inhibitory 
NK receptors (CD94/NKG2, CD158a and CD158b) on mycobacterial-specific Vδ2 
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TCRγδ T cells have been shown to predict paradoxical TB-IRIS (105). Thus while no 
deficiency in T-regulatory cell numbers in mycobacterial IRIS has been shown, data 
suggest there may be functional impairment of regulatory components of the immune 
system that contributes to dysregulated inflammation. 
 
Figure 5: Immunopathogenesis of IRIS: mechanisms that have been 
hypothesized and studied 
 
 
 
 
*No study has demonstrated deficient numbers of T-regulatory cells in TB-IRIS 
patients although studies have suggested impaired function 
 
(Originally produced for reference (68)) 
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What of the role of the innate immune system? It has been suggested that the recovery 
of mycobacterial-specific T cell numbers and function is not sufficient to explain the 
occurrence of TB-IRIS and that recovery of innate immune function may play an 
important role in pathogenesis (143, 144). Our study (reported in Chapter 5) 
demonstrated that some patients who developed TB-IRIS showed minimal or no 
ELISpot responses to mycobacterial antigens whereas some patients who had high 
numbers of mycobacterial-specific T cells on ELISpot did not develop TB-IRIS (138). 
It has been hypothesized that macrophages have an important role in the pathogenesis 
of IRIS (148). A fatal case of unmasking pulmonary TB-IRIS was found to have 
bronchiolitis obliterans organizing pneumonia at autopsy with an infiltrate consisting 
predominantly of macrophages (149). Neutrophils are likely involved given that 
suppurative lymphadenitis and abscess formations are frequent features of TB-IRIS. 
In a mouse model of MAC-IRIS marked alterations in blood and tissue CD11b+ 
myeloid cells were observed (150). The finding of higher levels of CXCL10 and IL-
18 in TB-IRIS patients by Oliver and colleagues discussed above was also suggested 
to be evidence of a role for the innate immune system (143). A study of 5 cases of 
TB-IRIS and 9 matched non-IRIS controls suggested a role for Toll-like receptor 2 
(TLR-2) induced pro-inflammatory cytokines produced by monocytes and dendritic 
cells in TB-IRIS pathogenesis. At 24 weeks on ART, TLR-2 expression on monocytes 
and lipomannan-induced TNFα production was significantly higher in TB-IRIS cases. 
Lipomannan is a TLR-2 ligand. Lipomannan-induced TNFα and IL-12p40 responses 
paralleled TB-IRIS in certain patients with high TLR-2 expression monocytes and 
myeloid dendritic cells, without a parallel increase in IL-10 production (151). 
 
A genetic predisposition to IRIS has been suggested from genetic polymorphism 
studies conducted in Australia. Although these studies were small, an association of 
alleles of certain cytokine genes (TNFA-308*2 and IL-6-174*G) with mycobacterial 
IRIS, and not IRIS associated with herpes virus infections, was shown (152). 
 
The finding that lower CD4 T cell counts (93, 98), lower concentrations of CCL2 
(143) and lower plasma levels of antibodies to PGL-Tb1 (153) prior to ART are 
associated with development of paradoxical TB-IRIS is evidence that 
immunodeficiency prior to ART may be an important factor in the development of 
TB-IRIS. It is possible that this immunodeficiency plays a role by allowing more 
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dissemination of TB bacilli prior to ART, thereby providing a greater antigen stimulus 
(of Mycobacterium tuberculosis antigen) when ART is commenced precipitating TB-
IRIS. 
 
Unmasking TB-IRIS and unmasking of TB by ART 
 
High TB incidence rates (5.6 - 23 TB cases per 100 person years) in the first 3 months 
of ART have reported from developing country ART programmes (80-82). It is likely 
that a number of factors account for this. Patients may seek medical attention and 
enter HIV care because of the symptoms of TB. Many such patients have TB 
diagnosed before ART, but because of the insensitivity of sputum smear (154) and 
chest radiography(155) in patients with advanced immunosuppression the diagnosis 
may be missed before ART initiation. Other patients may have subclinical TB at the 
time they start ART that becomes clinically apparent on ART. Other patients may 
reactivate latent TB or be infected or re-infected with TB around the time of ART 
initiation. Increased clinical surveillance in patients attending for clinical care likely 
also plays a role. 
 
There is a spectrum of clinical presentations among such TB cases occurring during 
early ART that is postulated to be influenced by the complex interplay between the 
infectious load of mycobacterial organism and immune recovery (which tends to 
result in TB becoming more clinically overt)(156). The dynamics of this interplay 
may result in TB remaining subclinical, a typical clinical presentation or an 
exaggerated inflammatory presentation. The effect of ART-mediated immune 
restoration, particularly in the presence of a high mycobacterial load, may be three 
fold:  the timing of onset of TB symptoms may be brought forward, there may be 
more rapid symptom onset and it may result in heightened inflammatory clinical 
manifestations (156). Lawn et al propose that only the latter category should be 
regarded as IRIS, and be termed unmasking TB-IRIS (156). 
 
Some authors have regarded any presentation of TB diagnosed while patients are on 
ART as TB-IRIS provided there was a CD4 rise and viral load reduction (157), 
however there is increasing consensus that IRIS plays a role in presentation in only a 
subset of patients presenting with TB on ART (110, 156). A nomenclature has been 
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proposed (156). All TB diagnosed while on ART should be termed “ART-associated 
TB”. TB that presents soon after ART initiation due to restoration of TB antigen-
specific immune responses should be termed “unmasking TB”. As stated above, a 
subset of these cases presenting with heightened intensity of clinical manifestations, 
particularly when there is evidence of a marked inflammatory component, during the 
first 3 months of ART should be termed “unmasking TB-IRIS”.  
 
“Unmasking” TB-IRIS is less well characterized than paradoxical TB-IRIS with 
fewer cases reported. Cases described include patients presenting with rapid onset of 
severe respiratory presentations (110, 149, 158, 159), one of whom required 
mechanical ventilation for adult respiratory distress syndrome associated with miliary 
TB (158).  A fatal case of unmasking TB-IRIS presenting after 6 weeks on ART was 
shown at post-mortem to have extensive infiltrate of the upper lobe of the right lung 
with histological appearance compatible with bronchiolitis obliterans organizing 
pneumonia (149). Complicated neurological involvement in unmasking TB-IRIS 
cases has been described (160, 161), as has pyomyositis (162).  
 
Breen et al reported 13 patients diagnosed with active TB in the first 3 months of 
ART. These patients more frequently developed paradoxical reactions (62%) than 
patients who were diagnosed with TB later on ART, none of whom had paradoxical 
reactions. They conclude that an “inflammatory phenotype” associated with early 
ART may have resulted in these paradoxical reactions, perhaps another manifestation 
of IRIS (163). Lawn et al noted in a South African cohort that during the first 4 
months of ART the adjusted TB incidence rate for those with a CD4 cell count < 200 
cells/µL was 1.7-fold higher that the incidence rate for patients with an updated CD4 
cell count < 200 cells/µL during long term ART. This excess adjusted risk was 
attributed to “unmasking” of active TB by recovering immunity (164). The proportion 
of these cases whose presentation was suggestive of unmasking TB-IRIS was not 
quantified. In Haiti, a three-fold increase in mortality in those diagnosed with TB in 
the first 3 months on ART (27% mortality) compared to other patients with AIDS and 
TB (8% mortality) was noted (165). This higher mortality may in part be attributable 
to unmasking TB-IRIS.  
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Clinicians should screen for TB symptoms prior to ART, investigate those with 
symptoms, be aware that a subset of patients with advanced HIV may have subclinical 
TB and be vigilant for the development of unmasking TB and TB-IRIS during early 
ART. It has been reported that around 50-70% of patients diagnosed with TB in the 
first 3 months of ART had TB symptoms at the time of ART initiation (163, 165). A 
simple screening tool for active TB in patients entering ART programmes or on ART 
in resource-poor settings has been proposed (166). The diagnosis of TB may be 
difficult to prove in patients with advanced HIV given the insensitivity of sputum 
smears and empiric treatment based on strong clinical suspicion and compatible 
radiography should be considered particularly in patients whose condition is rapidly 
deteriorating (167).  
 
Further research to characterize the clinical manifestations and immunological 
mechanisms of unmasking TB-IRIS will help in refining the proposed clinical case 
definition for this condition in the future (110).  
 
Corticosteroids for the treatment of tuberculosis 
 
Corticosteroids are known to exert anti-inflammatory effects on most types of 
immune cells through direct effects on transcription of inflammatory mediators via 
the Glucorticoid Responsive Element, indirect genomic effects via interference with 
other transcriptional factors such as NF-κB and AP-1, and non-genomic effects on 
anti-inflammatory proteins (168, 169). These effects result in increased transcription 
of a number of anti-inflammatory mediators and decreased transcription of pro-
inflammatory cytokines, chemokines, enzymes, receptors and adhesion molecules 
(170, 171). In addition corticosteroids have been shown to reduce T cell survival by 
enhancing apoptosis (171). 
 
Corticosteroids have been used as adjunctive treatment in TB for about six decades 
(106, 172). Because the host immune response plays an important part in the 
pathology caused by TB, corticosteroids have been used in both pulmonary and many 
forms of extrapulmonary forms of TB with the intention of improving outcomes and 
reducing complications such as pericardial constriction, hydrocephalus, focal 
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neurological deficits, pleural adhesions and intestinal strictures. However, evidence of 
benefit from controlled clinical trials exists only for TB meningitis and pericardial 
TB. In other forms of TB the clinical benefit is anecdotal, minor or not present (106). 
 
Thwaites and colleagues (173) conducted a randomized, double-blind, placebo-
controlled trial of dexamethasone for the treatment of TB meningitis in Vietnam 
among patients older than 14 years of age (n=545). The initial dose of intravenous 
dexamethasone used was 0.4mg/kg/d for patients with Grade 2 and 3 TBM disease 
and 0.3mg/kg/d in patients with Grade 1 disease. The total duration of dexamethasone 
(initially intravenous followed by oral) was 8 weeks in those with Grade 2 and 3 
disease and 6 weeks in those with Grade 1 disease. At 9 months follow-up, 
dexamethasone was associated with a reduced risk of death (relative risk = 0.69, 95% 
CI= 0.52 – 0.92), but no reduction in the proportion of patients with severe disability.  
Eighteen percent of participants were HIV seropositive and in a pre-specified 
subgroup analysis of these patients dexamethasone was associated with a non-
significant trend towards reduced mortality (relative risk = 0.78, 95%CI = 0.59 -1.04). 
Significantly fewer severe adverse events occurred in patients who received 
dexamethasone. In particular, 8 cases of severe hepatitis (one was fatal) occurred in 
the placebo group and none in the dexamethasone group. 
 
A Cochrane systematic review of corticosteroids as an adjunct to TB treatment in TB 
meningitis published in 2008 included seven trials and a total of 1140 participants 
(with 411 deaths). Dexamethasone or prednisolone was the corticosteroid used in all 
studies. Corticosteroids reduced the risk of death (relative risk = 0.78, 95% CI = 0.67 
- 0.91). The survival benefit occurred irrespective of the severity of TB meningitis. In 
three trials in which this was assessed, corticosteroids reduced the risk of death or 
disabling residual neurological deficit as a combined endpoint significantly. Adverse 
events that occurred across studies included gastro-intestinal bleeding, bacterial and 
fungal infections and hyperglycaemia, but were mild and treatable (174). 
 
A randomized, double blind, placebo-controlled trial of prednisolone (for 11 weeks) 
for the treatment of TB pericardial effusion was conducted in Transkei, South Africa, 
in the 1980’s prior to the HIV epidemic by Strang and colleagues. Patients in this 
study were also randomized to open pericardial biopsy and complete drainage of 
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pericardial fluid on admission or percutaneous aspiration when required. Among 
patients who did not have open drainage on admission, 3% given prednisolone 
compared with 14% given placebo died of pericarditis (p <0.05) (175). Patients who 
received prednisolone required repeat pericardiocentesis less frequently. A Cochrane 
review (176) of controlled trials evaluating the role of adjuvant corticosteroids for TB 
pericarditis included 2 trials from the pre-HIV era with a total of 383 participants (the 
2 trials included were the study published by Strang and colleagues in 1988 (175) and 
a prior trial in patients with TB constrictive pericarditis conducted by the same group 
(177)).  There was a non-significant trend towards reduced death in the intervention 
group (relative risk = 0.65, 95% CI = 0.36–1.16). There was a significant reduction in 
the combined endpoint of death or disability at 2 years although there was substantial 
heterogeneity in the trials. In a small randomised controlled trial of prednisolone for 
TB pericarditis in HIV-infected patients conducted in Zimbabwe (n=58) (178) there 
were 10 deaths among those who received placebo compared with 5 deaths among 
those who received prednisone. This represented significantly lower mortality in the 
prednisolone group using the log-rank test to compare Kaplan Meier survival curves 
(178). However, when cumulative mortality was compared the difference was not 
significant (RR=0.50, 95% CI = 0.19 - 1.28) (176).  The Cochrane review concluded 
that corticosteroids could have clinical benefit, but the trials published to date are too 
small to demonstrate an effect (176). In particular the efficacy and safety of 
corticosteroids in HIV-infected patients needs to be evaluated in a larger clinical trial. 
Adjuvant prednisolone for TB pericarditis is been evaluated in the IMPI Pilot trial, a 
multicenter collaboration involving sites in South Africa, Zimbabwe, Nigeria and 
India, currently recruiting both patients who are HIV-infected or uninfected 
(http://clinicaltrials.gov/ct2/show/NCT00810849). 
 
Tuberculomas involving the brain parenchyma or spinal cord may develop despite 
effective TB treatment resulting in focal neurological deficits or seizures. The host 
immune response is thought to play an important role in these paradoxical TB 
reactions. Corticosteroids have been used with anecdotal reports of symptomatic 
benefit (85). However, no clinical trials have been conducted. In TB pleural effusions 
a Cochrane systematic review found that corticosteroids had no significant effect on 
mortality, respiratory function, resolution of pleural effusion at 8 weeks, or 
development of pleural adhesions. However risk of pleural thickening was reduced, 
57
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
the significance of which is unclear (179). In a Ugandan trial that evaluated 
prednisolone in HIV-infected patients with TB pleural effusions, prednisolone was 
associated with more rapid clinical and radiological improvement, but an excess of 
Kaposi’s sarcoma (131). In peritoneal TB a small trial (n=47) conducted in India 
demonstrated a non-significant reduction in the late fibrotic complication of intestinal 
obstruction in patients who received corticosteroids (180). In miliary and pulmonary 
TB initiation of TB treatment may be complicated by the development of adult 
respiratory distress syndrome with acute respiratory failure (181). Corticosteroids are 
frequently used in this situation, but efficacy has not been determined in an 
adequately powered clinical trial. One study of 55 patients with miliary TB showed a 
non-significant trend towards improved survival with corticosteroids (182). 
 
Smego and Ahmed (183) have conducted a systematic review of studies that have 
evaluated corticosteroids in patients with pulmonary TB. Ten of the 11 studies 
identified were conducted in the pre-HIV era. Two of the studies involved patients 
receiving rifampicin-based regimens. In the larger of these two studies (n=600) 
corticosteroids had no significant effect on radiological or bacteriological outcomes 
(184). In 9 of the 11 trials corticosteroids were associated with more rapid 
radiographic resolution of pulmonary infiltrates and in 6 more rapid closure of 
cavities. In many of the studies patients receiving corticosteroids experienced 
moderate clinical benefit in terms of more rapid defervescence and weight gain. On 
the basis of the review it was concluded that corticosteroids confer little, if any, 
significant effect on long-term pulmonary function in patients with TB. In the 
majority of studies corticosteroids did not have any appreciable effect on the speed or 
rate of sputum conversion. Importantly in only one of these 11 studies did 
corticosteroids delay sputum conversion suggesting that bacteriological outcome is 
not adversely affected by receipt of corticosteroids while on effective TB treatment. 
No serious side effects or increase in rate of bacteriological relapse was noted. Thus 
in pulmonary TB, corticosteroids result in modest benefits in terms of more rapid 
clinical and radiological improvement, but do not impact on mortality or the 
development of late complications such as chronic restrictive lung disease (172).  
 
A review of the literature of corticosteroids used for all forms of TB also concluded 
that corticosteroids do not diminish the efficacy of TB treatment (172). In contrast in 
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patients with latent TB corticosteroids increase the risk of reactivation and active TB 
disease (185). Risk of TB is increased approximately two-fold in rheumatological 
patients receiving corticosteroids in North American clinics (186). 
 
One study has been conducted in Uganda specifically in HIV-infected patients with 
pulmonary TB. In a phase 2 trial of short-term prednisolone in HIV-infected TB 
patients with CD4 count ≥ 200 cells/mm3, prednisolone was associated with more 
rapid clearance of MTB from sputum, reduced immune activation and resulted in a 
non-significant increase in CD4 count, but caused a transient increase in HIV viral 
load and worsened underlying hypertension and caused fluid retention and 
hyperglycaemia. On the basis of these findings the investigators advised against the 
use of prednisolone in these patients because risks outweigh benefits (132).   
 
There are special considerations when considering the use of corticosteroids for TB in 
HIV-infected patients. Some investigators have documented no serious adverse 
effects of corticosteroid therapy in HIV-infected patients (178, 187, 188), whereas 
other studies have raised concerns related to reactivation of herpes infections and the 
development of Kaposi’s sarcoma (130, 131). Another important factor to be 
considered in the use of corticosteroids with TB treatment is the drug-drug interaction 
with rifampicin, a potent inducer of cytochrome P450 enzymes. Rifampicin increases 
the clearance of prednisolone by 45% resulting in reduction in the area under the 
plasma concentration time curve of prednisolone by 66% (189).  
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Tuberculosis-associated immune reconstitution inflammatory syndrome: case 
definitions for use in resource-limited settings 
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Tuberculosis-associated immune reconstitution 
inﬂ ammatory syndrome: case deﬁ nitions for use in 
resource-limited settings
Graeme Meintjes, Stephen D Lawn, Fabio Scano, Gary Maartens, Martyn A French, William Worodria, Julian H Elliott, David Murdoch, 
Robert J Wilkinson, Catherine Seyler, Laurence John, Maarten Schim van der Loeﬀ , Peter Reiss, Lut Lynen, Edward N Janoﬀ , Charles Gilks, 
Robert Colebunders, for the International Network for the Study of HIV-associated IRIS
The immune reconstitution inﬂ ammatory syndrome (IRIS) has emerged as an important early complication of 
antiretroviral therapy (ART) in resource-limited settings, especially in patients with tuberculosis. However, there are 
no consensus case deﬁ nitions for IRIS or tuberculosis-associated IRIS. Moreover, previously proposed case deﬁ nitions 
are not readily applicable in settings where laboratory resources are limited. As a result, existing studies on 
tuberculosis-associated IRIS have used a variety of non-standardised general case deﬁ nitions. To rectify this problem, 
around 100 researchers, including microbiologists, immunologists, clinicians, epidemiologists, clinical trialists, and 
public-health specialists from 16 countries met in Kampala, Uganda, in November, 2006. At this meeting, consensus 
case deﬁ nitions for paradoxical tuberculosis-associated IRIS, ART-associated tuberculosis, and unmasking 
tuberculosis-associated IRIS were derived, which can be used in high-income and resource-limited settings. It is 
envisaged that these deﬁ nitions could be used by clinicians and researchers in a variety of settings to promote 
standardisation and comparability of data.
Introduction
The immune reconstitution inﬂ ammatory syndrome 
(IRIS; also known as immune reconstitution disease, 
immune reconstitution syndrome, or immune 
restoration disease) is a widely recognised phenomenon 
that can complicate antiretroviral therapy (ART).1,2 The 
condition results from rapid restoration of pathogen-
speciﬁ c immune responses to oppor unistic infections, 
causing either the deterioration of a treated infection or 
the new presentation of a previously subclinical 
infection. IRIS typically occurs during the initial 
months of ART and is associated with a wide spectrum 
of pathogens, most commonly mycobacteria, herpes-
viruses, and deep fungal infections such as cryptococcal 
meningitis.1–3 
In recent years, access to ART has increased rapidly in 
resource-limited settings, reaching over 2 million people 
by December, 2006, with an estimated 1 340 000 of these 
individuals living in sub-Saharan Africa.4 Since the 
burden of HIV/tuberculosis co-infection is very high in 
many low-income and middle-income countries,5 many 
of the patients who enter ART programmes in these 
settings have a current diagnosis of tuberculosis, or later 
develop tuberculosis following initiation of ART. For 
example, one South African study reported that 238 (25%) 
of 944 patients attending a community-based ART 
programme were receiving tuberculosis treatment at 
ART initiation and in the ﬁ rst year of ART the incidence 
of tuberculosis was 13·4 cases per 100 person-years 
(95% CI 10·4–16·9).6 Up to one-third of patients with 
HIV/tuberculosis co-infection who begin ART in such 
settings could be at risk of developing 
tuberculosis-associated IRIS (also known as TB-IRIS),3 
and this condition is emerging as an important clinical 
challenge in resource-limited settings.7–10 
Since there is no diagnostic test for IRIS, conﬁ rmation 
of the disease relies heavily upon case deﬁ nitions 
incorporating clinical and laboratory data. However, 
clinical management and research on IRIS are hindered 
by the lack of consensus case deﬁ nitions and deﬁ nitions 
that are speciﬁ c to particular opportunistic infections. To 
address this shortcoming, an international meeting of 
researchers working in this ﬁ eld was convened in 
Kampala, Uganda, in November, 2006, and the 
International Network for the Study of HIV-associated 
IRIS (INSHI) was formed. The speciﬁ c aim of the 
meeting was to develop consensus case deﬁ nitions for 
tuberculosis-associated IRIS that are appropriate for 
low-income settings where laboratory capacity is often 
limited, and that can be used by researchers working in 
diﬀ erent settings to permit comparability of results. We 
present these consensus case deﬁ nitions in this paper. 
Participants and consensus methods 
The need for a public-health deﬁ nition for 
tuberculosis-associated IRIS was ﬁ rst proposed at the 
WHO consultation on tuberculosis and HIV research 
priorities in resource-limited settings in February, 2005.11 
The organisers of the meeting in Kampala contacted 
individuals involved in research related to 
tuberculosis-associated IRIS, particularly those working 
in resource-limited settings or collaborating with 
researchers in these settings. Contacting these individuals 
was dependent on whether they had published or 
presented data about tuberculosis-associated IRIS at 
international conferences, whether they were involved 
in ongoing research projects about the disease, or 
whether they had clinical experience of the disease. 
97 researchers from 16 countries on six continents 
attended the meeting. Among the delegates were 
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microbiologists, immunologists, clinicians, epidemi-
ologists, clinical trialists, public-health specialists, and 
representatives from WHO. 
At the meeting a subgroup was assembled to develop 
the case deﬁ nitions. Two participants presented 
published IRIS case deﬁ nitions (panel 1)2,7,12–14 as well as 
eight diﬀ erent tuberculosis-associated IRIS case 
deﬁ nitions currently being used by researchers in 
ongoing cohort and intervention studies. The common 
features among these case deﬁ nitions were highlighted, 
and their practical use in resource-limited settings was 
discussed. Tuberculosis-associated IRIS case deﬁ nitions 
were agreed and taken back to a plenary session for 
further discussion and consensus building. Thereafter, 
Panel 1: Existing case deﬁ nitions for IRIS and tuberculosis-associated IRIS that have been most widely used
General IRIS case deﬁ nition 1 (French et al, 2004)2
Diagnosis requires two major criteria (A+B) or major criterion (A) plus two minor criteria to be fulﬁ lled:
Major criteria
(A) Atypical presentation of opportunistic infections or tumours in patients responding to ART
• Localised disease
• Exaggerated inﬂ ammatory reaction
• Atypical inﬂ ammatory response in aﬀ ected tissues
• Progressive organ dysfunction or enlargement of pre-existing lesions after deﬁ nite clinical improvement with pathogen-
speciﬁ c therapy before the initiation of ART and exclusion of treatment toxicity and new alternative diagnoses
(B) Decrease in plasma HIV RNA concentration by more than 1 log10 copies per mL
Minor criteria
• Increase in blood CD4 T-cell count after starting ART
• Increase in an immune response speciﬁ c to the relevant pathogen—eg, delayed-type hypersensitivity skin test response to 
mycobacterial antigens
• Spontaneous resolution of disease without speciﬁ c antimicrobial therapy or tumour chemotherapy with continuation of ART
General IRIS case deﬁ nition 2 (Shelburne et al, 2006)13
Criteria for IRIS diagnosis include:
• HIV-infected patient
• Receiving eﬀ ective ART as evidenced by a decrease in HIV-1 RNA concentration from baseline or an increase in CD4+ T cells from 
baseline (may lag behind HIV-1 RNA decrease)
• Clinical symptoms consistent with inﬂ ammatory process
• Clinical course not consistent with expected course of previously diagnosed opportunistic infection, expected course of newly 
diagnosed opportunistic infection, or drug toxicity
Case deﬁ nition speciﬁ c for tuberculosis-associated IRIS (Colebunders et al, 2006)7
For patients receiving treatment for tuberculosis and starting ART:
Suspected tuberculosis-associated IRIS case
Cases must meet the following three criteria:
• An initial clinical response to tuberculosis treatment, based on a combination of some of the following factors: cessation of 
fever, relief of pulmonary symptoms, decrease in lymph node size, termination of signs of meningeal irritation (depending on 
presenting symptoms)
• New persistent fevers without another identiﬁ able cause and/or one or more of the following: worsening or emergence of 
dyspnoea, stridor, an increase in lymph node size, development of abscesses, development of abdominal pain with ultrasound 
evidence of abdominal adenopathies, unexplained CNS symptoms
• Adequate adherence to ART and tuberculosis treatment
Conﬁ rmed tuberculosis-associated IRIS case
Cases must meet the following three criteria:
• Radiological examinations showing worsening or emergence of intrathoracic lymphadenopathy, pulmonary inﬁ ltrates, pleural 
eﬀ usions, abdominal lymph nodes, hepatosplenomegaly
• A good virological response and/or increase in CD4+ lymphocyte count, and/or conversion of tuberculin skin test from negative 
to positive, and/or adequate adherence to ART and tuberculosis treatment
• A clear exclusion of other conditions that could explain the clinical manifestations of the patient, such as tuberculosis treatment 
failure or other concomitant infections, tumours, or allergic reactions
ART=antiretroviral therapy. IRIS=immune reconstitution inﬂ ammatory syndrome.
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a writing committee of 17 members was appointed to 
ﬁ nalise the consensus case deﬁ nitions.
Changes to existing case deﬁ nitions
General case deﬁ nitions for IRIS have previously been 
published (panel 1).2,12–14 These case deﬁ nitions include 
the following criteria: conﬁ rmed HIV diagnosis, 
temporal association with initiation of ART, 
demonstration of response to ART (ie, plasma viral load 
reduction, blood CD4 cell count increase, or another 
marker of immune recovery such as conversion of 
tuberculin skin test from negative to positive for 
mycobacterial IRIS), clinical deterioration with an 
inﬂ ammatory process, and exclusion of other causes 
that could explain deterioration (such as antimicrobial 
drug resistance, drug hypersensitivity reaction, or 
another opportunistic infection). However, since 
manifestations of IRIS are infection-speciﬁ c, it has been 
recognised that particular deﬁ nitions applicable to 
individual diseases such as tuberculosis would be 
useful.7 The case deﬁ nitions presented in this manuscript 
focus speciﬁ cally on the clinical manifestations of 
tuberculosis-associated IRIS. 
Case deﬁ nitions should be readily applicable in 
resource-limited settings where the vast majority of 
patients requiring ART live and yet where facilities for 
diagnosis and management of the complications of ART 
are least well developed. In this respect, the requirement 
within existing deﬁ nitions for documentation of changes 
in CD4 cell count and plasma viral load is not achievable in 
these settings. Viral load testing has limited availability 
and is very costly. In the South African public sector a viral 
load test costs US$39, more than the cost of 1 month’s 
supply of ﬁ rst-line ART. Even where CD4 and viral load 
testing are available (such as in South Africa), use of these 
tests under programmatic conditions is usually permitted 
for monitoring of ART at 6-monthly intervals only and not 
for individual patient diagnostic work-up. 
We believe that omission of these laboratory parameters 
would not substantially compromise case deﬁ nitions for 
tuberculosis-associated IRIS. First, within the initial 
months of ART—when most cases of tuberculosis-
associated IRIS arise—most ART-naive patients adhering 
to tr atment have substantial viral load reductions;15–17 thus, 
inclusion of viral load changes in deﬁ nitions is largely 
redundant in the context of a patient who adheres to 
therapy. Second, tuberculosis-associated IRIS frequently 
develops shortly after initiation of ART and before any 
measurable increase in peripheral blood CD4 cell count. In 
a series of 51 patients presenting with non-tuberculous 
mycobacterial IRIS, six (12%) of 51 IRIS events occurred 
without a substantial increase in CD4 cell count (four 
patients had a CD4 increase from baseline to time of IRIS 
diagnosis of less than 25 cells per μL and in two patients 
the CD4 cell count had actually fallen at the time of 
presentation).18 The number of CD4 T cells measured in 
peripheral blood does not necessarily reﬂ ect function nor 
how many cells are actually present at the site of an 
opportunistic infection. Moreover, it is very likely that CD4 
T cells are not the only cellular mediators of IRIS.19,20 For 
these reasons we, like others,12 propose that a rise in 
peripheral blood CD4 cell count should not be a necessary 
marker for the diagnosis of tuberculosis-associated IRIS.
A further important modiﬁ cation to existing deﬁ nitions 
is the inclusion of a timeframe of the ﬁ rst 3 months of 
ART. Such a timeframe is not present in the widely used 
case deﬁ nitions to date (panel 1). Onset of the clinical 
manifestations of tuberculosis-associated IRIS should 
occur within this timeframe for a diagnosis of 
tuberculosis-associated IRIS to be made, since this 
represents the period when rapid immune recovery usually 
occurs.3,21
Categories of tuberculosis-associated IRIS
Tuberculosis-associated IRIS can present as one of two 
main syndromes: (1) a paradoxical reaction after the start 
of ART in patients receiving tuberculosis treatment (here 
termed paradoxical tuberculosis-associated IRIS), or (2) a 
new presentation of tuberculosis that is “unmasked” in the 
weeks following initiation of ART with an exaggerated 
A B
DC
Figure 1: Illustrative case of paradoxical tuberculosis-associated IRIS
A 36-year-old HIV-infected man was diagnosed with culture-positive pulmonary tuberculosis (sensitive to rifampicin 
and isoniazid) without evidence of extrapulmonary involvement. His CD4 count was 39 cells per μL and HIV-1 viral 
load 1 300 000 copies per mL. He commenced antiretroviral therapy (ART; stavudine, lamivudine, and efavirenz) 7 
weeks after initiating antituberculous therapy. 1 week later he presented with a recurrence of tuberculosis symptoms 
and cervical node enlargement. Paradoxical tuberculosis-associated IRIS was diagnosed. Over the next 18 months he 
presented with several tuberculosis-associated IRIS manifestations that sequentially emerged, despite corticosteroid 
therapy, then resolved. Photographs show development of massive cervical lymphadenitis (A), a chest wall cold 
abscess (B, arrows), and a massive right psoas abscess shown here on CT scan (C, arrow) from which over 2 L of pus 
was aspirated (D). Repeated mycobacterial cultures of aspirates from these collections have been negative. After 6 
months on ART his CD4 count was 181 cells per μL and viral load undetectable. After 12 months his CD4 count was 
448 cells per μL and viral load 35 copies per mL. This was an unusually prolonged course for paradoxical tuberculosis-
associated IRIS given that the median duration of symptoms is reported to be 2 months (see text).
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inﬂ ammatory clinical presentation or complicated by a 
paradoxical reaction (here termed unmasking tuberculosis-
associated IRIS).
Paradoxical tuberculosis-associated IRIS
In paradoxical tuberculosis-associated IRIS, patients have 
been diagnosed with active tuberculosis before initiation 
of ART, and have typically been responding to 
antituberculosis treatment. Following initiation of ART, 
IRIS presents as the development of recurrent, new, or 
worsening symptoms or signs of tuberculosis, such as 
fever, return of cough, or lymph node enlargement, or 
recurrent, new, or deteriorating radiological manifestations 
(ﬁ gure 1). These symptoms typically occur within the ﬁ rst 
few weeks and up to 3 months after ART is initiated, 
restarted, or changed because of treatment failure. 
Reports of the frequency of paradoxical 
tuberculosis-associated IRIS using a variety of existing 
case deﬁ nitions range from 8% to 43% (table).8–10,21–28 
Paradoxical tuberculosis-associated IRIS has been linked 
with large expansions of puriﬁ ed protein derivative-speciﬁ c 
T cells in peripheral blood and increased pro-inﬂ ammatory 
cytokine levels.29 Risk factors for the disease are shown in 
table 1 and include more advanced HIV disease with lower 
CD4 cell count, disseminated and extrapulmonary 
tuberculosis, a shorter delay between the start of 
tuberculosis treatment and initiation of ART, and a more 
vigorous immunological and virological response to ART. 
Most cases of paradoxical tuberculosis-associated IRIS are 
self-limiting. The median duration of symptoms reported 
in the literature is 2 months,26,28 but this ranges from mild 
cases where symptoms resolve after a few days to isolated 
prolonged cases that have still been symptomatic after 
more than a year (ﬁ gure 1).28 Mortality from tuberculosis-
Country Number of patients on 
tuberculosis treatment 
starting ART
Number of patients with 
paradoxical tuberculosis-
associated IRIS
Interval from 
initation of ART to 
IRIS presentation
Risk factors for tuberculosis-associated 
IRIS
Narita et al (1998)22 USA 33 12 (36%) Mean 15 days 
(SD 11 days)
Puriﬁ ed protein derivative conversion
Breen et al (2004)23 UK 28 8 (29%) Median 11 days 
(range 8–18 days)
Starting ART within 6 weeks of 
tuberculosis diagnosis
Breton et al 
(2004)24
France 37 16 (43%) Median 12 days 
(range 2–114 days)
Greater increase in CD4 percentage and 
CD4/CD8 ratio; disseminated tuberculosis
Kumarasamy et al 
(2004)8 
India 144 11 (8%) Median 42 days 
(range 10–89 days)
··
Shelburne et al 
(2005)†21
USA 86 26 (30%) Median 46 days 
(range 3–658 days)
Shorter interval to starting ART; more 
rapid initial fall in viral load
Michailidis et al 
(2005)‡25
UK 28 9 (32%) Median 0·6 months 
(IQR 0·1–9·1 months)
Lower baseline CD4 cell count; 
disseminated tuberculosis; greater CD4 
rise on ART 
Manosuthi et al 
(2006)9
Thailand 167 21 (13%) Median 32 days 
(IQR 14–115 days)
Extrapulmonary tuberculosis
Lawn et al (2007)10 South
Africa
160 19 (12%) Median 2 weeks 
(IQR 1·5–3·5 weeks)
Lower baseline CD4 cell count; shorter 
interval to starting ART
Burman et al 
(2007)26
USA 109 19 (17%) Median 34 days 
(IQR 8–97 days)
Black ethnic origin; shorter interval to 
starting ART; extrapulmonary tuberculosis
··=not reported. ART=antiretroviral therapy. IRIS=immune reconstitution inﬂ ammatory syndrome. *Only studies where more than eight patients with paradoxical tuberculosis-
associated IRIS were reported are included. This table is an updated version of a previously published table.27 Studies are presented in chronological order. †The authors reported 
57 cases of tuberculosis, Mycobacterium avium complex, and cryptococcal IRIS (26 of 57 were tuberculosis-associated IRIS). Five of these 57 patients started ART before the 
opportunistic infection was diagnosed, and were thus not paradoxical IRIS cases. The data shown regarding risk factors and median interval relate to all 57 patients. 
‡14 tuberculosis-associated IRIS cases were reported. Nine of these were paradoxical tuberculosis-associated IRIS cases. Data shown regarding risk factors relate to all 14 cases.
Table: Paradoxical tuberculosis-associated IRIS: cohort studies reported in the literature*
A B
Figure 2: Illustrative case of unmasking tuberculosis-associated IRIS
A 48-year-old HIV-infected man with a CD4 count of 10 cells per μL presented with low-grade fevers, retrosternal 
chest pain, and a dry cough. Examination was non-contributory. He could not produce sputum and his chest 
radiograph showed no features of active tuberculosis (A). No other investigations for tuberculosis were available in 
this resource-limited setting (Uganda). Antiretroviral therapy (ART) was started (zidovudine, lamivudine, and 
efavirenz). 10 days later he returned acutely unwell with a productive cough. His temperature was 38·7°C and he 
was in respiratory distress. Chest radiograph now showed left mid-zone consolidation (B) and his sputum was 
positive for acid-fast bacilli. The unusual rapidity and clinical severity of his tuberculosis presentation was attributed 
to unmasking tuberculosis-associated IRIS. He responded well to continued ART and tuberculosis treatment. 
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associated IRIS has been reported infrequently in the 
literature,3,9,10,26 but morbidity and the need for hospital 
admission and therapeutic procedures can be substantial.26 
Rates of morbidity and mortality attributable to paradoxical 
tuberculosis-associated IRIS may be higher in 
resource-limited settings where diagnostic and treatment 
options are restricted. Neurological tuberculosis-associated 
IRIS in particular can be associated with poor outcome. 
Tuberculosis paradoxical reactions, such as enlargement 
of lymph nodes or cerebral tuberculomas, can also occur 
in HIV-uninfected individuals and HIV-infected 
individuals who are receiving appropriate tuberculosis 
treatment but who are not receiving ART;30–32 however, 
the frequency of paradoxical reactions is much lower in 
these groups compared with patients receiving ART.22,23 
In one study, paradoxical reactions following tuberculosis 
treatment occurred in one (2%) of 55 HIV-seronegative 
patients, two (7%) of 28 HIV-infected patients not on 
ART, and 12 (36%) of 33 HIV-infected patients on 
tuberculosis treatment and ART.22 The timing of the 
paradoxical reaction in the latter group was more closely 
related to the initiation of ART than it was to the initiation 
Tuberculosis diagnosed 
and treatment started 
before ART initiation
Not on tuberculosis 
treatment when ART 
is initiated
Paradoxical reaction 
within 3 months
ART initiated
Active tuberculosis 
diagnosed on ART
ART-associated tuberculosis 
(a subset of these patients 
could have unmasking 
tuberculosis-associated IRIS)
Paradoxical 
tuberculosis-associated 
IRIS
Tuberculosis treatment status Outcome Case deﬁnition
Figure 3: Schematic representation showing the diﬀ erent forms of tuberculosis-associated IRIS and 
ART-associated tuberculosis
ART=antiretroviral therapy.
Panel 2: Case deﬁ nition for paradoxical tuberculosis-associated IRIS
There are three components to this case deﬁ nition:
(A) Antecedent requirements
Both of the two following requirements must be met:
• Diagnosis of tuberculosis: the tuberculosis diagnosis was made before starting ART and this should fulﬁ l WHO criteria for diagnosis 
of smear-positive pulmonary tuberculosis, smear-negative pulmonary tuberculosis, or extrapulmonary tuberculosis44 
• Initial response to tuberculosis treatment: the patient’s condition should have stabilised or improved on appropriate 
tuberculosis treatment before ART initiation—eg, cessation of night sweats, fevers, cough, weight loss. (Note: this does not 
apply to patients starting ART within 2 weeks of starting tuberculosis treatment since insuﬃ  cient time may have elapsed for a 
clinical response to be reported)
(B) Clinical criteria
The onset of tuberculosis-associated IRIS manifestations should be within 3 months of ART initiation, reinitiation, or regimen 
change because of treatment failure.
Of the following, at least one major criterion or two minor clinical criteria are required:
Major criteria 
• New or enlarging lymph nodes, cold abscesses, or other focal tissue involvement—eg, tuberculous arthritis
• New or worsening radiological features of tuberculosis (found by chest radiography, abdominal ultrasonography, CT, or MRI)
• New or worsening CNS tuberculosis (meningitis or focal neurological deﬁ cit—eg, caused by tuberculoma)
• New or worsening serositis (pleural eﬀ usion, ascites, or pericardial eﬀ usion)
Minor criteria
• New or worsening constitutional symptoms such as fever, night sweats, or weight loss
• New or worsening respiratory symptoms such as cough, dyspnoea, or stridor
• New or worsening abdominal pain accompanied by peritonitis, hepatomegaly, splenomegaly, or abdominal adenopathy
(C) Alternative explanations for clinical deterioration must be excluded if possible*
• Failure of tuberculosis treatment because of tuberculosis drug resistance
• Poor adherence to tuberculosis treatment
• Another opportunistic infection or neoplasm (it is particularly important to exclude an alternative diagnosis in patients with 
smear-negative pulmonary tuberculosis and extrapulmonary tuberculosis where the initial tuberculosis diagnosis has not been 
microbiologically conﬁ rmed)
• Drug toxicity or reaction
ART=antiretroviral therapy. IRIS=immune reconstitution inﬂ ammatory syndrome. *It might be diﬃ  cult or impossible in resource-poor settings to conﬁ rm tuberculosis drug resistance and 
to exclude certain other infections or neoplasia. Cases where alternative diagnoses cannot be fully excluded because of limited diagnostic capacity should be regarded as “probable 
paradoxical tuberculosis-associated IRIS”. In these probable cases, should resolution of clinical or radiological ﬁ ndings of the suspected IRIS episode occur without a change in tuberculosis 
treatment or ART having been made, they could then be reclassiﬁ ed as ”paradoxical tuberculosis-associated IRIS” cases.
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of tuberculosis treatment. Thus, the greatly increased 
frequency of paradoxical reactions in patients receiving 
ART suggests that ART-related immunological changes 
have an important role in their aetiology. Additionally, 
our clinical experience is that paradoxical tuberculosis-
associated IRIS is more severe and more frequently a 
multisystemic condition in ART patients than paradoxical 
reactions in patients not receiving ART. 
ART-associated tuberculosis and unmasking 
tuberculosis-associated IRIS
Compared with paradoxical tuberculosis-associated IRIS, 
there is much less clarity surrounding the second major 
category of tuberculosis-associated-IRIS. High rates of 
tuberculosis have been diagnosed during ART, especially 
in the initial months of treatment in ART programmes in 
resource-limited settings.6,33–36 The mechanisms underlying 
the presentation of tuberculosis after the initiation of ART 
are likely to be heterogeneous.37 Since ART-induced 
immune recovery is a time-dependent process and some 
patients initially fail to show an increased circulating CD4 
T-cell count,38,39 a proportion of cases might present as a 
result of persisting immunodeﬁ ciency. Diagnoses of active 
tuberculosis before ART initiation might be missed 
because of the inherent insensitivity of tuberculosis 
diagnostics in patients with advanced immunodeﬁ ciency 
and only conﬁ rmed later during ART. Other patients 
might have active subclinical disease at the time of ART 
initiation and presentation of symptomatic disease might 
result from ART-induced restoration of an immune 
response against Mycobacterium tuberculosis antigens that 
causes inﬂ ammation. Some patients with a missed 
tuberculosis diagnosis or active subclinical tuberculosis at 
the time of ART initiation may later present with exuberant 
inﬂ ammatory clinical features that are consistent with a 
diagnosis of unmasking tuberculosis-associated IRIS 
(ﬁ gure 2). 
Paradoxical reactions in patients started on tuberculosis 
treatment while receiving ART have also been described,26,40 
and one study reported that paradoxical reactions are more 
frequent in patients who are diagnosed with tuberculosis 
in the ﬁ rst 3 months of ART than in patients who start 
ART after tuberculosis treatment (eight [62%] of 13 patients 
vs nine [30%] of 30 patients, respectively, p=0·05).40 This 
ﬁ nding suggests that ART-related immunological changes 
have a role in the development of paradoxical reactions in 
patients who present with tuberculosis while receiving 
ART and that these reactions are a form of 
tuberculosis-associated IRIS. 
Only a few cases of unmasking tuberculosis-associated 
IRIS have been described in the literature to date.40–43 In the 
absence of a diagnostic test, it is currently diﬃ  cult to 
diﬀ erentiate the varied mechanisms underlying most 
cases of tuberculosis that present during early ART, 
especially in resource-limited settings where rates of 
infection are high. We therefore propose that, as 
elsewhere,37 the term ART-associated tuberculosis is used 
to refer to all patients who present with active tuberculosis 
while receiving ART (ﬁ gure 3). We also suggest a 
provisional case deﬁ nition for unmasking tuberculosis-
associated IRIS and clinical scenarios where the diagnosis 
could be considered. 
Further research into the clinical characteristics and 
immunological mechanisms underlying cases of 
ART-associated tuberculosis will permit a more reﬁ ned 
case deﬁ nition for unmasking tuberculosis-associated 
IRIS in the future. However, in view of the heterogeneity 
in the natural history and clinical manifestations of 
tuberculosis it is unlikely that a clinical case deﬁ nition that 
robustly separates patients with unmasking 
tuberculosis-associated IRIS from others with 
ART-associated tuberculosis will be derived.37 
Case deﬁ nitions
With the rationale described above, we have developed case 
deﬁ nitions for “paradoxical tuberculosis-associated IRIS” 
(panel 2), “ART-associated tuberculosis” (panel 3), and 
“unmasking tuberculosis-associated-IRIS” (panel 3). The 
case deﬁ nitions are presented schematically in ﬁ gure 3. 
These case deﬁ nitions have been designed for use in 
resource-limited settings and are consensus case 
deﬁ nitions that need validation in clinical practice. 
Panel 3: Case deﬁ nition for ART-associated tuberculosis and provisional case 
deﬁ nition for unmasking tuberculosis-associated IRIS
ART-associated tuberculosis
We propose that ART-associated tuberculosis (all cases of tuberculosis that are diagnosed 
during ART) should be deﬁ ned as follows:
• Patient is not receiving treatment for tuberculosis when ART is initiated
• Active tuberculosis is diagnosed after initiation of ART
• The diagnosis of tuberculosis should fulﬁ l WHO criteria for smear-positive pulmonary 
tuberculosis, smear-negative pulmonary tuberculosis, or extrapulmonary 
tuberculosis44  
Unmasking tuberculosis-associated IRIS (provisional)
We propose that the following could suggest a diagnosis of unmasking tuberculosis-
associated IRIS:
• Patient is not receiving treatment for tuberculosis when ART is initiated and then 
presents with active tuberculosis within 3 months of starting ART
AND one of the following criteria must be met:
• Heightened intensity of clinical manifestations, particularly if there is evidence of a 
marked inﬂ ammatory component to the presentation. Examples include tuberculosis 
lymphadenitis or tuberculosis abscesses with prominent acute inﬂ ammatory features, 
presentation with pulmonary tuberculosis that is complicated by respiratory failure 
due to adult respiratory distress syndrome, and those who present with a marked 
systemic inﬂ ammatory syndrome related to tuberculosis. See example in ﬁ gure 2
• Once established on tuberculosis treatment, a clinical course that is complicated by a 
paradoxical reaction
ART=antiretroviral therapy. IRIS=immune reconstitution inﬂ ammatory syndrome. Researchers in the ﬁ eld are encouraged not 
to regard all patients with ART-associated tuberculosis as having tuberculosis-associated IRIS, but only those that ﬁ t this 
provisional unmasking tuberculosis-associated-IRIS case deﬁ nition. We suggest that the clinical manifestations of all patients 
developing ART-associated tuberculosis should be well characterised and reported in studies, which will assist with reﬁ nement 
of this case deﬁ nition in the future. Studies of the immunological processes underlying the presentation of these cases are also 
likely to assist with reﬁ ning this case deﬁ nition. 
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Conclusions
The use of standardised case deﬁ nitions in diﬀ erent 
populations will help to provide greater insight into the 
incidence, clinical manifestations, risk factors, and impact 
of tuberculosis-associated IRIS, ultimately leading to better 
prevention and management strategies for this condition. 
Further clinical and immunological research on patients 
with ART-associated tuberculosis is needed to better 
diﬀ erentiate the subset of cases that have unmasking 
tuberculosis-associated IRIS and to further reﬁ ne this case 
deﬁ nition. It is hoped that open research networks such as 
INSHI will provide opportunities for researchers to engage 
in collaborative research into tuberculosis-associated IRIS 
using these case deﬁ nitions. 
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest. 
Acknowledgments
This manuscript arose from a meeting of the International Network for 
the Study of HIV-associated IRIS (INSHI) hosted by the Infectious 
Diseases Institute, Makerere University, Kampala, Uganda. This meeting 
was funded by the European and Developing Countries Clinical Trials 
Partnership Programme, the Belgian General Development Corporation, 
the Research Foundation-Flanders, and Tibotec. Graeme Meintjes, 
Stephen D Lawn, and Robert J Wilkinson are funded by the Wellcome 
Trust, UK. Martyn French is supported by the National Health and Medical 
Research Council, Australia. We thank Dominique J Pepper for assistance 
with preparing the illustrative case in ﬁ gure 1 and Charles Steinberg for 
providing the radiographs in ﬁ gure 2.
The following participants attended the INSHI meeting: Francis Adatu 
(National TB Control Programme, Kampala, Uganda), Rebecca Adlington 
(Médecins Sans Frontières, Bukavu, Democratic Republic of the Congo), 
Barbara Amuron (MRC/Uganda Virus Research Institute, Entebbe, 
Uganda), Per Bjorkman (Lund University, Malmoe, Sweden), Paul Bohjanen 
(University of Minnesota, Minneapolis, MN, USA), David Boulware 
(University of Minnesota, Minneapolis, MN, USA), Steven Callens (Catholic 
University Leuven, Leuven, Belgium), Mariah Carroll (University of 
Minnesota, Minneapolis, MN, USA), Barbara Castelnuovo (Infectious 
Disease Institute, Kampala, Uganda), Robert Colebunders (Institute Tropical 
Medicine and University of Antwerp, Antwerp, Belgium), 
Caroline De Schacht (Elizabeth Glaser Pediatric AIDS Foundation, Maputo, 
Mozambique), Aggrey Dhabangi (Paediatric Infectious Disease Institute, 
Kampala, Uganda), Philippa Easterbrook (Kings College, London, UK), 
Alison Elliot (MRC/Uganda Virus Research Institute, Entebbe, Uganda), 
Julian Elliott (National Centre in HIV Epidemiology and Clinical Research, 
Sydney, Australia), Joseph Emoko (WHO/NTLP, Kampala, Uganda), 
Martyn French (University of Western Australia, Perth, Australia), 
Charles Gilks (WHO, Geneva, Switzerland), Lewis Haddow (University of 
KwaZulu-Natal, Durban, South Africa), David Iglesias (Instituto de 
Medicina Tropical Alexander von Humboldt, Universidad Peruana 
Cayetano Heredia, Lima, Peru), Edward Janoﬀ  (University of Colorado, 
CO, USA), Laurence John (Chelsea and Westminster Hospital, London, 
UK), Andrew Kambugu (Infectious Disease Institute, Kampala, Uganda), 
Moses R Kamya (Makerere University, Kampala, Uganda), 
Addy Kekitiinwa (Paediatric Infectious Disease Institute, Makerere 
University, Kampala, Uganda), Luc Kestens (Institute Tropical Medicine, 
Antwerp, Belgium), Hannah Kibuuka (Makerere University/Walter Reed 
Project, Kampala, Uganda), Bruce Kirenga (Makerere University, Kampala, 
Uganda), Sabrina Kitaka (Paediatric Infectious Disease Institute, Makerere 
University, Kampala, Uganda), Oliver Koole (Institute Tropical Medicine, 
Antwerp, Belgium), David Lalloo (Liverpool School of Tropical Medicine, 
Liverpool, UK), Stephen Lawn (University of Cape Town, Cape Town, 
South Africa), Jonathan Levin (MRC/Uganda Virus Research Institute, 
Entebbe, Uganda), Nathalie Lorent (Kigali University Hospital, Kigali, 
Rwanda), Swaibu Lule (MRC/Uganda Virus Research Institute Entebbe, 
Uganda), Jim Reeves Lutagira (MRC/Uganda Virus Research Institute, 
Entebbe, Uganda), Simon Luzige (Makerere University, Kampala, 
Uganda), Henry Luzze (Mulago Hospital, Kampala, Uganda), Lut Lynen 
(Institute Tropical Medicine, Antwerp, Belgium), Yukari Manabe (Johns 
Hopkins, Baltimore, MD, USA), Harriet Mayanja-Kizza (Makerere 
University, Kampala, Uganda), Enid Mbabazi (Makerere University, 
Kampala, Uganda), Keith McAdam (Infectious Disease Institute, Kampala, 
Uganda), David McNeeley (Tibotec, Durham, NC, USA), Graeme Meintjes 
(University of Cape Town, Cape Town, South Africa), Joris Menten 
(Institute Tropical Medicine, Antwerp, Belgium), David Meya (Infectious 
Disease Institute, Kampala, Uganda), Giampaolo Mezzabotta (WHO, 
Kabul, Afganistan), Monica Millard (Makerere University/Walter Reed 
Project Kampala, Uganda), Lisa Mills (Johns Hopkins, Baltimore, MD, 
USA), Juliet Mpendo (MRC/Uganda Virus Research Institute, Entebbe, 
Uganda), Paula Munderi (MRC/Uganda Virus Research Institute, Entebbe, 
Uganda), David Murdoch (University of North Carolina, Durham, NC, 
USA), David Muyanja (Makerere University, Kampala, Uganda), 
Sylvia Muyingo (MRC/Uganda Virus Research Institute Entebbe, Uganda), 
Denis Mwaka (Makerere University, Kampala, Uganda), Doris Mwesigire 
(Mulago-Mbarara Hospitals Joint Aids Programme, Kampala, Uganda), 
Damalie Nakanjako (Infectious Disease Institute, Kampala, Uganda), 
Ann Nakanwagi (Makerere University, Kampala, Uganda), Leatitia Namale 
(Makerere University, Kampala, Uganda), Edith Namulema (Makerere 
University, Kampala, Uganda), Francis Okidi (Gulu, Uganda), Martin Okot 
Nwang (Mulago Hospital, Kampala, Uganda), Alphonse Okwera (Mulago 
Hospital, Kampala, Uganda), Pascale Ondoa (Institute Tropical Medicine, 
Antwerp, Belgium), Eric Ouattara (Programme PAC-CI, Abidjan, Côte 
d’Ivoire), Nadine Pakker (Project Interact, Kampala, Uganda), 
Rosalind Parkes (MRC/Uganda Virus Research Institute, Masaka, 
Uganda), Dylan Pillai (University of California, San Francisco, CA, USA), 
Molebogeng Rangaka (University of Cape Town, Cape Town, South Africa), 
Peter Reiss (Academic Medical Center, Amsterdam, Netherlands), 
Steven Reynolds (SAIC Frederick, MD, USA), Fabio Scano (WHO, Geneva, 
Switzerland), Kinda Schepers (Free University Brussels, Brussels, 
Belgium), Maarten Schim van der Loeﬀ  (Academic Medical Center, 
Amsterdam, Netherlands), Walter Schlech (Dalhousie University, Halifax, 
Canada), Paul Seguya (Kampala, Uganda), Semitala Fred (Mulago 
Hospital, Kampala, Uganda), Ibrahim Sendagire (Kampala City Council 
AIDS Programme, Kampala, Uganda), Cathérine Seyler (University of 
Bordeaux, Bordeaux, France), Patrick Soentjens (Institute Tropical 
Medicine, Antwerp, Belgium), Sok Thim (Cambodian Health Committee, 
Phnom Penh, Cambodia), Fred Sewankambo (Infectious Disease Institute, 
Kampala, Uganda), Judy Tatwangire (Paediatric Infectious Disease 
Institute, Kampala, Uganda), Jim Todd (MRC/Uganda Virus Research 
Institute, Entebbe, Uganda), Estée Torok (Oxford University, Oxford, UK), 
Nathan Tumwesigye (Regional Centre for Quality Care, Kampala, Uganda), 
Lisine Tuyisinge (University Hospital, Kigali, Rwanda), 
Rafael Van den Bergh (Free University Brussels, Brussels, Belgium), 
Dimitri Van der Linden (Pietermaritzburg Metropolitan Hospitals 
Complex, Pietermaritzburg, South Africa), Lieve Vanderpaal (MRC/
Uganda Virus Research Institute, Masaka, Uganda), Musa Waiswa 
(Makerere University, Kampala, Uganda), Robert Wilkinson (University of 
Cape Town, Cape Town, South Africa), Eric Wobudeya (Makerere 
University, Kampala, Uganda), William Worodria (Mulago Hospital, 
Kampala, Uganda), Samuel Yoo (Mulago Hospital, Kampala, Uganda), 
Rony Zachariah (Médecins Sans Frontières, Brussels, Belgium).
References
1 Shelburne SA, Hamill RJ. The immune reconstitution inﬂ ammatory 
syndrome. AIDS Rev 2003; 5: 67–79.
Search strategy and selection criteria
Data for this Personal View were obtained by searching 
Medline for articles published from 1990 to 2008. Search 
terms included “immune reconstitution”, “immune 
restoration”, “immune recovery”, “IRIS”, “antiretroviral”, 
“tuberculosis”, and “paradoxical reaction”. Only English 
language papers were reviewed. Additionally, unpublished 
data and tuberculosis-associated IRIS case deﬁ nitions 
presented by researchers at the INSHI meeting were used.
91
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
www.thelancet.com/infection   Vol 8   August 2008 523
Personal View
2 French MA, Price P, Stone SF. Immune restoration disease after 
antiretroviral therapy. AIDS 2004; 18: 1615–27.
3 Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease 
associated with mycobacterial infections in HIV-infected individuals 
receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361–73.
4 Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in 
resource-limited settings: successes and challenges. AIDS 2007; 
21 (suppl 4): S5–10.
5 Corbett EL, Watt CJ, Walker N, et al. The growing burden of 
tuberculosis: global trends and interactions with the HIV epidemic. 
Arch Intern Med 2003; 163: 1009–21.
6 Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an 
antiretroviral treatment programme in sub-Saharan Africa: impact on 
treatment outcomes and implications for tuberculosis control. AIDS 
2006; 20: 1605–12.
7 Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L. 
Tuberculosis immune reconstitution inﬂ ammatory syndrome in 
countries with limited resources. Int J Tuberc Lung Dis 2006; 
10: 946–53.
8 Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune 
reconstitution syndrome in HIV/tuberculosis-coinfected patients after 
initiation of generic antiretroviral therapy in India. J Acquir Immune 
Deﬁ c Syndr 2004; 37: 1574–76.
9 Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. 
Immune reconstitution inﬂ ammatory syndrome of tuberculosis 
among HIV-infected patients receiving antituberculous and 
antiretroviral therapy. J Infect 2006; 53: 357–63.
10 Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated 
immune reconstitution disease: incidence, risk factors and impact in 
an antiretroviral treatment service in South Africa. AIDS 2007; 
21: 335–41.
11 WHO. TB/HIV research priorities in resource-limited settings. 
Report of an expert consultation. Geneva, Switzerland: World Health 
Organization, February 14–15, 2005.
12 Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune 
reconstitution syndrome in HIV: validating a case deﬁ nition and 
identifying clinical predictors in persons initiating antiretroviral 
therapy. Clin Infect Dis 2006; 42: 1639–46.
13 Shelburne SA, Montes M, Hamill RJ. Immune reconstitution 
inﬂ ammatory syndrome: more answers, more questions. 
J Antimicrob Chemother 2006; 57: 167–70.
14 Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune 
reconstitution inﬂ ammatory syndrome: emergence of a unique 
syndrome during highly active antiretroviral therapy. 
Medicine (Baltimore) 2002; 81: 213–27.
15 Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of 
providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 
2004; 18: 887–95.
16 Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC. Immunological 
and virological responses to highly active antiretroviral therapy in a 
non-clinical trial setting in a developing Caribbean country. HIV Med 
2006; 7: 99–104.
17 Orrell C, Harling G, Lawn SD, et al. Conservation of ﬁ rst-line 
antiretroviral treatment regimen where therapeutic options are 
limited. Antivir Ther 2007; 12: 83–88.
18 Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial 
immune reconstitution syndrome in HIV-infected patients: spectrum 
of disease and long-term follow-up. Clin Infect Dis 2005; 41: 1483–97.
19 Van den Bergh R, Vanham G, Raes G, De Baetselier P, 
Colebunders R. Mycobacterium-associated immune reconstitution 
disease: macrophages running wild? Lancet Infect Dis 2006; 6: 2–3.
20 Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune 
reconstitution inﬂ ammatory syndrome in HIV-infected patients 
receiving antiretroviral therapy: pathogenesis, clinical manifestations 
and management. Drugs 2008; 68: 191–208.
21 Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk 
factors for immune reconstitution inﬂ ammatory syndrome during 
highly active antiretroviral therapy. AIDS 2005; 19: 399–406.
22 Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical 
worsening of tuberculosis following antiretroviral therapy in patients 
with AIDS. Am J Respir Crit Care Med 1998; 158: 157–61.
23 Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during 
tuberculosis treatment in patients with and without HIV co-infection. 
Thorax 2004; 59: 704–07.
24 Breton G, Duval X, Estellat C, et al. Determinants of immune 
reconstitution inﬂ ammatory syndrome in HIV type 1-infected 
patients with tuberculosis after initiation of antiretroviral therapy. 
Clin Infect Dis 2004; 39: 1709–12.
25 Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, 
Gazzard BG. Clinical characteristics of IRIS syndrome in patients 
with HIV and tuberculosis. Antivir Ther 2005; 10: 417–22.
26 Burman W, Weis S, Vernon A, et al. Frequency, severity and duration 
of immune reconstitution events in HIV-related tuberculosis. 
Int J Tuberc Lung Dis 2007; 11: 1282–89.
27 McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of 
antiretroviral therapy in patients with tuberculosis: drug interactions, 
toxicity, and immune reconstitution inﬂ ammatory syndrome. 
J Infect Dis 2007; 196 (suppl 1): S63–75.
28 Olalla J, Pulido F, Rubio R, et al. Paradoxical responses in a cohort of 
HIV-1-infected patients with mycobacterial disease. 
Int J Tuberc Lung Dis 2002; 6: 71–75.
29 Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-
speciﬁ c Th1-responses induces immune restoration syndrome in 
tuberculosis and HIV co-infected patients. AIDS 2006; 20: F1–7.
30 Hawkey CR, Yap T, Pereira J, et al. Characterization and management 
of paradoxical upgrading reactions in HIV-uninfected patients with 
lymph node tuberculosis. Clin Infect Dis 2005; 40: 1368–71.
31 Cheng VC, Yam WC, Woo PC, et al. Risk factors for development of 
paradoxical response during antituberculosis therapy in HIV-negative 
patients. Eur J Clin Microbiol Infect Dis 2003; 22: 597–602.
32 Reiser M, Fatkenheuer G, Diehl V. Paradoxical expansion of 
intracranial tuberculomas during chemotherapy. J Infect 1997; 
35: 88–90.
33 Bonnet MM, Pinoges LL, Varaine FF, et al. Tuberculosis after HAART 
initiation in HIV-positive patients from ﬁ ve countries with a high 
tuberculosis burden. AIDS 2006; 20: 1275–79.
34 Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected 
patients receiving HAART: long term incidence and risk factors in 
a South African cohort. AIDS 2005; 19: 2109–16.
35 Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk 
factors for active tuberculosis after antiretroviral treatment initiation 
in Abidjan. Am J Respir Crit Care Med 2005; 172: 123–27.
36 Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and 
mortality associated with tuberculosis in HIV-infected patients 
initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21: 713–19.
37 Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune 
reconstitution and “unmasking” of tuberculosis during antiretroviral 
therapy. Am J Respir Crit Care Med 2008; 177: 680–85.
38 Moore DM, Hogg RS, Yip B, et al. Discordant immunologic and 
virologic responses to highly active antiretroviral therapy are 
associated with increased mortality and poor adherence to therapy. 
J Acquir Immune Deﬁ c Syndr 2005; 40: 288–93.
39 Kaplan SS, Ferrari G, Wrin T, et al. Longitudinal assessment of 
immune response and viral characteristics in HIV-infected 
patients with prolonged CD4(+)/viral load discordance. 
AIDS Res Hum Retroviruses 2005; 21: 13–16.
40 Breen RA, Smith CJ, Cropley I, Johnson MA, Lipman MC. Does 
immune reconstitution syndrome promote active tuberculosis in 
patients receiving highly active antiretroviral therapy? AIDS 2005; 
19: 1201–06.
41 Goldsack NR, Allen S, Lipman MC. Adult respiratory distress 
syndrome as a severe immune reconstitution disease following 
the commencement of highly active antiretroviral therapy. 
Sex Transm Infect 2003; 79: 337–38.
42 John L, Baalwa J, Kalimugogo P, et al. Response to “does immune 
reconstitution promote active tuberculosis in patients receiving highly 
active antiretroviral therapy?” AIDS 2005; 19: 2049–50.
43 Dautremer J, Pacanowski J, Girard PM, Lalande V, Sivignon F, 
Meynard JL. A new presentation of immune reconstitution 
inﬂ ammatory syndrome followed by a severe paradoxical reaction in 
an HIV-1-infected patient with tuberculous meningitis. AIDS 2007; 
21: 381–82.
44 WHO. Improving the diagnosis and treatment of smear-negative 
pulmonary and extrapulmonary tuberculosis among adults and 
adolescents: recommendations for HIV-prevalent and 
resource-constrained settings. Geneva: Stop TB Department, 
Department of HIV/AIDS, World Health Organization, 2006.
92
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 4 
 
Novel relationship between tuberculosis immune reconstitution inflammatory syndrome 
and antitubercular drug resistance 
  
93
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
94
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
HIV/AIDS • CID 2009:48 (1 March) • 667
H I V / A I D SM A J O R A R T I C L E
Novel Relationship between Tuberculosis Immune
Reconstitution Inflammatory Syndrome and
Antitubercular Drug Resistance
Graeme Meintjes,1,2,5 Molebogeng X. Rangaka,1 Gary Maartens,1,2,3 Kevin Rebe,2,5 Chelsea Morroni,4
Dominique J. Pepper,1,5 Katalin A. Wilkinson,1,6 and Robert J. Wilkinson1,2,5,6,7
1Institute of Infectious Diseases and Molecular Medicine, 2Department of Medicine, 3Division of Clinical Pharmacology, and 4Women’s Health
Research Unit, School of Public Health and Family Medicine, University of Cape Town, and 5Infectious Diseases Unit, GF Jooste Hospital, Cape
Town, South Africa; and 6National Institute for Medical Research, Mill Hill, and 7Division of Medicine, Wright Fleming Institute, Imperial College
London, United Kingdom
(See the editorial commentary by Friedland on pages 677–9)
Background. Tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS) is emerging as an
important early complication of combination antiretroviral therapy in patients with TB in developing countries.
The differential diagnosis of TB IRIS includes deterioration caused by other human immunodeficiency virus–
related morbidities and drug-resistant TB.
Methods. We prospectively evaluated consecutive patients with suspected TB IRIS from February 2005 through
July 2006 at a community-based secondary hospital in Cape Town, South Africa, by means of clinical case definitions
for TB IRIS. Specimens were sent for TB culture and susceptibility testing, and a rapid test (FASTplaque-Response)
was performed to expedite determination of rifampin susceptibility.
Results. One hundred patients with suspected TB IRIS were evaluated, 26 of whom were being retreated for
TB. IRIS symptoms developed a median of 14 days (interquartile range, 7–25 days) after the initiation of com-
bination antiretroviral therapy. In 7 patients, an alternative opportunistic disease was diagnosed. Rifampin-resistant
TB was present in 13 patients, 9 of whom received a diagnosis after study entry (7 of 9 had multidrug-resistant
TB). Undiagnosed rifampin-resistant TB was thus present in 10.1% of patients (95% confidence interval, 3.9%–
16.4%) who presented with TB IRIS, once those with alternative diagnoses and TB with known rifampin resistance
were excluded. In the remaining 80 patients, TB IRIS without rifampin resistance was the final diagnosis.
Conclusions. TB IRIS that is clinically indistinguishable from TB IRIS that occurs in the context of drug-
susceptible disease may occur in patients with undiagnosed multidrug-resistant TB. Antitubercular drug resistance
should be excluded in all cases of suspected TB IRIS, and corticosteroids should be used with caution for patients
with presumed TB IRIS until the result of drug-susceptibility testing is known.
The scale-up of combination antiretroviral therapy
(cART) in the developing world is progressing rapidly,
improving survival among HIV-infected persons [1, 2].
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An emerging complication of cART in countries with
high rates of tuberculosis (TB) is TB immune recon-
stitution inflammatory syndrome (IRIS). “Paradoxical”
TB IRIS manifests with new, worsening, or recurrent
symptoms, signs, and/or radiological manifestations of
TB after cART is initiated in patients receiving treat-
ment for TB [3]. It occurs in 8%–43% of patients who
initiate cART while receiving TB treatment [4–11] and
is associated with exuberant antimycobacterial immune
responses [12]. There is no diagnostic test for TB IRIS,
and the differential diagnosis is wide, including failure
of TB treatment attributable to antimicrobial resistance,
or suboptimal antitubercular drug concentrations [13],
drug reactions, or an alternative opportunistic condi-
tion. Published case definitions require that these be
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Table 1. Case definitions for tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS).
Criteria that must be met for the diagnosis of TB IRIS before the initiation of cART
Microbiologic, histologic, or very strong clinical evidence of TB
Initial improvement of 1 of the following during multidrug TB treatment: symptoms, Karnofsky
score, weight, fever, clinical signs, or radiographic findings
The infecting strain of Mycobacterium tuberculosis is susceptible to rifampin (if this result is available)
The patient was receiving antitubercular therapy when cART was initiated
Criteria that must be met for the diagnosis of TB IRIS within 3 months after the initiation of cART
New or recurrent TB-related symptoms and/or
New or worsening TB manifestations, such as 1 of the following:
New or expanding lymph nodes
New or expanding tuberculous cold abscesses
New or expanding intracranial tuberculomas
New or expanding pulmonary infiltrates (radiographically confirmed)
New or recurrent tuberculous meningitis (after exclusion of bacteria and fungi)
New or enlarging serous effusions (pericardial, pleural, or ascitic; radiographically confirmed)
New or worsening granulomatous hepatitis
New or worsening granulomatous infiltration of bone marrow
Other new or worsening tuberculous lesions
No other opportunistic disease to explain the new or recurrent symptoms and/or ne or worsening
TB manifestations
excluded before a diagnosis of TB IRIS is made [14, 15]. TB
IRIS can be severe and life-threatening, and there are anecdotal
reports that suggest the use of adjunctive corticosteroid therapy
[16, 17].
Concurrent with the increase in the prevalence of TB IRIS,
the emergence of multidrug-resistant (MDR) and extensively
drug resistant TB in settings in Southern Africa where HIV
infection is prevalent has recently been highlighted [18, 19].
Determining the cause of deterioration in patients with TB
during cART in resource-limited settings is important, because
adjunctive corticosteroid therapy may worsen an already im-
munosuppressed patient’s condition if used in the presence of
incompletely efficacious TB treatment or other opportunistic
infections. This study prospectively evaluated clinical case def-
initions of TB IRIS among 100 patients who were considered
to have likely cases of TB IRIS. We found a high prevalence of
unsuspected drug-resistant TB in this cohort, which has im-
portant implications for the diagnosis and management of this
condition, as well as wider policy implications.
PATIENTS AND METHODS
Study site and participants. A prospective observational
study was conducted under program conditions that involved
100 consecutive patients who were referred to GF Jooste Hos-
pital (Cape Town, South Africa) with likely cases of TB IRIS.
The TB incidence rate in the Western Cape province in 2006
was 1031 cases per 100,000 population [20], and the prevalence
of antenatal HIV infection was as high as 33% [21]. More than
10,000 people have initiated cART within the catchment area
of GF Jooste Hospital (M. Osler, Provincial Government of the
Western Cape, personal communication). The national TB pro-
gram treats new TB cases with 6 months of therapy (rifampin,
isoniazid, pyrazinamide, and ethambutol for 2 months, fol-
lowed by rifampin and isoniazid for 4 months). The retreatment
regimen includes the addition of streptomycin, as follows: 2
months of rifampin, isoniazid, pyrazinamide, ethambutol, and
streptomycin; 1 month of rifampin, isoniazid, pyrazinamide,
and ethambutol; and 5 months of rifampin, isoniazid, and
ethambutol. Routine TB drug susceptibility testing (DST) is
not performed for new TB cases. Patients receiving retreatment
and patients not responding to TB treatment may have DST
performed. DST was only performed for rifampin, isoniazid,
and ethambutol during the study, in accordance with national
guidelines.
First-line cART in South Africa is stavudine, lamivudine, and
either nevirapine or efavirenz. Efavirenz is preferred for patients
receiving rifampin-based TB treatment. Patients with a CD4
cell count !200 cells/mL and/or World Health Organization
stage 4 disease are eligible to commence cART.
Clinical case definitions of TB IRIS (table 1) were prepared,
circulated, and discussed with participating primary care phy-
sicians. The definitions were in accordance with other published
case definitions for IRIS [14, 15], in that they excluded patients
with drug-resistant TB. Our case definitions, however, specif-
ically used known resistance to rifampin as an exclusion cri-
terion. We obtained information regarding initial TB diagnosis
from the referral letter and by search of records from the re-
gional laboratory, which processes all TB microbiologic spec-
imens in our referral area. All patients aged 13 years who
were referred to the hospital with suspected TB IRIS were in-
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Figure 1. Final diagnosis for 100 patients with suspected cases of
tuberculosis (TB) immune reconstitution inflammatory syndrome (IRIS).
MDR, multidrug resistant; NTM, nontuberculous mycobacteria.
cluded. TB treatment adherence was assessed by self-report and
on the basis of the patient’s TB clinic card, on which each daily
dose taken was documented with a tick. Patients who had !80%
adherence to TB treatment reported were not included as pa-
tients with suspected TB IRIS. The Research Ethics Committee
of the University of Cape Town approved this study (REC 337/
2004).
Clinical assessment sought to exclude differential diagnoses
based on clinical presentation. For example, for patients with
respiratory symptoms, bacterial and pneumocystis pneumonia
were investigated. Clinical specimens were sent for TB micro-
scopic examination, culture, and DST at the time of presen-
tation with suspected TB IRIS. DST for rifampin and isoniazid
was performed at 2 nationally accredited laboratories. Both
laboratories used the indirect proportion method: one labo-
ratory used liquid media with the MGIT system, and the other
used solid culture medium (Middlebrook 7H11 agar). For 36
patients, a rapid rifampin resistance assay was performed
(FASTplaque-Response; Biotec Laboratories) [22]. The result
of this assay was confirmed by culture-based DST, and the latter
result is reported unless stated otherwise. A purified protein
derivative enzyme-linked immunospot assay was performed, as
described elsewhere [23]. Patients were classified as having TB
IRIS if 2 clinicians agreed that, at initial assessment and during
the follow-up period, the patient fulfilled at least 1 of the case
definitions.
Statistical methods. Fisher’s exact test was used to compare
proportions, and the Mann Whitney U test was used to analyze
differences between medians. The unpaired Student’s t test with
Welch’s correction was used to compare enzyme-linked im-
munospot assay results.
RESULTS
One hundred patients (66 female and 34 male patients) with
suspected TB IRIS were evaluated from February 2005 through
July 2006. The median age was 31 years (interquartile range
[IQR], 26–35 years), and the median baseline CD4 cell count
was 50 cells/mL (IQR, 26–94 cells/mL). Twenty-six patients had
received 1 course of prior TB treatment. Patients developed
symptoms prompting referral with suspected TB IRIS a median
of 14 days (IQR, 7–25 days) after starting cART. These patients
were assessed during screening for a randomized placebo-con-
trolled trial of prednisone for mild and moderate TB IRIS
(ISRCTN 21322548). Thirty-eight patients were enrolled in that
study, and 25 received corticosteroid treatment for TB IRIS
outside that study, usually for severe TB IRIS. Final diagnoses
are shown in figure 1.
Follow-up CD4 cell counts during the first year of cART
were available for 77 patients. In 73 patients (95%), the follow-
up CD4 cell count increased (median increase, 139 cells/mL;
IQR, 64–241 cells/mL) from the pre-cART value. In 4 patients,
the CD4 cell count decreased by 1–50 cells/mL during the first
year of cART. Follow-up viral loads, usually measured after 6
months of cART, were available for 74 patients. The viral load
was !400 copies/mL in 65 patients, 400–1000 copies/mL in 5,
and 11000 copies/mL in 4. In all 4 of these patients, the CD4
cell count increased by 77–365 cells/mL during cART.
Among the whole cohort, the initial TB diagnosis was made
on the basis of culture of Mycobacterium tuberculosis in a clinical
specimen for 41 patients and positive smear microscopy results
for 31 patients. For 25 patients, a diagnosis of smear-negative
or extrapulmonary TB was made on the basis of clinico-ra-
diological data [24–26]. Although the other 3 patients were
receiving TB treatment at presentation, the initial diagnosis of
TB was incorrect, and they had nontuberculous mycobacterial
infection.
Seven of the 25 patients with a clinico-radiological diagnosis
had microbiological confirmation when they presented with
suspected TB IRIS (4 were smear positive, and 3 were culture
positive). For the other 18 patients, the diagnosis of TB was
not microbiologically proven. These patients had TB symptoms
and lymphadenopathy on abdominal ultrasound (5 patients),
on chest radiograph (2), or peripherally (1); miliary infiltrates
on chest radiograph (4); other radiographic pulmonary infil-
trates (2); pericardial effusion (2); or pleural effusion (2). One
of the patients who received a diagnosis on the basis of symp-
toms and abdominal nodes on ultrasound was subsequently
found to have lymphoma and probably did not have TB.
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Table 2. Cases of rifampin-resistant tuberculosis (TB) diagnosed after presentation with suspected TB immune reconsti-
tution inflammatory syndrome (IRIS).
Patient
Age,
years Sex
Nadir CD4
cell count,
cells/mL Previous TB Initial TB diagnosis Course of events TB IRIS manifestations
1 24 F 94 No Pleural and pulmonary; not
confirmed
microbiologically
Symptoms improved and
pleural effusion de-
creased while receiving
Rif, INH, Pza, and Eth;
started cART 8 weeks
later; suspected TB IRIS
onset 14 days later;
sputum culture negative
for TB twice at IRIS on-
set; sputum and pleural
aspirate samples from
8–10 weeks after IRIS
onset grew MDR M.
tuberculosis
Recurrent constitutional,
respiratory, and abdomi-
nal symptoms; fever
and weight loss; cervi-
cal node enlargement,
hepatomegaly; CXR
showed progressively
worsening nodular infil-
trates and enlarging
pleural effusion
2 29 F 16 No Disseminated (pulmonary
infiltrates on CXR and
ascites on ultrasound);
not confirmed
microbiologically
Started on Rif, INH, Pza,
and Eth; symptoms im-
proved; started cART 13
weeks later; suspected
TB IRIS onset 39 days
later; bronchoscopy per-
formed 8 weeks later
(bronchial brushings
grew MDR TB); thereaf-
ter, ongoing IRIS mani-
festations despite MDR
TB treatment
High fevers, weight loss,
and abdominal and con-
stitutional symptoms;
right hilar node enlarge-
ment on CXR with bron-
chial compression (on
bronchoscopy); new
right middle lobe infil-
trate on CXR; enlarging
cervical nodes
3 26 F 44 Yes Disseminated; lymphade-
nopathy and hepatos-
plenomegaly on abdomi-
nal ultrasound; urine
sample culture positive
for Mycobacterium tu-
berculosis; DST not re-
quested at the time
Started Rif, INH, Pza, Eth,
and Stm; reported 2-kg
weight gain, and CRP
level decreased (202 to
69 mg/L); started cART
1 month later; 5 days
later, developed sus-
pected TB IRIS; DST re-
quested on initial urine
isolate revealed Rif
monoresistance
Abdominal pain, constitu-
tional symptoms, and
weight loss; progres-
sively enlarging hepato-
megaly, cervical node
enlargement, para-um-
bilical cold abscess, per-
itonism, and marked
tachycardia
4 51 F 35 No Pulmonary; sputum sam-
ple cultured for M. tu-
berculosis; DST not per-
formed at the time
Symptomatic improve-
ment while receiving
Rif, INH, Pza, and Eth
(cough and night
sweats resolved, and
patient felt stronger);
started cART 2 months
later; 7 days later, devel-
oped suspected TB
IRIS; lymph node aspi-
rate culture positive for
MDR M. tuberculosis
Constitutional symptoms,
marked weight loss,
and respiratory symp-
toms; cervical node en-
largement; CXR showed
pulmonary infiltrates
and enlarging thoracic
nodes
5 31 F 3 No Disseminated (CXR re-
vealed pulmonary infil-
trates and cervical ade-
nitis); lymph node
aspirate smear positive
and sputum culture pos-
itive for M. tuberculosis;
no DST performed at
the time
Initially improved while re-
ceiving Rif, INH, Pza,
and Eth (night sweats
resolved and general
condition improved);
then had chronic diar-
rhea followed by recur-
rent TB symptoms prior
to cART; started cART 4
months after TB treat-
ment; 3 days later, be-
gan deteriorating more
rapidly, requiring admis-
sion; sputum culture
positive for MDR M.
tuberculosis
Recurrent cough; constitu-
tional and abdominal
symptoms; new pulmo-
nary infiltrates with cavi-
tation on CXR
(continued)
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Table 2. (Continued.)
Patient
Age,
years Sex
Nadir CD4
cell count,
cells/mL Previous TB Initial TB diagnosis Course of events TB IRIS manifestations
6 24 M 47 No Disseminated; CXR re-
vealed pulmonary infil-
trates; abdominal ultra-
sound showed
lymphadenopathy and
splenic microabscesses;
urine sample culture
positive for M. tubercu-
losis; no DST was per-
formed at the time
Reported symptomatic im-
provement while receiv-
ing Rif, INH, Pza, and
Eth; started cART 6
months after TB treat-
ment; 29 days later, de-
veloped suspected TB
IRIS; node aspirate
grew M. tuberculosis
and NTM; thus, formal
DST could not be done;
FASTplaque demon-
strated Rif resistance
Constitutional symptoms,
fever, new axillary
lymphadenopathy, and
tender hepatomegaly
with jaundice
7 28 F 187 Yesa Pulmonary (smear
positive)
Started receiving Rif, INH,
Pza, Eth, and Stm with
some adherence lapses,
but symptomatically
better when started
cART 5 months later; 7
days after starting cART,
developed suspected
TB IRIS; sputum culture
positive for MDR M.
tuberculosis
Fever and constitutional
symptoms; pulmonary
infiltrates on CXR
8 28 F 103 No Disseminated; abdominal
ultrasound showed
lymphadenopathy and
splenic microabscesses;
sputum culture positive
for M. tuberculosis; sus-
ceptible to Rif and INH
Symptomatically improved
while receiving Rif, INH,
Pza, and Eth, with re-
ported weight gain; 6
weeks after TB treat-
ment, started cART; de-
veloped suspected TB
IRIS 13 days later; then
sputum culture positive
for MDR M.
tuberculosis
Respiratory, abdominal,
and constitutional symp-
toms; weight loss, fe-
ver, and tachycardia;
peritonism on examina-
tion; cervical node en-
largement; CXR showed
progressive pulmonary
infiltrates and enlarging
thoracic nodes
9 31 M 12 Yesa Disseminated; CXR re-
vealed pulmonary infil-
trates and CSF smear
positive for acid-fast ba-
cilli; patient also re-
ceived a diagnosis of
cryptococcal meningitis
before initiation of cART
Symptomatically improved
while receiving treat-
ment for TB and crypto-
coccal meningitis prior
to cART; 48 days after
starting cART, devel-
oped suspected TB
IRIS; sputum culture
positive for MDR M.
tuberculosis
Respiratory and constitu-
tional symptoms,
weight loss, and head-
aches; hepatomegaly;
CXR showed infiltrates
with cavitation; CSF
showed worsened lym-
phocytic meningitis that
could have been due to
TB or cryptococcal IRIS
NOTE. cART, combined antiretroviral therapy; CRP, C-reactive protein; CXR, chest radiograph; DST, drug susceptibility testing; Eth, ethambutol;
INH, isoniazid; MDR, multidrug resistant; NTM, nontuberculous mycobacteria; Pza, pyrazinamide; Rif, rifampin; Stm, streptomycin.
a Previously defaulted TB treatment.
Seven patients with suspected TB IRIS had clear evidence of
an alternative opportunistic condition (figure 1). In 3 patients,
this was a nontuberculous mycobacterial infection. These pa-
tients had experienced some symptomatic improvement while
receiving TB treatment before initiation of cART and were then
referred with suspected TB IRIS after commencing cART. Re-
view of the initial sputum culture results revealed nontuber-
culous mycobacterial infection. In 2 of the 3 patients, nontu-
berculous mycobacteria were also cultured from blood samples
at the time of assessment for suspected TB IRIS.
Twenty-five patients had DST performed at initial TB di-
agnosis. For 19 of these patients, the isolate was susceptible to
rifampin and isoniazid; 2 had isolates monoresistant to iso-
niazid, 1 had an isolate monoresistant to rifampin, and 3 had
MDR TB. In an additional patient (patient 3), DST of the isolate
at TB diagnosis was performed retrospectively after presenta-
tion with suspected TB IRIS, and the isolate demonstrated mo-
noresistance to rifampin (table 2). For this patient, the culture
result at the time of presentation with TB IRIS was negative.
All 4 patients who presented with suspected TB IRIS with
known rifampin resistance were receiving appropriate therapy
for MDR TB and reported at least partial clinical improvement
before initiation of cART. These patients then presented with
clinical deterioration 7–45 days after starting cART. Their clin-
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Table 3. Characteristics of the cohort.
Characteristic
Patients
Received a diagnosis
of TB IRIS without
Rif resistance
(n p 80)
Presented with suspected
TB IRIS and then
received a diagnosis of
Rif-resistant TB
(n p 9)
Known to have
Rif-resistant TB
at presentation with
suspected TB IRIS
(n p 4)
Presented with suspected
TB IRIS and then
received a diagnosis of
an alternative OD
(n p 7)
Female sex 52 (65) 7 (78) 1 (25) 6 (86)
Age, years 31 (27–36) 29 (26–31) 31 (28–35) 30 (24–34)
Previous TB 18 (23) 3 (33) 2/3 (67) 3 (43)
Prior cARTa 4 (5) 1 (11) 1 (25) 0 (0)
WHO clinical stageb
3 28 (35) 2 (22) 0 (0) 2 (29)
4 52 (65) 7 (78) 4 (100) 5 (71)
cART regimen at assessment
d4T, 3TC, and EFV 64 (80) 8 (89) 4 (100) 6 (86)
Other 16 (20) 1 (11) 0(0) 1 (14)
TB disease formc
Pulmonary 36 (45) 3 (33) 2 (50) 3 (43)
Extrapulmonary 44 (55) 6 (67) 2 (50) 4 (57)
Time from start of TB treatment to start of cART, days 68 (35–93) 84 (47–115) 199 (121–447) 69 (21–125)
Time from start of cART to TB IRIS onset, days 14 (8–23) 13 (7–29) 35 (17–45) 35 (7–52)
Baseline CD4 cell count, cells/mL 50(26–94) d 44(16–94) 84 (55–184) 72 (13–85)
Baseline viral load measured 61 (76) 5 (56) 0 (0) 5 (71)
Baseline viral load, value  105 copies/mL 2.1 (9.8– 5.0) 1.7 (1.4–5.6) … 2.5 (1.1–5.0)
NOTE. Data are no. (%) of patients or median value (interquartile range). cART, combination antiretroviral therapy; d4T, stavudine; EFV, efavirenz; IRIS, immune
reconstitution inflammatory syndrome; OD, opportunistic disease; Rif, rifampin; TB, tuberculosis; 3TC, lamivudine; WHO, World Health Organization.
a Excludes patients who received single-dose nevirapine for prevention of mother-to-child transmission.
b WHO staging includes current TB diagnosis.
c The pulmonary TB category includes patients who had pulmonary TB only, and the extrapulmonary TB category includes patients with extrapulmonary TB
only and those with both pulmonary TB and extrapulmonary TB.
d Seventy-nine of these 80 patients had a baseline CD4 cell count available.
ical manifestations included fever or night sweats (2 patients),
marked weight loss (2), new peripheral nodes (1), new pul-
monary infiltrates on chest radiograph (2), and other recurrent
TB symptoms. Although these features are typical of TB IRIS,
the case definitions that we used excluded this diagnosis.
Eighty-five patients had at least 1 culture for M. tuberculosis
performed during assessment for TB IRIS. Cultures for M.
tuberculosis were performed on sputum (for 55% of patients),
lymph node or abscess aspirate (18%), pleural fluid (8%), CSF
(8%), or other clinical specimens (11%). Culture yielded M.
tuberculosis for 17 patients (20%; 8 had MDR TB, 1 had iso-
niazid-monoresistant TB, and 7 had TB that was susceptible
to rifampin and isoniazid). Drug susceptibility was undeter-
mined for 1 patient (patient 6) (table 2), because the culture
of the patient’s sample yielded both nontuberculous mycobac-
teria and M. tuberculosis. This patient had a FASTplaque assay
indicative of rifampin resistance. Including the patient whose
initial isolate was rifampin resistant (patient 3) (table 2) and
the patient with a FASTplaque result indicating rifampin re-
sistance (patient 6) (table 2), 10 patients were found to have
rifampin-resistant TB at the time of TB IRIS presentation. One
of these patients was previously known to have MDR TB; thus,
9 (10.1%; 95% CI, 3.9%–16.4%) of 89 patients with suspected
TB IRIS had rifampin-resistant TB that was previously unsus-
pected (table 2). All 9 of these patients reported symptomatic
improvement after commencing standard TB treatment. For 1
of these patients (patient 8) (table 2), culture and DST at initial
TB diagnosis revealed susceptibility to rifampin and isoniazid,
but repeat DST performed for suspected TB IRIS revealed MDR
TB.
Table 3 compares the baseline characteristics of the 4 diag-
nostic groups. No statistically significant differences existed in
univariate analysis, with the exception of shorter duration from
initiation of TB treatment to initiation of cART in the group
of patients who received diagnoses of TB IRIS with no rifampin
resistance, compared with those who were known to have rif-
ampin-resistant disease when they presented with suspected TB
IRIS (median, 68 days vs. 199 days; ).Pp .02
Table 4 shows clinical, radiological, and laboratory features
of the TB IRIS episode for the 80 patients who received a final
diagnosis of TB IRIS without rifampin resistance. The TB IRIS
case definitions that were fulfilled are also shown. Many patients
fulfilled 11 case definition, and frequently, TB IRIS involved
11 organ system. The most frequent TB IRIS symptoms among
these 80 patients were constitutional (68 patients; 85%), in-
cluding night sweats, malaise, anorexia, and weight loss; re-
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Table 4. Clinical, radiographic, and laboratory features of tuberculosis (TB) immune reconstitution
inflammatory syndrome (IRIS) in 80 patients who received a diagnosis of TB IRIS without rifampin
resistance.
Variable Patients
TB IRIS case definitions fulfilled
New, recurrent, or worsening symptoms 80 (100)
New or worsening TB manifestations 59 (74)a
New or expanding lymph nodes 35 (44)
New or expanding cold abscesses 3 (4)
New or expanding intracranial tuberculomas 1 (1)
New or expanding pulmonary infiltrates 22 (28)
New or recurrent TB meningitisb 6 (8)
New or enlarging serous effusions 13 (16)
New or worsening granulomatous hepatitis 2 (3)
New or worsening granulomatous bone marrow infiltrate 5 (6)
Other new or worsening TB lesionc 3 (4)
Other physical signs
Fever (temperature, 137.4C) 31 (39)
Hepatomegaly 45 (56)
Splenomegaly 7 (9)
Peritonism 4 (5)
New neurological signs 7 (9)
Radiographic features
On chest radiograph
Pulmonary infiltrates 52/80 (65)
Hilar/mediastinal nodes 30/80 (38)
Pleural effusion 17/80 (21)
On ultrasound
Abdominal nodes 27/35 (77)
Ascites 10/35 (29)
Pericardial effusion 10/35 (29)
Focal splenic lesions 7/35 (20)
On CT: head lesions 3/8 (38)d
Laboratory features
Total bilirubin level, mmol/L (n p 13)e 54 (16–103) [0–21]
Alkaline phosphatase level, IU/L (n p 56) 181 (103–326) [40–120]
Alanine aminotransferase level, IU/L (n p 62) 41.5 (28–59.8) [5–40]
g-Glutamyl transferase level, IU/L (n p 15) 217 (152–482) [0–35]
Hemoglobin level, g/dL (n p 73) 9.1 (7.8–10) [M: 13.0–17.0; F: 12.0–15.0]
WBC count, value  109 cells/L (n p 71) 5.4 (3.7–8.7) [4.0–10.0]
Platelet count, value  109 cells/L (n p 65) 362 (268–462) [178–400]
C-reactive protein level, mg/L (n p 72) 96 (70–152) [0–10]
C-reactive protein level 110 mg/L (n p 72) 71 (99)
NOTE. Data are no. (%) of patients or median value (interquartile range) [reference range].
a The other 21 patients fulfilled only the case definition relating to new, worsening, or recurrent symptoms.
b TB IRIS meningitis was defined as 5 lymphocytes and/or polymorphs in a CSF sample from a patient with new or
recurrent meningism or other new neurological symptoms after exclusion of bacterial and fungal meningitis.
c The other manifestations were arthritis (in 2 patients) and bursitis (in 1 patient).
d Eight patients had CT performed: tuberculomas were shown for 1 patient and a new infarct ( in 1 patient) and hydrocephalus
(in 1 patient) were shown for the others.
e Bilirubin level measurement was performed mainly for those patients in whom jaundice was clinically apparent. Nine of
the 13 patients who had their bilirubin level measured had a total bilirubin level 121 mmol/L.
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Figure 2. Comparison of purified protein derivative enzyme-linked im-
munospot assay results for 33 patients with tuberculosis (TB) immune
reconstitution inflammatory syndrome (IRIS) with no rifampin (RIF) resis-
tance (median, 1047 spot-forming cells [SFC]  106 PBMCs; interquartile
range, 417–1700 SFC  106 PBMCs) with those for 5 patients who
received a diagnosis of RIF-resistant TB after presenting with TB IRIS
(median, 529 SFC  106 PBMCs; interquartile range, 89–680 SFC  106
PBMCs; ).Pp .04
spiratory (48; 60%); and abdominal (47; 59%), including ab-
dominal pain, nausea, vomiting, and diarrhea. The symptoms,
signs, and radiological findings for the 9 patients with rifampin-
resistant TB diagnosed after presentation with suspected TB
IRIS did not differ significantly from those of the patients who
had TB IRIS without rifampin-resistant TB, with the exception
of more frequent presence of lymphadenopathy on chest ra-
diograph (7 of 9 patients vs. 30 of 80 patients; ). BloodPp .03
investigations were also similar between the 2 groups, although
for the 9 patients with rifampin-resistant TB, the median C-
reactive protein level was higher (179 mg/L [IQR, 100–212 mg/
L] vs. 96 mg/L [IQR, 70–152 mg/L]; ). Purified proteinPp .05
derivative enzyme-linked immunospot assay demonstrated evi-
dence of immune activation in both groups, although the de-
gree was less in the patients with rifampin-resistant TB (fig-
ure 2).
DISCUSSION
In Cape Town, the triple coincidence of very high TB case
notification rates, an expanding epidemic of HIV infection, and
the large-scale roll-out of cART has led to a large increase in
the number of cases of TB IRIS (to date, there are hundreds
of cases) presenting at our health care service. We prospectively
evaluated clinical case definitions for TB IRIS for 100 cases;
this was, to our knowledge, the largest TB IRIS case series
reported to date. Once patients with alternative conditions (7
patients) and known rifampin-resistant TB (4 patients) were
excluded, 9 (10%) of the remaining 89 patients were found to
have rifampin-resistant TB only after presenting with suspected
TB IRIS. This has important implications for the diagnosis and
treatment of HIV-infected patients with TB whose conditions
deteriorate after the introduction of cART.
In the 9 patients with rifampin-resistant TB, presentation
was suggestive of TB IRIS, with improvement while receiving
TB treatment before initiation of cART and then deterioration
during the weeks after the initiation of cART. The obvious
question is whether the condition of the patients with drug-
resistant TB deteriorated because of suboptimally treated TB,
TB IRIS, or both? Our case definitions, which are similar to
those used by other researchers [14, 15], classified known rif-
ampin resistance as excluding TB IRIS. However, in light of
our observations, we propose that antitubercular drug resis-
tance and TB IRIS are not mutually exclusive and may overlap
in the same person. First, given that TB IRIS immunopathology
is attributable to restored antigen-specific immunity to M. tu-
berculosis antigens [12], it is reasonable to conclude that TB
IRIS may occur in response to drug-susceptible or drug-resis-
tant strains, whether the latter are treated or untreated. The
antigen stimulus for TB IRIS is unlikely to differ in these
scenarios.
Second, in the 4 patients ith known rifampin-resistant TB,
all improved while receiving treatment for MDR TB, and then
their conditions deteriorated after cART initiation. The dete-
rioration of their conditions was most likely attributable to TB
IRIS, given the timing. These patients may be at higher risk of
TB IRIS than patients with rifampin-susceptible TB. M. tuber-
culosis bacillary load has been suggested as a risk factor for the
condition [7], and even those patients who are effectively
treated for MDR TB are likely to have slow bacillary clearance.
This may partially account for our observation that these 4
patients developed TB IRIS despite a long interval between
initiation of TB therapy and initiation of cART (table 3).
Third, 9 patients had undiagnosed rifampin-resistant TB
when they presented with suspected TB IRIS. These patients
all reported at least partial symptomatic response to standard
TB treatment before the initiation of cART. It is possible for
patients with MDR TB to initially respond to first-line TB
treatment [27–29], either because the organism is sensitive to
ethambutol and pyrazinamide or because the patient is dually
infected with MDR TB and a susceptible strain [30]. In ad-
dition, patients may improve while receiving treatment for
drug-susceptible TB and then be reinfected with drug-resistant
TB, or the infecting organism may develop rifampin resistance
during treatment. Either of these scenarios could have occurred
for patient 8 (table 2). For these 9 patients who received a
diagnosis of rifampin-resistant TB after presenting with sus-
pected TB IRIS, symptomatic deterioration occurred 3–48 days
after the initiation of cART—the characteristic timing of TB
IRIS. The clinical and radiological features of these patients
when they presented with suspected TB IRIS, with the exception
of more frequent presence of lymphadenopathy on chest ra-
diograph, were not significantly different from those of patients
with TB IRIS with no drug resistance. We propose that TB IRIS
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exacerbated undiagnosed drug-resistant TB. Support for the
idea that TB IRIS was present in this group comes from the
enzyme-linked immunospot assay data, which showed expan-
sions of purified protein derivative–specific IFN-g–producing
T cells (which are a reported characteristic of TB IRIS [12]),
irrespective of drug susceptibility. The overlap of IRIS and drug
resistance with respect to cryptococcal infection has been high-
lighted elsewhere [31].
Seven patients with suspected TB IRIS had alternative op-
portunistic diseases that explained their clinical deterioration.
Patients with advanced immunosuppression may have multiple
opportunistic conditions. A thorough examination for alter-
native infections and malignancies before diagnosis of TB IRIS
is essential. Three patients receiving TB treatment at their local
clinic actually had nontuberculous mycobacterial infection
when the result of the original culture was followed up; this
underscored the importance of reviewing the original TB di-
agnosis during the assessment of these patients. The perfor-
mance of these case definitions may not be the same in settings
with lower TB incidence rates, where patients might more fre-
quently present with other reasons for deterioration.
Frequently, patients had signs, symptoms, and radiological
manifestations suggestive of multiple organ system involvement
with TB IRIS. This may be explained by profound immuno-
suppression (median nadir CD4 cell count, 50 cells/mL), pre-
disposing to disseminated TB. The most frequent organ systems
involved were the respiratory system (respiratory symptoms
and chest radiograph infiltrates) and, hitherto little appreciated,
the abdominal organs. Of the 80 patients with TB IRIS with
no rifampin resistance, 59% had abdominal symptoms; 56%
had hepatomegaly, 9% had splenomegaly, and 5% had peri-
tonism. Abdominal nodes were present in 77% of those who
underwent ultrasonography. Liver function derangement, par-
ticularly a cholestatic pattern, was common. These findings
suggest that, if patients develop abdominal symptoms or liver
function derangement after commencing cART, TB IRIS should
be considered in the differential diagnosis in addition to drug-
related adverse effects, such as pancreatitis, lactic acidosis, and
drug-induced hepatitis.
There were several limitations to our study. For most pa-
tients, the initial TB diagnosis had been made in primary care
according to program guidelines, and only 41% of the cases
were confirmed by culture. Most patients also initiated cART
at the same facilities; thus, examination and radiographic data
were incomplete. All patients had a chest radiograph performed
to investigate TB IRIS, but few were performed at the time of
cART initiation. In addition, patients who are smear positive
do not routinely undergo chest radiography at TB diagnosis.
Therefore, for many patients with symptoms of TB IRIS who
had radiographic pulmonary infiltrates (65% had infiltrates),
it was impossible to determine whether these were new or
expanding, which potentially underestimated the number of
cases fulfilling the pulmonary infiltrate case definition and, sim-
ilarly, the serous effusion case definition. Many patients had
hepatomegaly (56% of patients) with cholestatic liver derange-
ment, which suggested granulomatous hepatitis [32], but this
was only confirmed in 2 patients, because severity otherwise
was insufficient to warrant a biopsy. The number of cases ful-
filling the granulomatous hepatitis case definition might, for
this reason, also be underestimated. It is for these reasons that
the diagnosis of TB IRIS was made exclusively on the basis of
a clear history of symptom improvement before the initiation
of cART, followed by new, worsening, or recurrent TB symp-
toms after the initiation of cART in many patients (26% of
patients). Follow-up CD4 cell count and HIV viral load mea-
surements during cART were unavailable for one-quarter of
the patients. These tests are performed every 6 months during
cART under program conditions; however, many patients were
transferred to other facilities, and some were lost to follow-up
or died by 6 months. Determination of viral load or CD4 cell
count at the time of TB IRIS diagnosis did not, however, form
part of our case definitions. For patient 6 (table 2), the FASTp-
laque assay demonstrated rifampin resistance. This could not
be confirmed by culture-based DST. The presence of nontu-
berculous mycobacterial coinfection in the patient’s specimen
may have affected the FASTplaque result, but it is worth noting
that the specimen was culture positive for M. tuberculosis after
7 months of TB treatment; this supported a diagnosis of rif-
ampin-resistant TB.
Corticosteroids have been proposed as a treatment for TB
IRIS, although the only evidence currently available is anecdotal
[17]. There are potential risks of corticosteroid treatment for
HIV-infected patients with TB, including herpes virus reacti-
vation and Kaposi sarcoma [33, 34]. There is no present clinical
trials evidence supporting the use of corticosteroids for the
treatment of TB IRIS, other than for TB meningitis and, per-
haps, pericardial disease (neither with evidence in the context
of cART [35, 36]). Assessment of suspected TB IRIS should
trigger re-evaluation of the TB diagnosis and the adequacy of
antimicrobial therapy. Such assessment should occur before the
instigation of corticosteroid therapy; otherwise, there is a risk
that patients who remain deeply immunosuppressed (despite
IRIS) may receive steroid therapy without adequate antimicro-
bial coverage. Our study highlights the pressing need to develop
and implement rapid techniques to diagnose drug resistance
that are appropriate to resource-limited conditions. The use of
the FASTplaque assay in the present study was an attempt to
overcome this problem, and there are encouraging data emerg-
ing from other studies of rapid tests [37]. Overall, our data
also support the use of routine DST for HIV-infected patients
with TB.
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Type 1 Helper T Cells and FoxP3-positive T Cells in
HIV–Tuberculosis-associated Immune Reconstitution
Inflammatory Syndrome
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Rationale: Tuberculosis-associated immune reconstitution inflam-
matory syndrome (TB–IRIS) induced by combination antiretroviral
therapy (cART) has been attributed to dysregulated expansion of
tuberculin PPD–specific IFN-g–secreting CD41 T cells.
Objectives: To investigate the role of type 1 helper T cell expansions
and regulatory T cells in HIV–TB IRIS.
Methods: Longitudinal and cross-sectional studies of Mycobacterium
tuberculosis–specific IFN-g enzyme-linked immunospot responses and
flow cytometric analysis of blood cells from a total of 129 adults with
HIV-1–associated tuberculosis, 98 of whom were prescribed cART.
Measurements and Main Results: In cross-sectional analysis the fre-
quencyof IFN-g–secretingTcells recognizingearly secretoryantigenic
target (ESAT)-6, a-crystallins 1 and 2, and PPD of M. tuberculosis was
higher inpatientswithTB–IRIS than insimilarpatients treated forboth
HIV-1 and tuberculosis who did not develop IRIS (non-IRIS; P< 0.03).
The biggest difference was in the recognition of a-crystallin mole-
cules: peptide mapping indicated a polyclonal response. Flow cyto-
metric analysis indicated equal proportions of CD41 and CD81 cells
positive for activationmarkersHLA-DR and CD71 in both patientswith
TB–IRIS and non-IRIS patients. The percentage of CD41 cells positive
for FoxP3 (Forkhead box P3) was low in both groups (TB–IRIS, 5.3 6
4.5; non-IRIS, 2.46 6 2.46; P 5 0.13). Eight weeks of longitudinal
analysis of patients with tuberculosis who were starting cART showed
dynamic changes in antigen-specific IFN-g–secreting T cells in both
the TB–IRIS and non-IRIS groups: the only significant trend was an
increased response to PPD in the TB–IRIS group (P5 0.041).
Conclusions: There is an association between h lper T-cell type 1
expansions and TB–IRIS, but the occurrence of similar expansions in
non-IRIS brings into question whether these are causal. The defect in
immune regulation responsible for TB–IRIS remains to be fully eluci-
dated.
Keywords: tuberculosis; HIV; immune reconstitution inflammatory
syndrome; FoxP3; type 1 helper T cells
HIV-1–associated tuberculosis is a major cause of mortality in
sub-Saharan Africa (1). The widespread introduction of com-
bination antiretroviral therapy (cART) has, however, been
associated with a decrease of between 50 and 80% in the
annual risk of tuberculosis in HIV-1–infected persons (2–4).
cART partially and beneficially restores pathogen-specific im-
munity (5), but is also associated under some circumstances
with paradoxical deterioration of existing, or unmasking of,
unapparent infection (6, 7). This phenomenon is presumed to
reflect the simultaneous restoration of immunopathological as
well as protective immunity during antitubercular and cART.
Deterioration of mycobacterial disease was recognized early as
one of the forms of aberrant immune restoration or immune
reconstitution inflammatory syndrome (IRIS) (8, 9). A number
of case series of tuberculosis–IRIS (TB–IRIS) have been reported
(reviewed by Dhasmana and coworkers [10]) with recognized risk
factors being disseminated tuberculosis, a low nadir CD41 cell
count, high viral load, and short interval between starting
antituberculosis chemotherapy and cART. Initially reported
from specialized centers (11, 12), TB–IRIS is now a frequent
diagnosis in areas of the world where tuberculosis and HIV
frequently coexist (13, 14).
The diverse clinical presentations of TB–IRIS have been
characterized (10), but little is known of its immunopatho-
genesis. It has been related to expansion of tuberculin purified
protein derivative (PPD)–specific interferon-g–secreting CD41
T cells during cART (8, 9, 15). In the most comprehensive
analysis to date, expansion of PPD-specific T cells was sug-
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gested as the cause of the syndrome: the maximal median value
in 7 patients who developed TB–IRIS being higher than the
maximal median values obtained from 12 similar patients who
did not experience IRIS (16). In addition, T-cell reactivity to the
species-specific and immunodominant early secretory antigenic
target (ESAT)-6 protein was reported as low in patients with
IRIS, suggesting that TB–IRIS may be associated with specific
recognition of components of PPD. These findings in turn have
led to the suggestion that regulatory T cells that secrete trans-
forming growth factor-b or IL-10 may not expand at an equal
rate during cART, thereby setting up conditions favorable to
immunopathology (17, 18). This study was therefore performed
to investigate the role of helper T-cell type 1 (Th1) expansions
and regulatory cells in much larger numbers of patients than has
hitherto been possible. We chose a range of previously well-
characterized antigens of Mycobacterium tuberculosis including
the species-specific, secreted and immunodominant antigen
ESAT-6, the 38-kD cell wall antigen, and two cytoplasmic heat
shock proteins, a-crystallin-1 (Acr1) and Acr2, to address the
possibility that the immune response underlying TB–IRIS is
antigen specific. Some of the results of these studies have been
previously reported in the form of an abstract (19, 20).
METHODS
Subjects
The University of Cape Town (Cape Town, South Africa) Research
Ethics Committee approved the study (REC references 337/2004 and
173/2005). In a cross-sectional analysis 35 cases of paradoxical TB–
IRIS (see Table E1 in the online supplement for the case definition and
also Meintjes and coworkers [21] for the consensus definition) were
compared with 29 persons treated for HIV-associated tuberculosis with
similar baseline CD41 cell count and duration of combination anti-
retroviral treatment (cART) who did not develop IRIS (non-IRIS). A
third group consisted of 31 HIV-infected persons with tuberculosis
sampled before antitubercular treatment and who were not receiving
cART (untreated HIV1TB). Tuberculosis was diagnosed primarily on
the basis of smear or culture positivity. Where this was negative or
unavailable, diagnosis was in line with guidelines for smear-negative or
extrapulmonary tuberculosis in HIV-infected persons (22, 23). TB–
IRIS was diagnosed according to case definitions shown in Table E1.
New TB cases were treated with 6 months duration of first-line therapy
(isoniazid, rifampin, pyrazinamide, and ethambutol [HRZE] for 2
months followed by HR for 4 months [2HRZE/4HR]). The retreatment
regimen added streptomycin (S) as follows: 2HRZES/1HRZE/5HRE.
All non-IRIS patients and 28 of 35 patients with TB–IRIS were
prescribed the cART combination of stavudine (d4T), lamivudine
(3TC), and efavirenz (EFZ). Six patients with TB–IRIS were prescribed
zidovudine (AZT), 3TC, and EFZ and one was prescribed AZT, 3TC,
and nevirapine (NVP). No patient had received prior cART.
Longitudinal analysis was of a prospective cohort of 63 adults who
started cART in primary care while undergoing TB treatment between
January 2006 and September 2007. Participants were monitored four
times for a period of 2 months after initiation of cART. The main
outcome was TB–IRIS, with suspected cases being referred to second-
ary care for investigation and further management.
Immunological Analysis
Blood was drawn for IFN-g enzyme-linked immunospot (ELISpot)
analysis and peptide mapping as previously described (24, 25). For flow
cytometric analysis peripheral blood mononuclear cells (PBMCs) were
separated by standard protocols, and plated at 106/ml per well in
24-well plates in RPMI210% fetal calf serum (FCS). Heat-killed M.
tuberculosis H37Rv was added to the wells at a multiplicity of infection
of 1:15 (hkH37Rv:PBMC) and the plates were incubated overnight at
378C in 5% CO2. Cells were then surface stained for 20 minutes on ice,
using the following fluorescent antibodies (all from BD Biosciences,
San Jose, CA): CD3–allophycocyanin (APC), CD4–peridinin chloro-
phyll protein (PerCP), CD8–PerCP, HLA-DR–fluorescein isothiocya-
nate (FITC), and CD71–phycoerythrin (PE). After washing, stained
cells were fixed in phosphate-buffered saline (PBS)22% FCS contain-
ing 1.6% paraformaldehyde and acquired with a FACSCalibur flow
cytometer (BD Biosciences). Intranuclear staining for FoxP3 (Forkhead
box P3) was performed with the PE-conjugated anti-human FoxP3
staining set from eBioscience (San Diego, CA). Cells were stimulated
as described previously for 2 hours, after which brefeldin A was added at
a concentration of 5 mg/ml (an unstimulated control well was also
included). Cells were first surface stained with anti-CD3–APC and anti-
CD4–PerCP, followed by incubation for 45 minutes on ice in eBioscience
Fix/Perm buffer. After washing in permeabilization buffer, cells were
incubated for 15 minutes on ice in 2% normal rat serum, followed by
incubation for 30 minutes on ice in 10 ml of anti-human FoxP3 (clone
PCH101) antibody. The cells were then washed again, fixed in PBS22%
FCS containing 1.6% paraformaldehyde, and acquired. Analysis was
performed with FlowJo software (Tree Star, Ashland, OR). First, the
lymphocyte population was gated on the basis of forward scatter and side
scatter, and analyzed for CD4 and FOXP3. For the activation and
proliferation markers HLA-DR and CD71, CD31 cells were selected out
of the lymphocyte population, followed by CD41/CD711 or CD41/
HLA-DR1 cells. Serum C-reactive protein was determined by analysis
with a SYNCHRON CX system (Beckman Coulter, Fullerton, CA).
Statistical Analysis
The normality of data was assessed by the D’Agostino and Pearson
omnibus normality test. Medians are given with the interquartile range
(IQR) and means are presented with the standard deviation (SD).
Paired parametric data were analyzed by Student paired t test or
repeated-measures analysis of variance, and nonparametric paired
data were analyzed by Wilcoxon matched-pairs test or by the Fried-
man test. Unpaired parametric variables were assessed by Student
unpaired t test and nonparametric variables were assessed by Mann-
Whitney U test.
RESULTS
We first compared the frequency of M. tuberculosis antigen–
specific IFN-g spot-forming cells (SFCs) cross-sectionally in
TB–IRIS at presentation, non-IRIS after 2 weeks of cART, and
untreated HIV1TB groups (Table 1). The TB–IRIS and non-
IRIS groups were similar in age, tuberculosis disease form,
duration of cART at sampling, baseline CD41 cell count, and
sex (see Table 1). They did, however, differ in the median interval
between starting TB treatment and cART, which was shorter in
the TB–IRIS group (55 d, IQR 30–82 vs. 80 d, IQR 44–141; P 5
0.011). In the untreated HIV1TB group more TB diagnoses
were microbiologically confirmed and the baseline CD41 cell
count was higher than for the both TB–IRIS and non-IRIS
groups (see Table 1). In addition the median age of the untreated
HIV1TB group was lower than that of the non-IRIS group
(28 yr, IQR 25–36 vs. 35.6 yr, IQR 30–41; P 5 0.018). In 25 of 30
(83%) patients with TB–IRIS for whom a result was available the
convalescent (i.e., post-IRIS episode) viral load was below the
detection limit. In the patients with a detectable load, no value
exceeded 1,000 copies/ml. In addition, an increase in CD41 cell
count occurred in 31 of 33 (94%) patients, with a median increase
of 130 cells/ml (IQR 63–209).
The antigens assayed included the secreted and species-
specific ESAT-6 molecule (26, 27); a 38-kD cell wall antigen
(28, 29); two small cytoplasmic heat shock proteins, Acr1 and
Acr2 (25, 30); and PPD. The response to the 38-kD antigen was
not assayed in the untreated HIV1TB group. Overall responses
were highly heterogeneous with strong positive responses to
some antigens in some non-IRIS patients and a lack of response
to some antigens in some patients with TB–IRIS (Figure 1).
However, the median frequency of IFN-g SFCs was higher in
the TB–IRIS group than in the non-IRIS group, with the
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IQR 322–1,908 vs. 624, IQR 0–1,481 [P 5 0.024]; Acr1: 1,080,
IQR 432–1,363 vs. 228, IQR 7–1,037 [P 5 0.019]; Acr2: 1,313,
IQR 196–1,785 vs. 281, IQR 0–1,032 [P 5 0.027]; 38-kD: 1,026,
IQR 222–1,761 vs. 710, IQR 0–1,340 [P 5 0.25]; PPD: 1,047,
IQR 347–1,620 vs. 168, IQR 34–1,333 [P 5 0.047]). When the
TB–IRIS group was compared with the untreated HIV1TB
group (median ESAT-6: 353, IQR 99–977 [P 5 0.004]; Acr1: 57,
IQR 0–139 [P 5 0.0001]; Acr2: 58, IQR 22–189 [P 5 0.0002];
PPD: 279, IQR 130–693 [P 5 0.001]) the higher response of
patients with TB–IRIS was even more pronounced. By contrast,
there were no significant differences between the non-IRIS and
untreated HIV1TB groups in response to any antigen. An alter-
native to effector T cells as a marker of immune activation is the
serum C-reactive protein (CRP). We therefore determined CRP
concentrations in the TB–IRIS and non-IRIS groups. The
median CRP concentration was three times higher in the TB–
IRIS group than in the non-IRIS group (99 mg/L, IQR 80–169 vs.
32 mg/L, IQR 9–83; P , 0.0001). Elevation of CRP above the
reference laboratory range (10 mg/L) was invariable in the pa-
tients with TB–IRIS, but it was also elevated in 20 of 29 (69%) of
the non-IRIS patients. Although this difference in proportions is
significant (P 5 0.0004) these data again reflect considerable im-
mune activation in the non-IRIS group in the absence of reported
symptoms or signs of TB–IRIS.
The high response to several classes of M. tuberculosis
antigens in the TB–IRIS group implies polyclonal, rather than
oligoclonal, T-cell expansion. To further test this hypothesis we
peptide-mapped responses to the two heat shock proteins Acr1
and Acr2, antigens that showed the greatest fold difference in
recognition between the TB–IRIS and non-IRIS groups (see
Figure 1). PBMCs from 13 patients with TB–IRIS known to
respond to either Acr1, Acr2, or both were selected for this
purpose. The median number of Acr1 peptides recognized per
donor was 10 (IQR 3–14) and 6 (IQR 3–10) for Acr2.
Immunodominant determinants (defined by a response exceed-
Figure 1. Frequency of Mycobac-
terium tuberculosis antigen–specific
IFN-g spot-forming cells (SFCs) in
HIV-infected patients with tuber-
culosis-associated immune recon-
stitution inflammatory syndrome
(TB–IRIS). Two comparator groups
were patients with HIV-associated
tuberculosis before treatment and
not receiving combination antire-
troviral therapy (cART) (untreated
HIV1TB), and patients with treated
HIV-associated TB also receiving
cART for a similar duration to the
patients with TB–IRIS (non-IRIS).
The frequency of IFN-g SFCs was
higher in patients with TB–IRIS
than in non-IRIS patients (P <
0.03), with the exception of the
response to 38-kD cell wall anti-
gen. The frequency of IFN-g SFCs
was also higher in patients with TB–IRIS than in patients with untreated HIV1TB in every instance (P< 0.004). By contrast, the frequency of IFN-g
SFCs did not differ between the non-IRIS and untreated HIV1TB groups in response to any antigen.
TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS WITH TUBERCULOSIS-ASSOCIATED IMMUNE
RECONSTITUTION INFLAMMATORY SYNDROME AND COMPARATOR NON-IRIS AND UNTREATED
HIV1TB GROUPS
TB–IRIS Non-IRIS Untreated HIV1TB
N 35 29 31
Median age, yr (IQR) 31.4 (25.8–36.2) 35.6 (30.3–41.0) 28 (25–36)*
Baseline CD41 cell count, cells/ml (IQR) 51 (29–106) 45 (23–122) 195 (111–331)†
TB treatment before cART, d 55 (30–82) 78 (38–132)‡ N/A
Days of cART to IRIS or to sample 14 (8–21) 14 (14, 15) N/A
Females, n (%) 23 (66) 19 (66) 18 (58)
Previous TB, n (%) 12 (34) 4 (14) 7 (23)
TB disease form, n (%)
Pulmonary or pleural 21 (60) 22 (76) 31 (100)
Disseminated 11 (31) 4 (14)
Lymphadenopathic 3 (9) 3 (10)
Smear or culture confirmed? 19 (54) 16 (55) 30 (97)x
Definition of abbreviations: cART 5 combination antiretroviral therapy; N/A 5 not applicable; TB 5 tuberculosis; TB–IRIS 5
tuberculosis-associated immune reconstitution inflammatory syndrome.
* Significantly lower than non-IRIS: P 5 0.018.
† Significantly higher than TB–IRIS and non-IRIS: P , 0.0001.
‡ Significantly more than TB–IRIS: P 5 0.011.
x Significantly more than TB–IRIS and non-IRIS: P , 0.0001.
Meintjes, Wilkinson, Rangaka, et al.: Pathogenesis of HIV–TB-associated IRIS 1085
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ing 30 IFN-g SFCs per 106 PBMCs) were distributed widely
across both molecules (see Figure E1 in the online supplement).
Taken together, these findings strongly suggest a polyclonal
response.
It has been suggested that defective restoration of regulatory
T-cell function may contribute to the pathogenesis of TB–IRIS
(10, 18). This was examined by flow cytometric analysis of PBMCs
from a subset of TB–IRIS (n5 11) and non-IRIS (n5 8) patients
for whom sufficient cells were available. The percentage of
unstimulated CD41 cells positive for the transcription factor
FoxP3, although higher in the TB–IRIS group, did not signifi-
cantly differ between the groups (TB–IRIS: mean, 5.3 6 4.5; vs.
non-IRIS: mean, 2.46 6 2.46 [P 5 0.13]; Figure 2). hkH37Rv
restimulation of PBMCs for 24 hours did not appreciably change
the detection frequency in the TB–IRIS group or make the
difference between groups significant (TB–IRIS: mean, 5.6 6
4.6; vs. non-IRIS: mean, 2.9 6 2.3 [P 5 0.15]; see Figure 2). In
these subjects we also evaluated lymphocyte activation as deter-
mined by CD71 (transferrin receptor) and HLA-DR expression
(see Figure 2). The percentage of activated CD41 cells did not
differ between groups (TB–IRIS: mean CD41CD711, 26.6 6
17.2; vs. non-IRIS: mean CD41CD711, 29.9 6 11.2 [P 5 0.64];
TB–IRIS: mean CD41 DR1, 45.2 6 22.3 vs. non-IRIS: mean
CD41 DR1, 38.06 15.0 [P 5 0.44]). There was also evidence of
a similar degree of CD81 cell activation (TB–IRIS: mean CD41
DR1, 28.86 18.9 vs. non-IRIS: mean CD41DR1, 22.46 9.6 [P5
0.40]; TB–IRIS: mean CD81 DR1, 32.46 8.6 vs. non-IRIS: mean
CD81 DR1, 37.0 6 12.1 [P 5 0.35]), but again this did not
differentiate the TB–IRIS group from the non-IRIS group.
Cross-sectional analyses only provide partial insight and we
were therefore interested to determine whether our findings
could be repeated in a prospective longitudinal analysis of
patients with TB commencing cART. In the prospective
analysis 8 of 62 participants had insufficient clinical follow-up
to exclude IRIS, 1 was withdrawn because of drug-induced
hepatitis, 1 declined further study involvement after Week 1,
and 1 died of Escherichia coli septicemia 12 days after starting
cART. Ten of 51 (19.6%) of those with sufficient follow-up
developed TB–IRIS according to our case definitions (see Table
E1 and Table 2). ELISpot data gathered at three or more time
points was available for 39 participants, all patients with IRIS,
and 29 of 41 non-IRIS patients. Responses showed marked
dynamic changes within both groups (Figure 3). Within-cate-
gory (non-IRIS and TB–IRIS) data in the longitudinal study
were first assessed by repeated measures analysis (Friedman).
The only significant trend was the increase in response to PPD
in the TB–IRIS group over 8 weeks (P 5 0.041). Within-
category analysis by less stringent two–time point paired testing
confirmed the increase in median PPD response in the TB–IRIS
group, from 495 SFCs per 106 PBMCs (IQR 169–630) to 1,549
SFCs per 106 PBMCs (IQR 725–2432) between Weeks 0 and 8,
to be significant (P 5 0.008). In addition, the increase in PPD
response in the non-IRIS group between Week 0 (66 SFCs per
106 PBMCs [IQR 10–358]) and both Week 2 (161 SFCs per 106
PBMCs [IQR 5–1414]; P 5 0.04) and Week 4 (376 SFCs per 106
PBMCs [IQR 37–1140]; P 5 0.01) was significant. Expansion of
PPD-specific SFCs to more than twice baseline at any time was
observed in 8 of 10 (80%) patients with TB–IRIS and in 18 of
29 (62%) non-IRIS patients (P 5 0.45). No other significant
intragroup changes occurred, despite the highly dynamic nature
of these responses. When comparing IRIS and non-IRIS groups
the only significant difference was between the 8-week response
to PPD in the non-IRIS group (174 SFCs per 106 PBMCs; IQR
87–556) and the group that developed TB–IRIS (1,541 SFCs per
106 PBMCs; IQR 725–2432) (P 5 0.001). Two or more CRP
results were also available from all 10 TB–IRIS cases and 29 of
41 non-IRIS cases (see Figure 3). Repeated-measures tests did
not confirm overall trends, partially because of data gaps at
some time points that reduced the overall power of the analysis.
Within-category analysis by two–time point paired testing
showed the increase in median CRP response in the TB–IRIS
group, from 10 mg/L (IQR 9–25) to 104 mg/L (IQR 56–175)
between Weeks 0 and 2, to be significant (P 5 0.031). In
addition, the increase in CRP in the non-IRIS group between
Week 0 (15 mg/L, IQR 7–20) and both Week 2 (39 mg/L, IQR
9–87; P 5 0.004) and Week 4 (39 mg/L, IQR 12–78; P 5 0.006)
was significant. When comparing IRIS and non-IRIS groups
significant differences were found between the 2-week response
in the non-IRIS group (39 mg/L, IQR 9–87) and the group that
developed TB–IRIS (104 mg/L, IQR 56–175) (P 5 0.027). Of
the 10 TB–IRIS patients shown in Figure 3, 4 were prescribed
corticosteroid therapy and 2 were randomized to a double-blind
trial of prednisone versus placebo for mild to moderate TB–
IRIS. No obvious trend with respect to the effect of corticoste-
roid therapy on the Th1 expansions was observed.
DISCUSSION
Cape Town has a high tuberculosis case notification rate
(.1,000/100,000 per annum in the area in which this study was
conducted), rising adult HIV prevalence (antenatal seropreva-
lence exceeds 30% in some areas where the study was con-
ducted), and rapidly increasing access to cART with roll-out to
more than 20,000 people in the city so far. This triple coincidence
has led to a substantial increase in cases of TB–IRIS presenting
to our service: we have been referred nearly 400 cases in the last
3 years. This situation is mirrored in other large urban areas of
sub-Saharan Africa. TB–IRIS is an opportunity to better un-
derstand aberrant immunopathological immunity in tuberculosis
Figure 2. FoxP3 and T-cell activation markers in peripheral blood
mononuclear cells (PBMCs) of patients with tuberculosis-associated
immune reconstitution inflammatory syndrome (TB–IRIS). PBMCs from
11 TB–IRIS and 8 non-IRIS patients were analyzed. Although the pro-
portion of activated T cells (both CD41 and CD81) was high in both
groups, there were no significant differences between clinical groups. For
FoxP3 analysis cells were either unstimulated (unstim) or restimulated
(stim) with PPD for 24 hours. Again, there were no significant differences
between TB–IRIS and non-IRIS groups. Error bars show the SD.
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and thereby not only to treat TB–IRIS more effectively but also
to reduce the tissue damage that is characteristic of tuberculosis
in both HIV-infected and uninfected persons.
Cross-sectional analysis clearly confirmed that TB–IRIS is
associated with high frequencies of M. tuberculosis antigen–
specific IFN-g–secreting T cells, as previously reported (16).
These cells seem likely to contribute to the inflammatory
reactions observed clinically. The biggest difference in recogni-
tion between TB–IRIS and non-IRIS was in the recognition of
the small cytoplasmic heat shock proteins Acr1 and Acr2 (see
Figure 1). Both are upregulated by M. tuberculosis during
conditions of stress (31, 32), and it is possible that the combined
stresses of antituberculosis chemotherapy and an improving
immune response lead to such upregulation, thereby rendering
these molecules prominent antigenic targets. In this respect the
general principle of antigenic specificity implied by the poor
recognition of ESAT-6 in the patients with TB–IRIS studied
by Bourgarit and coworkers is borne out (16). However, and
contrary to those findings, we observed ESAT-6 to be a signif-
icant antigenic target in patients with TB–IRIS. This difference
may relate to ethnicity, disease extent, or length of antituber-
culosis therapy, as the response to ESAT-6 tends to decline
Figure 3. Longitudinal analysis of the frequency of M. tuberculosis antigen–specific IFN-g spot-forming cells in response to five antigens and C-
reactive protein (CRP) in HIV-TB patients receiving combination antiretroviral therapy (cART). An open triangle in the TB–IRIS group indicates the
point at which tuberculosis-associated immune reconstitution inflammatory syndrome (TB–IRIS) was diagnosed. Repeated measures analysis
demonstrated a significant increase in PPD response only in the TB–IRIS group (P 5 0.041). Within-category analysis confirmed the increase in
median PPD response in the TB–IRIS group between Weeks 0 and 8 to be significant (P 5 0.008). In addition, the increase in PPD response in the
non-IRIS group between Week 0 and both Weeks 2 and 4 was significant (P < 0.04). When comparing IRIS and non-IRIS groups the only significant
difference was between the 8-week response to PPD (P 5 0.001). The increase in median CRP response in the TB–IRIS group from between Weeks
0 and 2 was significant (P5 0.031). In addition, the increase in CRP in the non-IRIS group between Week 0 and both Weeks 2 and 4 (P< 0.006) was
significant. When comparing IRIS and non-IRIS groups significant differences in CRP were found between the 2-week response in the non-IRIS group
when compared with those who developed TB–IRIS (P 5 0.027).
TABLE 2. CLINICAL CHARACTERISTICS OF TB–IRIS THAT AROSE DURING LONGITUDINAL FOLLOW-UP OF HIV-INFECTED PATIENTS
WITH TUBERCULOSIS WHO RECEIVED COMBINATION ANTIRETROVIRAL THERAPY
Patient
no. Sex
Age
(yr)
CD41 Cell
Count Nadir
(cells/ml )
Presenting
Form of TB
Days of cART
to TB–IRIS Presentation of IRIS
B13 F 38 92 Culture-positive PTB 13 Developed new right cervical lymphadenopathy
B20 M 36 92 Clinical PTB 28 Transient worsening of pulmonary symptoms
B28 M 46 30 Disseminated 7 Worsening pulmonary infiltrate, hepatomegaly, and tachycardia.
B31 F 37 71 Culture-positive disseminated 13 Hepatic enlargement and cholestatic LFT derangement: liver
biopsy showed necrotizing granulomas
B30 F 42 42 Clinical PTB 14 Anemia and new cervical lymphadenopathy
B33 M 28 5 Culture-positive pleural 14 Worsening pulmonary infiltrate
B34 M 30 13 Culture-positive PTB 15 Pleurisy, cough, and high fever.
B38 M 37 10 Disseminated, smear positive 7 Fever, confusion, and lymphocytic meningitis
B49 F 36 113 Disseminated, smear positive 12 New headache and fever, found to have meningitis and a
tuberculoma
B52 F 20 48 Disseminated 28 New bilateral cervical lymphadenopathy
Definition of abbreviations: cART 5 combination antiretroviral therapy; F 5 female; LFT 5 liver function test; M 5 male; PTB 5 pulmonary tuberculosis; TB–IRIS 5
tuberculosis-associated immune reconstitution inflammatory syndrome.
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during successful treatment (33). We have also previously docu-
mented a high frequency of recognition of ESAT-6 (60–90%) in
HIV-infected persons with both active and latent tuberculosis in
this population (24, 34, 35).
Our flow cytometric analysis (see Figure 2) indicated that
both CD41 and CD81 cells from patients with TB–IRIS (and
non-IRIS patients) are activated, with a high percentage of cells
expressing HLA-DR or CD71. We attribute the CD81 cell
activation to the restoration of effector responses to HIV-1
itself. Expression of the transcription factor FoxP3 has been
associated with depression of M. tuberculosis antigen–specific
effector T-cell responses (36–38), leading to the hypothesis that
delayed cART-mediated restoration of such presumed regula-
tory T-cell responses underlies TB–IRIS (18). We found only
low levels of FoxP3-expressing CD41 T cells, perhaps in
keeping with this idea but, if anything, their level was actually
higher in patients with TB–IRIS than in non-IRIS patients.
Flow cytometry was performed on a relatively small subset of 11
patients with TB–IRIS and 8 non-IRIS subjects; this, given the
heterogeneous responses, limits power. However, we cannot
readily ascribe the difference between clinical groups to CD41
T cells that express FoxP3.
In the longitudinal analysis 10 patients developed TB–IRIS
(see Figure 3). These data, however, illustrate an important
point that was partially apparent from the cross-sectional anal-
ysis (see Figure 1). Dynamic expansion (and reductions) of M.
tuberculosis antigen–specific T cells also occurred in the major-
ity of non-IRIS patients, as did elevation of CRP. This had the
consequence that stringent tests for trend (with the exception of
the response to PPD in the TB–IRIS group) did not yield sig-
nificant results. Overall, the highly variable patterns of fluctu-
ation observed did not differ between persons who did and did
not develop TB–IRIS. Although an association between dy-
namic T-cell expansions and TB–IRIS therefore exists, these
data bring into question whether an explosion of tuberculin-
specific Th1 responses is the cause of this syndrome (16). Our
data favor the interpretation that during early cART in HIV-1–
infected patients with tuberculosis, effector responses are highly
dynamic, most likely reflecting a complex mixture of recircula-
tion, immune restoration, and a variably falling mycobacterial
antigen and HIV-1 viral load. The clinical heterogeneity of the
syndrome (see Table 2) also cautions against drawing conclu-
sions from limited numbers of patients.
In additional to clinical heterogeneity, a limitation of all
studies of TB–IRIS is the selection of control subjects. We
chose to study similar HIV-1–infected patients with tuberculosis
sampled after a similar duration of cART (14 d, the character-
istic time to onset of TB–IRIS) (see Table 1), but who did not
develop the condition during 2 months of follow-up. However,
the median duration of antituberculosis treatment was longer in
the non-IRIS group (see Table 1). It is recognized that a risk
factor for TB–IRIS is a short interval between the initiation of
antituberculosis therapy and cART. As prescribing practice
trends toward the earlier initiation of cART in patients with
tuberculosis because of likely mortality benefits (7), we can
expect the incidence and thus clinical importance of TB–IRIS to
increase. Another limitation is that the study was conducted
under program conditions and thus World Health Organization
clinical case definitions of HIV-1–associated tuberculosis (23)
and a clinical case definition of TB–IRIS (see Table E1) that
excluded documentation of increased CD41 cell count and a fall
in HIV-1 viral load were in use. However, in patients with TB–
IRIS for whom results were available 83% had complete HIV
suppression in samples taken after the IRIS episode and 94%
showed an increase in CD41 cell count: highly consistent with
general program conditions in which the HIV-1 viral load was
undetectable in 88.1% persons at 3 months and the median
increase in CD41 cell count was 134 cells/ml at 6 months (39). A
final limitation is that, in keeping with many studies of the
immunology of tuberculosis, we studied blood cells as a readily
accessible compartment. It would be of interest to conduct
similar analyses on cells from disease sites.
TB–IRIS is associated with high frequencies of M. tubercu-
losis antigen–specific IFN-g–secreting T cells and invariably
with CRP elevation, both indicative of vigorous cART-medi-
ated immune restoration. However, dynamic expansion of M.
tuberculosis antigen–specific T cells also occurred in the major-
ity of non-IRIS patients, as did CRP elevation. The frequency
of CD41 cells expressing FoxP3 did not differ between persons
who developed TB–IRIS and those who did not. Therefore the
differences in immune regulation that mark orderly or dysregu-
lated cART-mediated immune restoration in the context of
antituberculosis treatment in HIV-infected persons remain to
be fully elucidated.
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Objective: Paradoxical tuberculosis-associated immune reconstitution inflammatory
syndrome (TB-IRIS) is a frequent complication of antiretroviral therapy in resource-
limited countries. We aimed to assess whether a 4-week course of prednisone would
reduce morbidity in patients with paradoxical TB-IRIS without excess adverse events.
Design: A randomized, double-blind, placebo-controlled trial of prednisone (1.5mg/
kg per day for 2 weeks then 0.75mg/kg per day for 2 weeks). Patients with immediately
life-threatening TB-IRIS manifestations were excluded.
Methods: The primary combined endpoint was days of hospitalizati n and outpatient
therapeutic procedures, which were counted as one hospital day.
Results: One hundred and ten participants were enrolled (55 to each arm). The primary
combined endpoint was more frequent in the placebo than the prednisone arm {median
hospital days 3 [interquartile range (IQR) 0–9] and 0 (IQR 0–3), respectively; P¼0.04}.
There were significantly greater improvements in symptoms, Karnofsky score, and
quality of life (MOS-HIV) in the prednisone vs. the placebo arm at 2 and 4weeks, but not
at later time points. Chest radiographs improved significantly more in the prednisone
arm at weeks 2 (P¼0.002) and 4 (P¼0.02). Infections on study medication occurred in
more participants in prednisone than in placebo arm (27 vs. 17, respectively; P¼0.05),
but there was no difference in severe infections (2 vs. 4, respectively; P¼0.40). Isolates
from 10 participants were found to be resistant to rifampicin after enrolment.
Conclusion: Prednisone reduced the need for hospitalization and therapeutic pro-
cedures and hastened improvements in symptoms, performance, and quality of life. It is
important to investigate for drug-resistant tuberculosis and other causes for deterioration
before administering glucocorticoids.
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The roll out of antiretroviral therapy (ART) in resource-
limited countries has been associated with dramatic
improvements in survival and quality of life. In these
settings, a high proportion of patients commence ART
while on treatment for active tuberculosis, resulting in
a range of management challenges [1]. Paradoxical
tuberculosis-associated immune reconstitution inflam-
matory syndrome (TB-IRIS) is increasingly recognized as
an early complication of ART [2,3]. Paradoxical TB-
IRIS is thought to result from restoration of tuberculosis-
specific immune responses resulting in inflammation at
disease sites of tuberculosis wherein antigen persists
despite antitubercular treatment [4,5]. Typically, there
is initial improvement on antitubercular therapy, then,
after commencing ART, new, recurrent, or worsening
tuberculosis symptoms, signs, or radiographic manifes-
tations occur. Paradoxical TB-IRIS occurs in 8–43%
patients starting ART while on antitubercular therapy
[3,6–13]. Paradoxical TB-IRIS causes substantial mor-
bidity, often resulting in hospitalization and/or the need
for diagnostic and therapeutic procedures [13].
Glucocorticoids have been recommended for the
treatment of paradoxical TB-IRIS [14,15], but there is
little evidence for this recommendation, the largest study
being a retrospective report of nine patients [7]. In
tuberculous meningitis, glucocorticoids reduce mortality
[16], in tuberculous pericarditis, reduce mortality and the
need for repeat aspiration [17,18], and in pulmonary
tuberculosis, cause modest clinical and radiographic
improvement [19]. However, there is potential for harm
when prescribing glucocorticoids in HIV-infected
patients. Increased risk or progression of herpes zoster
and Kaposi’s sarcoma [20–22] have been reported. We
have recently reported that a substantial proportion of
patients presenting with suspected paradoxical TB-IRIS
have undiagnosed drug-resistantMycobacterium tuberculosis
[23], another situation in which glucocorticoids may
potentially cause harm.
We, therefore, conducted a randomized controlled trial of
glucocorticoid therapy for patients with paradoxical TB-
IRIS with the hypothesis that a 4-week course of
prednisone would reduce morbidity without an excess of
adverse events.Methods
Study participants
Patients were recruited at GF Jooste Hospital, a
secondary-level university-affiliated hospital in the
Western Cape Province of South Africa serving com-
munities with an antenatal HIV seroprevalence of up to
33% [24]. In 2006, the annual tuberculosis casepyright © Lippincott Williams & Wilkins. UnauthoCa
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notification rate in the province was 1031/100 000
[25]. Most patients initiate antitubercular treatment
and ART in primary care clinics. We have previously
described the ART and antitubercular therapy regimens
used in these clinics [23]. In accordance with national
guidelines, antitubercular drug susceptibility testing
(DST) is not routinely performed for new tuberculosis
cases, but in patients receiving re-treatment or not
responding to antitubercular treatment. Clinicians at the
primary care ART clinics were informed of the study and
encouraged to refer all patients with suspected paradoxical
TB-IRIS for assessment.
Consecutive patients were screened using standardized
case definitions for paradoxical TB-IRIS [23].We limited
enrolment to four TB-IRIS manifestations to reduce
clinical heterogeneity and allow longitudinal radiographic
comparison. Only patients with new or recurrent tuber-
culosis symptoms and at least one of the following TB-
IRIS manifestations were enrolled: infiltrate on chest
radiograph, enlarging lymph node(s), serous effusion, or
cold abscess. Each participant underwent full clinical
evaluation and chest radiography. Further investigations
were conducted to exclude alternative reasons for clinical
deterioration, according to presentation.
Exclusion criteria were age less than 18 years, known
rifampicin-resistant tuberculosis, previous glucocorticoid
therapy during this tuberculosis episode, prior ART
exposure, pregnancy, uncontrolled diabetes mellitus,
Kaposi’s sarcoma, and immediately life-threatening TB-
IRIS [defined as respiratory failure with arterial pO2
<8 kPa, altered level of consciousness, new focal neuro-
logical sign(s), or compression of a vital structure].
The study was approved by the University of Cape Town
Research Ethics Committee (337/2004). Written
informed consent was provided by all participants. The
trial was registered on 17 August 2005 with the
International Standard Randomised Controlled Trial
Number Register (ISRCTN 21322548). The trial was
conducted in accordance with the Helsinki Declaration.
Laboratory investigations
One or more clinical specimens (e.g., sputum, lymph
node aspirate) were sent for tuberculosis microscopy,
culture, and drug susceptibility testing. Specimens were
also sent for rapid rifampicin resistance determination
using a mycobacteriophage reporter system (FASTPla-
que) [26]. Repeat samples were sent if deterioration
occurred during follow-up.
Baseline investigations included electrolytes, urea and
creatinine, random glucose, full blood count, liver
function tests, calcium and albumin, random cortisol,
C-reactive protein (CRP), CD4þ lymphocyte count
(CD4 cell count), and hepatitis B surface antigen. Arterial
blood gas determination was performed in patients withrized reproduction of this article is prohibited.
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respiratory distress. Routine follow-up investigations
included CRP and glucose at each visit. CD4 cell count
was repeated at week 4.
Treatment
Study medication consisted of prednisone tablets (5mg)
or matching placebo. Prior to the study, a randomization
sequence assigning participants in a 1 : 1 ratio was
generated using Excel by the study statistician and given
to an independent pharmacist. Study medication was
packaged according to sequence by the independent
pharmacist off-site. The study medication was then
transferred to the GF Jooste Hospital pharmacy. The
hospital pharmacists, study clinicians, and participants
remained blind to sequence and randomization through-
out the trial. Participants were enrolled by the study
clinicians and consecutive participants received the next
study medication container from number 1 to 110.
Participants received study medication 1.5mg/kg per day
for 2 weeks followed by 0.75mg/kg per day for 2 weeks.
The initial high dose of prednisone (1.5mg/kg per day)
was chosen because rifampicin induces prednisone meta-
bolism [27]. Follow-up was at weeks 1, 2, 4, 8, and 12
with a full clinical assessment at each visit.
If significant clinical deterioration occurred after 2 weeks
of follow-up, the study protocol allowed participants to
be switched to open-label prednisone. If life-threatening
deterioration occurred before 2 weeks, participants could
be switched earlier. Unblinding, after switch to open-
label prednisone, was considered only if this information
influenced clinical management. Participants with sig-
nificant relapse of TB-IRIS symptoms after completing
4 weeks of study medication could also receive open-label
prednisone. Initiation of open-label prednisone required
agreement between at least two senior clinical investi-
gators. Participants were re-investigated at deterioration
for alternative diagnoses.
Most patients with respiratory presentations were
prescribed broad-spectrum antibiotics prior to enrol-
ment. If such patients experienced symptom resolution
on antibiotics, the diagnosis of TB-IRIS was reconsidered
and the patient was not enrolled. Nonsteroidal anti-
inflammatory drugs were not prescribed.
Assessment of outcome
The primary endpoint was cumulative days of hospital
admission during the 12-week study period, combined
with outpatient therapeutic procedures (including aspira-
tion of lymph nodes, cold abscesses, and serous effusions)
that were assigned a value of one hospital day. Procedures
performed prior to or at enrolment were not included.
There were several secondary outcome measures. At each
study visit, participants were asked about the TB-IRIS
symptoms they had presented with and the study clinician
enquired about any new TB-IRIS symptoms. The studyopyright © Lippincott Williams & Wilkins. Unauthf C
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clinician, blinded to treatment allocation, graded TB-
IRIS symptom response at week 2 and 4 visits in relation
to the symptoms described at study entry. Symptom
response was graded in one of three categories: deterio-
rated, no change, or improved/resolved. All patients who
developed new TB-IRIS symptoms were graded as
‘deteriorated’. Participants who switched to open-label
prednisone within 2 weeks or between 2 and 4 weeks had
their symptoms scored at the time of switching for their
2-week and 4-week scores, respectively. Symptoms of
participants who switched to open-label prednisone at or
before week 2 were not scored at week 4. The Medical
Outcomes Study-HIV (MOS-HIV) Health Survey [28]
and Karnofsky performance score were performed at each
visit. Participants were assessed for glucocorticoid adverse
drug reactions and new infections.
Two radiologists, blinded to study allocation, compared
chest radiographs at weeks 2 and 4 with baseline (week 0).
They utilized a three-point scale (deteriorated, no
change, or improved/resolved). If there was a disagree-
ment, they met to agree on a final consensus score.
Ultrasound scans (measuring lymph node diameter or
pericardial effusion width) were also scored at the same
time points using a three-point scale: more than 25%
increase, less than 25% increase or decrease, and more
than 25% decrease in size.
Statistical analysis
Defervescence in paradoxical TB-IRIS is reported to
occur in 50% by 2 weeks [6]. We based our sample size
calculation on the assumption that spontaneous resolution
of paradoxical TB-IRIS at 2 weeks would occur in 50% of
the participants who received placebo. We estimated
resolution in 80% of the participants on prednisone by 2
weeks. A sample size of 90 would be required to detect
these rates of resolution for an a of 0.05 and b of 0.2.
Therefore, we planned recruitment of 100 patients,
assuming a 10% drop-out rate. Sample size was sub-
sequently increased to 110, as we found that appro-
ximately 10% of our participants had unsuspected
rifampicin-resistant tuberculosis [23].
A data and safety monitoring board (DSMB) of three
clinical researchers and an independent statistician
reviewed the study results after 50 participants had
completed the study follow-up. They advised continuing
based on predetermined stopping rules.
The analysis of the primary endpoint included all
participants, according to the intention-to-treat prin-
ciple. Analysis of the primary combined endpoint was
performed using the Wilcoxon rank-sum test. Other
comparisons between the two groups were made using
Wilcoxon rank-sum, chi-squared, and Fisher’s exact tests,
as appropriate. Quantile regression was performed to
adjust the primary endpoint for baseline differences
between the two groups in duration from start oforized reproduction of this article is prohibited.
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cortisol level. Kaplan–Meier methods were used to
construct time-to-event curves for the two groups and
the Gehan–Breslow–Wilcoxon test was used for
comparison. Reported P values are two-sided.Results
Two hundred and eighty-seven patients were screened
and 110 were enrolled (55 to prednisone, 55 to placebo).
Progress of participants through the trial is shown in
Fig. 1. There were six protocol deviations (Supple-
mentary Table 4, http://links.lww.com/QAD/A85).
Seventy (64%) were women and the median age was 31.6
years (range 19–56). Median CD4 cell count prior to
ARTwas 53 cells/ml and at enrolment was 116 cells/ml.
Table 1 shows baseline characteristics comparing the two
arms. Median duration from antitubercular therapy to
ART initiation was significantly longer in the prednisoneUn
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Fig. 1. Progress of participants through the trial. aCommon altern
(eight), cryptococcosis (four), diarrhoeal illness (four), and heart
immediately life-threatening manifestation was neurological tuber
drome (TB-IRIS) (n¼25).ow
n
arm. Random cortisol was significantly lower in the
prednisone arm, but no participant had a value below
reference range. Otherwise the arms were evenly
matched. Forty-four participants received antibiotics
prior to enrolment.
Initial tuberculosis diagnosis was made by culture of M.
tuberculosis in 46 (42%), a positive smear for acid-fast bacilli
in 26 (24%), and was empiric based on clinical and
radiographic findings in 38 (35%). Fourteen of the 38
participants with an initial empiric tuberculosis diagnosis
had microbiologic confirmation at some stage during the
study (seven culture positive and seven smear positive).
Outcomes are shown in Table 2 and Fig. 2. The median
cumulative number of hospital days (with outpatient
therapeutic procedures counted as one additional day)
was 0 [interquartile range (IQR) 0–3] in the prednisone
arm and 3 (IQR 0–9) in the placebo arm (P¼ 0.04). In a
multivariate regression model controlling for baseline
differences between the two arms, this difference
remained significant (P¼ 0.009).Ca
pe
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ative diagnoses were drug reaction (nine), bacterial infection
failure (four). bAmong these 33 patients, the most frequent
culosis-associated immune reconstitution inflammatory syn-
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Table 1. Participant characteristics at enrolment.
Placebo arm (N¼55) Prednisone arm (N¼55) P value for comparison
Age 31.6 (19–56.9) 31.5 (19.1–46) 0.82
Female sex 32 (58%) 38 (69%) 0.23
Previous tuberculosis 10 (18%) 15 (27%) 0.26
CD4 cell count prior to ART (cells/ml) 48 (20–92) 56 (30–103) 0.15
WHO stage 4 at ART initiation 33 (60%) 29 (53%) 0.44
Duration antitubercular therapy to ART in days 43.5 (23.8–76) 66 (35–84) 0.02
Duration ART to TB-IRIS in days 10 (7–19) 14 (7–21) 0.21
Duration TB-IRIS to enrolment in days 14 (8–23.5) 12.5 (7–21) 0.24
TB-IRIS manifestations
New/recurrent lymphadenopathy 28 (51%) 19 (35%) 0.10
New/recurrent cold abscess 1 (2%) 1 (2%) 1.0
New/worsening pulmonary infiltrate 16 (29%) 19 (35%) 0.54
New/worsening serous effusion 9 (16%) 9 (16%) 1.0
Recurrent symptoms and consistent radiography,
but without baseline radiography available for comparison
14 (25%) 15 (27%) 0.83
CD4 cell count at enrolment (cells/ml) (n¼97) 109 (55–190) 138 (78–243) 0.07
Random glucose (mmol/l, 4.1–11.1) (n¼108) 5.3 (4.8–5.7) 5.1 (4.8–6) 0.79
Haemoglobin (g/dl, male 13–17, female: 12–15) (n¼107) 9.2 (7.8–10.1) 9.1 (8.1–10.3) 0.79
Albumin (g/l, 35–52) (n¼108) 23 (19.5–26.5) 23 (20–26) 0.62
C-reactive protein (mg/l, 0–10) (n¼108) 106 (79–172) 104 (50–150) 0.18
Random cortisol (nmol/l, 138–690) (n¼97) 559.5 (405.8–774) 471 (350–614) 0.03
Hepatitis B surface antigen positive (n¼94) 3/42 (7%) 3/52 (6%) 0.79
Weight (kg) 52.2 (46.6–58.8) 51.6 (48.1–56.5) 0.69
Hospitalized at enrolment 19 (35%) 14 (25%) 0.30
Antibiotics prior to enrolment 19 (35%) 25 (45%) 0.24
Karnofsky performance score (n¼107) 70 (30–80) 70 (30–80) 0.96
MOS-HIV Health Survey (n¼106)
Physical health summary score 37.9 (32.8–44.9) 36.3 (33.4–43.1) 0.97
Mental health summary score 49.8 (39.1–56.9) 49.7 (44.5–56) 0.75
Values shown are medians (interquartile range) or numbers (%). Reference ranges for laboratory tests are shown in brackets. ART, antiretroviral
therapy; MOS, Medical Outcomes Study; TB-IRIS, tuberculosis-associated immune reconstitution inflammatory syndrome.Un
ive
rsi
ty 
The symptom score showed more rapid improvement in
the prednisone arm at 2 weeks (P¼ 0.001) and 4 weeks
(P¼ 0.03) (Fig. 2a). The chest radiograph score demon-
strated greater improvement in the prednisone arm at
2 and 4 weeks (Fig. 2b). The ultrasound score (n¼ 29)
demonstrated no significant difference at either time
point (data not shown). There were significantly greater
improvements in MOS-HIV physical and mental health
summary scores, Karnofsky performance score, and CRP
at weeks 2 and 4 in the prednisone arm, but not at later
time points.
Five participants switched to open-label prednisone
during the period of study medication (first 4 weeks)
in the prednisone arm and 18 in the placebo arm
(P¼ 0.002) (Fig. 3). Three such participants had study
allocation unblinded. There was concern of hepatitis B
flare in one, oesophagitis due to herpes virus (not
confirmed) in another, and pancreatitis in a third. All
three had been allocated placebo. Ten participants in the
prednisone arm and two in the placebo arm were started
on open-label prednisone after completing the 4 weeks of
studymedication (P¼ 0.01) due to ongoing deterioration
or, more frequently, relapse after having improved on
study medication. Participants who initiated open-label
prednisone were weaned according to response. Median
duration of open-label prednisone was 84 days (IQR 60–
126).opyright © Lippincott Williams & Wilkins. UnauthfEight participants in the prednisone arm and three in
the placebo arm had events that could potentially be
attributed to a glucocorticoid adverse drug reaction while
on study medication (P¼ 0.11). Infections while on study
medication occurred in 27 participants in the prednisone
arm and 17 in the placebo arm (P¼ 0.05). The majority
of these infections were mild, mainly oral and vaginal
candidiasis, and uncomplicated herpes simplex (Supple-
mentary Table 1, http://links.lww.com/QAD/A82).
Severe infections, defined as invasive bacterial infections
or new World Health Organisation stage 4 conditions,
occurred in two participants in the prednisone arm and
four in the placebo arm during the 12-week study period
(P¼ 0.40). These severe infections were a Klebsiella
wound infection complicated by fatal sepsis syndrome,
oesophageal candidiasis, pneumocystis pneumonia, and
cryptococcal meningitis in the placebo arm. The
participant who developed oesophageal candidiasis was
on open-label prednisone when this occurred. In the
prednisone arm, the severe infections were fatal pneu-
monia and cytomegalovirus retinitis.
There were three deaths in the prednisone arm and two in
the placebo arm (P¼ 0.65). Causes of death are shown in
Supplementary Table 2 (http://links.lww.com/QAD/
A83). Six participants defaulted follow-up for more than
7 days (all in the placebo arm; P¼ 0.01). Five sub-
sequently returned to care.orized reproduction of this article is prohibited.
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Table 2. Primary and secondary outcomesa.
Placebo arm
(N¼55)
Prednisone arm
(N¼55)
P value for
comparison
Cumulative days hospitalized and outpatient
therapeutic procedures
3 (0–9) 0 (0–3) 0.04
Number of participants hospitalized 25 (45%) 17 (31%) 0.12
Cumulative number of days hospitalized 463 282 –
Median number of days hospitalized (all participants) 0 (0–8) 0 (0–3) 0.07
Median number of days hospitalized (among 42 participants
who were hospitalized)
12 (5–30) 4 (3–29) 0.26
Number of participants who had outpatient therapeutic
procedure performed
12 (22%) 12 (22%) 1.0
Cumulative number of outpatient therapeutic proceduresb 28 24 –
Karnofsky performance score
Week 2 (n¼92) 70 (50–90) 90 (80–90) <0.001
Week 4 (n¼86) 80 (60–90) 90 (80–100) <0.001
Week 8 (n¼91) 90 (75–100) 90 (90–100) 0.33
Week 12 (n¼89) 90 (90–100) 100 (90–100) 0.16
MOS-HIV Health Survey
Physical health summary score
Week 2 (n¼98) 44.5 (36.7–52.4) 51.5 (44.5–54.5) 0.01
Week 4 (n¼94) 48.3 (39.7–55) 51.2 (46.6–56.8) 0.04
Week 8 (n¼96) 52.9 (44.2–55.5) 53.3 (42.9–56) 0.97
Week 12 (n¼88) 52.4 (48.1–56.1) 52.4 (48.9–55.5) 0.93
Mental health summary score
Week 2 (n¼98) 57.4 (48.8–60) 59.9 (54.2–62.1) 0.02
Week 4 (n¼94) 55.5 (50.3–60) 58.5 (55.6–62.2) 0.01
Week 8 (n¼96) 60.6 (55.8–62.6) 60.6 (54.4–62.7) 0.79
Week 12 (n¼88) 61.7 (58.6–63) 60.7 (58.6–63.7) 0.68
CRP (mg/l)
Week 2 (n¼101) 96.5 (53.8–122.5) 35 (13.8–60.3) <0.001
Week 4 (n¼94) 63 (40.5–117.5) 34 (16.3–57) 0.001
Week 8 (n¼95) 42 (20–83.5) 39 (13–84.3) 0.49
Week 12 (n¼97) 36 (17–80) 25 (9–60.5) 0.12
Week 4 CD4 cell count (cells/ml) (n¼75) 145 (61–224) 154 (78–248) 0.51
Glucocorticoid adverse drug reactionc while on study medication 3 (5%) 8 (15%) 0.11
Infections while on study medication 17 (31%) 27 (49%) 0.05
Death 2 (4%) 3 (5%) 0.65
Values shown are medians (IQR) or numbers (%). ART, antiretroviral therapy; CRP, C-reactive protein; IQR, interquartile range; MOS, Medical
Outcomes Study.
aSymptom and radiographic scores are not shown here, but are shown in Fig. 2.
bOutpatient therapeutic procedures performedduring the12week studyperiodare shown inSupplementaryTable3,http://links.lww.com/QAD/A84.
cDefined as clinical events that could potentially be attributed to glucocorticoid adverse drug reaction: blood pressure higher than 140/90mmHg,
glucose higher than 11.1mmol/l, oedema, hypomania, Cushingoid features, acne or gastritis symptoms.Un
ivDrug resistance
Ten cases of rifampicin-resistant tuberculosis were diag-
nosed after studyenrolment. In eight, it was diagnosed after
completion of study medication. Three received open-
label prednisone. In the placebo arm, there were six cases
[five multidrug resistant (MDR) and one rifampicin
monoresistant] and in theprednisone arm four (twoMDR,
one rifampicin monoresistant, and one rifampicin resistant
on FASTPlaque assay, but other drug susceptibility testing
could not bedonedue to contamination) (P¼ 0.50). INH-
monoresistant tuberculosis was present in one participant
in the placebo arm (diagnosed at tuberculosis diagnosis)
and one in the prednisone arm (diagnosed at TB-IRIS
presentation).Discussion
We found that a 4-week course of prednisone reduced the
primary combined endpoint of days hospitalized andpyright © Lippincott Williams & Wilkins. Unauthooutpatient therapeutic procedures in patients presenting
with paradoxical TB-IRIS. Mortality was not chosen as a
primary outcome, as death due to paradoxical TB-IRIS is
infrequent in reported series [3,12,13,29]. Furthermore,
exclusion of patients with immediately life-threatening
manifestations reduced the likelihood that we would
demonstrate a significant difference. Additional benefits
of prednisone were seen across a range of secondary
outcome measures including symptom and Karnofsky
performance scores, quality-of-life assessments, radio-
graphic response, and reduction in CRP. The greatest
effects were seen at the 2-week visit. Thereafter, the effect
size and significance diminished, likely due to the
combined effect of cross-overs from placebo to open-
label prednisone for symptom deterioration and the self-
limiting nature of most cases of paradoxical TB-IRIS in
placebo group.
Switching to open-label prednisone while on study
medication occurred significantly more frequently in therized reproduction of this article is prohibited.
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Fig. 2. Symptom and chest radiograph scores. (a) Symptom score at weeks 2 and 4. The distribution of symptom scores in
percentage at weeks 2 and 4 in three categories (deteriorated, no change, improved/resolved) is shown. Participants who switched
to open-label prednisone at or before week 2 were not scored at week 4 (they are shown in a separate category together with those
who died within 2 weeks on the week 4 graph). There were significant differences between the two arms at week 2 (P¼0.001) and
week 4 (P¼0.03). (b) Chest radiograph scores at weeks 2 and 4. Participants who had a pulmonary infiltrate on chest radiograph at
baseline (week 0) had a chest radiograph score assigned at weeks 2 and 4 by two radiologists. Scores were allocated in three
categories (deteriorated, no change, improved/resolved) in comparison with the week 0 chest radiograph. The distribution of
scores in percentage is shown. There were significant differences between the two arms at week 2 (P¼0.002) and week 4
(P¼0.02).Un
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sone arm needed to restart prednisone after 4 weeks
suggests that this course was too short for a subset. Some
participants were treated with open-label prednisone for
several months. Paradoxical TB-IRIS is a heterogeneous
condition with variable natural history and the gluco-
corticoid regime should in clinical practice be tailored to
severity and response.
Prednisone was well tolerated. There was no excess of
glucocorticoid adverse drug reactions while on study
medication in the prednisone arm. More infections
occurred in the prednisone arm while on study drug. The
majority of these were mild infections and there was no
difference in the incidence of severe infections by study
arm.
When considering glucocorticoid therapy for paradoxical
TB-IRIS, it is crucial to exclude alternative diagnoses,
especially new infections or drug-resistant tuberculosis
[23], because glucocorticoids may cause harm if the
diagnosis of paradoxical TB-IRIS is incorrect. Most
patients who had a respiratory presentation were treated
with a broad-spectrum antibiotic prior to enrolment, as a
bacterial chest infection is an important differentialopyright © Lippincott Williams & Wilkins. Unauthdiagnosis in this context. An alternative diagnosis was
made in 44 of the paradoxical TB-IRIS suspects screened,
and rifampicin-resistant tuberculosis was diagnosed in a
further 10 participants after enrolment, even though we
excluded patients with known rifampicin-resistant tuber-
culosis and patients who had not symptomatically
improved prior to ART. There is currently no diagnos-
tic test for paradoxical TB-IRIS. In resource-limited
settings, where most cases of paradoxical TB-IRIS occur,
it is difficult to exclude alternative diagnoses and drug-
resistant tuberculosis. Some caution, therefore, has to be
exercised when prescribing glucocorticoids in resource-
limited settings. In any setting, it is prudent to avoid or
defer glucocorticoids until the diagnosis of paradoxical
TB-IRIS is firmly established and reassess the diagnosis of
paradoxical TB-IRIS should a patient further deteriorate
while being treated with glucocorticoids.
A major challenge in management and research of
paradoxical TB-IRIS is that there is no confirmatory
diagnostic test. We [23] have previously reported that
CRP is almost universally elevated in paradoxical TB-
IRIS and that its levels are higher in paradoxical TB-IRIS
suspects who are subsequently diagnosed with rifampi-
cin-resistant TB. However, CRP is unlikely to have
diagnostic utility, as most of the differential diagnoses fororized reproduction of this article is prohibited.
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Fig. 3. Thirty-five participants were started on open-label
prednisone (20 in the placebo arm and 15 in the prednisone
arm). This Kaplan–Meier graph demonstrates the differences
in the time that open-label prednisone was started between
the two arms. In the first four weeks, while participants were
receiving study medication, 18 in the placebo arm (33%)
comparedwith five in the prednisone arm (9%)were switched
to open-label prednisone (P¼ 0.002) because of significant
symptom deterioration. After 4 weeks, two in the placebo arm
(4%) compared with 10 in the prednisone arm (18%) were
started on open-label prednisone (P¼0.01) mainly because of
relapse of tuberculosis-associated immune reconstitution
inflammatory syndrome (TB-IRIS) symptoms.Un
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oparadoxical TB-IRIS also cause elevations of CRP.
Interferon-gamma release assays (IGRAs) have been
proposed as possible diagnostic tools. Certain studies
[4,30] have demonstrated that IGRAs, with purified
protein derivative as the antigen stimulus, differentiate
paradoxical TB-IRIS cases from controls. Our own study
[5] suggested that IGRAs do not sufficiently differentiate
cases from controls to be considered as a diagnostic test.
Other approaches being explored are the identification of
a characteristic cytokine profile or gene expression
signature for paradoxical TB-IRIS. In the interim,
diagnosis relies upon the use of clinical case definitions
[2].
The development of Kaposi’s sarcoma in HIV-infected
patients treated with glucocorticoids has been reported
[20,21]. Kaposi’s sarcoma was an exclusion criterion in
our study and no cases occurred in our study, possibly due
to the protective effect of ART. We recommend
avoidance of glucocorticoids in patients with Kaposi’s
sarcoma, as life-threatening exacerbation may occur [22].
Our study has several limitations. It was conducted at a
single site with a relatively small sample size that did not
permit subgroup analyses. Radiography from the time of
initial tuberculosis diagnosis and ART initiation was
unavailable in some participants. In these participants, thepyright © Lippincott Williams & Wilkins. UnauthoCa
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diagnosis of paradoxical TB-IRIS was made on the basis
of recurrent tuberculosis symptoms and the presence of
compatible radiographic tuberculosis manifestations (pul-
monary infiltrates, visceral lymphadenopathy, or serous
effusions), but we did not know for certain whether the
radiographic manifestations were worsening. Further-
more, it is possible that certain of the subjective measures
of improvement (symptom score, quality-of-life assess-
ment, and Karnofsky performance score) may have been
influenced by the euphoric effect associated with high-
dose glucocorticoids. Although the treatment allocation
was randomized, two characteristics were found not to be
evenly matched between the two arms (random cortisol
and duration of antitubercular therapy to ART). These
variables could thus potentially have confounded study
findings, but no such effect could be found on the
primary endpoint when these two variables were included
in a multivariate regression model. An additional limita-
tion was that the tuberculosis diagnosis was confirmed by
culture in only 48% of participants. This reflects the
practice in a programmatic setting in South Africa where
culture is limited and not routinely performed in new
tuberculosis cases.
In conclusion, a 4-week course of prednisone reduced
days hospitalized and outpatient therapeutic procedures
and resulted in more rapid improvements in symptoms,
radiography, markers of inflammation, performance, and
quality of life. An important caveat is that clinicians
should be certain of the diagnosis of paradoxical TB-IRIS
and investigate for antitubercular drug resistance when
considering glucocorticoid therapy. Knowing that there is
effective symptomatic therapy for paradoxical TB-IRIS
may make clinicians less reluctant to start ART early in
patients with tuberculosis and advanced immunosuppres-
sion [31].Acknowledgements
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CHAPTER 6 SUPPLEMENTARY TABLES 
 
Supplementary Table 1: New or recurrent infections while on study medication 
 
 Placebo arm Prednisone arm 
Oral or vaginal candidiasis  8 21 
Tinea 4 4 
Molluscum contagiosum 0 2 
Herpes simplex 3 6 
Warts 0 3 
Pneumonia 0 1 
Cystitis 1 0 
Otitis media 1 0 
Cryptococcal meningitis 1 0 
TOTAL 18 37 
 
 
While on study medication, in the placebo arm 18 infections occurred in 17 
participants and in the prednisone arm there were 37 infections in 27 participants. 
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Supplementary Table 2: Causes of death (n=5) 
 
Cause of death Study arm Study week 
Community-acquired pneumonia Prednisone 3 
Wasting syndrome and TB-IRIS Prednisone 2 
Wasting syndrome and abdominal TB-IRIS Prednisone 6 
Multidrug-resistant tuberculous meningitis Placebo 1 
Warfarin skin necrosis, klebsiella wound infection 
complicated by systemic sepsis 
Placebo 7 
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Supplementary Table 3: Outpatient therapeutic procedures performed after 
enrollment and during the 12 week study period 
 
 Placebo arm Prednisone arm 
Aspiration of lymph node or 
cold abscess 
23 22 
Aspiration of serous effusion 5 1 
Intercostal drain insertion 0 1 
TOTAL 28 24 
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Supplementary Table 4: Six protocol deviations 
 
Protocol deviation Study arm 
Participant found to have been ART non-naïve after study Prednisone 
After enrollment found that participant had previous 
adjunctive prednisone exposure, prior to ART, for 
tuberculous meningitis 
Prednisone 
Participant under-dosed in the first week due to 
misunderstanding 
Prednisone 
Participant had started ART 2 weeks before tuberculosis 
diagnosis then developed paradoxical reaction after starting 
antitubercular therapy. This sequence of events only became 
known after enrollment as the referral letter had stated ART 
was started after tuberculosis diagnosis. 
Placebo 
Participant received the study medication at the higher dose 
(1.5mg/kg) for week 3 
Placebo 
Participant took an overdose of study medication on day 1 
due to a misunderstanding 
Placebo 
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CHAPTER 7 
 
Corticosteroid modulated immune activation in HIV / tuberculosis-associated immune 
reconstitution inflammatory syndrome 
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Abstract  
 
Rationale 
HIV-tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an 
immunopathological reaction to mycobacterial antigens induced by antiretroviral therapy 
(ART). Prednisone reduces morbidity in TB-IRIS, but the mechanisms are unclear. 
 
Objectives 
To determine the effect of prednisone on the inflammatory response in TB-IRIS (antigen-
specific effector T cells, cytokines and chemokines). Samples from participants in a 
randomized placebo-controlled trial of prednisone for TB-IRIS, taken at 0, 2 and 4 weeks, 
were analysed using ELISpot, RT-PCR and Luminex multiplex cytokine analysis. 
 
Findings 
58 participants with TB-IRIS (31 prednisone, 27 placebo) were included. No differences in 
ELISpot responses comparing prednisone and placebo groups were shown in response to 
ESAT-6, Acr1, Acr2, 38kDa or heat killed H37Rv M. tuberculosis. PPD ELISpot responses 
increased over 4 weeks in prednisone group and decreased in placebo group (p=0.007). In 
serum, significant decreases in IL-6, IL-10, IL-12p40, TNFα, IFNγ and IP-10 concentrations 
during prednisone, but not placebo, treatment were observed.  
 
Conclusions 
The beneficial effects of prednisone in TB-IRIS appear mediated via suppression of 
predominantly innate pro-inflammatory cytokine responses, not via a reduction of the 
numbers of antigen-specific T cells. 
 
 
134
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
Introduction 
 
Inflammatory pathology driven by the immune response to mycobacteria is a characteristic 
feature of treatment in tuberculosis (TB), leprosy and other non-tuberculous mycobacterial 
infections. Paradoxical reactions after commencement of TB treatment (1, 2), immune 
reconstitution inflammatory syndrome (IRIS) after initiation of antiretroviral therapy (ART) 
(3-5), and type 1 and 2 reactions in patients being treated for leprosy (6, 7) are all examples 
of treatment-induced immunopathology. Corticosteroids are used to modulate these 
immunopathological reactions and in certain forms of TB, such as meningitis and 
pericarditis, adjunctive treatment with corticosteroids has been shown to improve clinical 
outcomes (8-10). The benefit of corticosteroids is likely related to reducing pathological 
inflammation caused by the immune response, but mechanisms are not well characterized. 
 
Paradoxical TB-IRIS occurs in 8-43% of HIV-infected patients who start ART while on 
treatment for TB (3). Within a few weeks of starting ART patients develop recurrent 
symptoms of TB and worsening of clinical and radiographic features of TB, such as 
enlargement of TB lymphadenitis (3, 4). We have recently reported a randomised placebo-
controlled clinical trial of prednisone for the treatment of paradoxical TB-IRIS (11). A 4-
week course of prednisone reduced the duration of hospitalization and the number of 
outpatient therapeutic procedures. In addition, participants on prednisone experienced 
significant improvement in TB-IRIS symptoms, chest radiographs and more rapid reduction 
in C-reactive protein (CRP). There was no mortality difference and no excess of severe 
infections in the prednisone-treated participants in this trial. 
 
The immunological mechanisms underlying paradoxical TB-IRIS are partially elucidated. 
Expansion of mycobacterial-specific effector T cells that produce interferon-gamma (IFNγ) 
after starting ART have been associated with TB-IRIS in several studies (12-14). However, 
we have questioned the causal role of such expansions because we observed similar 
expansions in control TB patients starting ART who did not develop TB-IRIS and some TB-
IRIS patients did not demonstrate expansions at the time of IRIS onset (14). Pro-
inflammatory cytokines, in particular TNFα, IFNγ and IL-6, likely play an important role in 
pathogenesis as their concentrations are significantly raised in TB-IRIS patients (15).  
Defective T regulatory cell function is also speculated to play a role (16, 17). 
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In this study we analysed samples collected during the randomised controlled trial of 
prednisone for paradoxical TB-IRIS (11) to assess the effect of prednisone on T cell 
expansions, cytokine and chemokine gene expression and protein concentrations after in vitro 
stimulation and cytokine/chemokine concentrations in vivo. The aim was to determine the 
effect of corticosteroids on the aberrant immune response in TB-IRIS.  
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Methods 
 
Setting. The study was conducted at GF Jooste Hospital, a community-based referral 
hospital, in Cape Town, South Africa, that serves communities with a high prevalence of HIV 
infection and TB. Most patients are commenced on TB treatment and ART in community 
primary care clinics, but are referred to GF Jooste Hospital when complications occur for 
investigations and/or admission. Patients with a first episode of TB are treated with 
rifampicin, isoniazid, ethambutol and pyrazinamide for 2 months followed by rifampicin and 
isoniazid for 4 months. For subsequent episodes the treatment duration is 8 months and 
includes streptomycin for the first 2 months. At the time of the study the preferred ART 
regimen for patients on TB treatment was stavudine, lamivudine and efavirenz. 
 
Clinical trial. Between 2 June 2005 and 20 December 2007 we enrolled participants into a 
randomized placebo-controlled clinical trial of prednisone for the treatment of paradoxical 
TB-IRIS. The methods have been described in detail (11), but are summarized here. 
Consecutive patients with suspected paradoxical TB-IRIS referred to the hospital were 
screened using standardized case definitions for paradoxical TB-IRIS (3). We limited 
enrollment to four TB-IRIS manifestations to reduce heterogeneity and allow longitudinal 
radiographic comparison. Only patients with new or recurrent tuberculosis symptoms and ≥1 
of the following manifestations were enrolled: (1) infiltrate on chest radiograph, (2) enlarging 
lymph node/s, (3) serous effusion/s or (4) cold abscess/es. Patients with immediately life 
threatening TB-IRIS were excluded. The TB diagnosis was made on the basis of culture, 
smear microscopy or clinico-radiological diagnosis (18, 19). 
 
Participants were randomized to receive study medication, either prednisone at 1.5mg/kg/day 
for 2 weeks followed by 0.75mg/kg/day for 2 weeks or identical placebo. If significant 
clinical deterioration occurred after 2 weeks of follow up, the study protocol allowed 
participants to be switched to open label prednisone or earlier if life-threatening deterioration 
occurred. Follow-up was for 12 weeks. The primary endpoint of the study was cumulative 
number of days hospitalized and number of outpatient therapeutic procedures performed 
counted as one additional hospital day. Secondary endpoints of efficacy included symptom 
score, quality of life score, Karnofsky performance score, chest radiography and C-reactive 
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protein. Mortality, metabolic side effects of prednisone and new infections were other 
secondary endpoints (11). 
 
Timing of blood samples. Blood samples were taken from participants enrolled in the clinical 
trial prior to starting study medication (week 0) and then at week 2 and week 4 on the trial. 
Placebo-treated participants who were switched to open-label prednisone were not excluded 
from this immunology study, but any sample taken after switch to prednisone was excluded. 
For all experiments, laboratory workers were blinded to the treatment allocation of 
participants. 
 
Participants. 110 patients were enrolled in the clinical trial (55 received placebo and 55 
prednisone).  Blood samples were taken from the first 73 participants in the clinical trial for 
this immunology study provided that laboratory staff were available to process specimens 
during working hours.  If at least one repeat specimen (at 2 or 4 weeks) was available then 
the participant was included in these analyses. The inclusion and exclusion of participants 
was not subject to systematic bias because the treatment allocation was randomized and 
unknown to clinical or laboratory staff at the time of specimen processing. To analyze 
ELISpot results by treatment response participants were classified as improvers (symptoms 
improving at week 2 and no new symptoms) or non-improvers (symptoms unchanged or 
worsened at week 2 in comparison with week 0 symptoms) irrespective of treatment 
allocation.  
 
Ethical permission and trial registration. The study was approved by the Research Ethics 
Committee of the Faculty of Health Sciences of the University of Cape Town (337/2004 and 
049/2009). Written informed consent was obtained from all participants. The trial was 
registered with the International Standard Randomised Controlled Trial Number register 
(ISRCTN 21322548). 
 
PBMC isolation. PBMC were isolated from 30ml of blood collected in Na-heparin BD 
vacutainers using the Ficoll separation method on day of collection. 
 
ELISPOT assay. ELISpot analysis was performed as previously described (14, 20-22) on the 
day the sample was taken. Antigenic stimuli were endotoxin free and were assayed in 
duplicate wells. The concentrations used were 5 µg/mL of early secreted antigen target-6 
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(ESAT‐6), 10 µg/mL of α-crystallin 1, 20 µg/mL of α-crystallin 2 and 2.5 µg/mL of 38kDa 
antigen. PPD was used at 200 IU/mL (4.6 µg/mL) and heat-killed (hk) H37Rv 
Mycobacterium tuberculosis at a multiplicity of infection (MOI) of 1:1 (200 000 H37Rv: 200 
000 PBMC). Control wells included phytohaemagglutinin (5 µg/mL) and no antigenic 
stimulus. The number of IFNγ spot forming cells/106 PBMC on ELISPOT plates were 
counted on an Immunospot Series 3B Analyzer (Cellular Technology) and plates were 
retained for visual inspection and confirmation in case of anomaly. Forty-one participants 
were included in the ELISPOT analysis (16 placebo-treated and 25 prednisone-treated). 
 
RNA isolation and quantitative RT-PCR following Mycobacterium tuberculosis 
stimulation of PBMC. After PBMC isolation, cells at 2.5 x 106 /ml in RPMI/10% FCS were 
rested overnight in an incubator at 37°C in 5% CO2. Thereafter the PBMC were restimulated 
with hkH37Rv Mycobacterium tuberculosis for 24 hrs by infecting PBMC at an MOI 1:1 and 
unstimulated cultures were also incubated. After restimulation, PBMC were harvested and 
lysed in 350 µl of RLT-lysing buffer (Qiagen, Valencia, CA). Lysates were collected for 
RNA analysis and tissue culture supernatants were preserved at -80ºC until used for the 
Luminex multiplex experiments (described below). 
 
RNA was extracted from PBMC lysates using the RNeasy Mini Kit Spin Protocol for 
isolation of total RNA from Animal Cells (Qiagen) as per manufacturer’s instructions and 
stored at -80ºC until further use. Primers and probes for RT-PCR were purchased from 
Applied Biosystems as predesigned inventoried assay reagents. We used the following 
TaqMan® Gene Expression Assays: IL-1β Catalogue Number, Hs00174097_m1; IL-2, 
Hs00174114_m1; IL-4, Hs00174122_m1; IL-6, Hs00985639_m1; IL-8, Hs01038788_m1; 
IL-10, Hs00174086_m1; IL-12p40, Hs01011518_m1; lL-13, Hs00174379_m1; IL-15, 
Hs00542562_m1; IL-17A, Hs00174383_m1; IL-22, Hs00220924_m1; IL-27, 
Hs00377399_m1; TNFα, Hs00174128_m1; IFNγ, Hs00174143_m1; GM-CSF, 
Hs00171266_m1; CCL3, Hs00234142_m1; CCL4, Hs99999148_m1; CCL5, 
Hs00174575_m1. RNA concentration was determined by Nanodrop and samples diluted to 
give a RNA working solution concentration of approximately 10ng/µl. RT-PCR was 
performed using the TaqMan® RNA-Ct 1 Step kit protocol (Applied Biosystems, Foster 
City, CA). The reaction mixture was prepared using the following outlined procedure: 1µl of 
Taqman Gene Expression assay, 10µl of 2X buffer, 0.5µl of RT-enzyme and 8.5µl of diluted 
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mRNA for each reaction. Beta-actin was used as an endogenous control throughout.  RT-
PCR was performed on an AB Prism 7000 platform under the following universal thermal 
cycling conditions: reverse transcription at 48°C for 15 minutes, enzyme activation at 95°C 
for 15 seconds (40 cycles), annealing/primer extension at 60°C for 1 minute (40 cycles). 
Transcript abundance was calculated by subtracting the cycle threshold (Ct) of β-actin from 
the Ct of the gene of interest to derive a ∆Ct value. Fold induction of genes in response to 
HkH37Rv stimulation was calculated using the ∆∆ method: the ∆Ct of the unstimulated 
sample was subtracted from the ∆Ct of the stimulated sample and 2 was then raised to the 
power of -∆∆Ct. Values obtained were normalized by log10 transformation and these values 
are reported. RT-PCR was performed in 25 participants (9 placebo-treated and 16 
prednisone-treated), who had cells available for RNA extraction at week 0 and at least one 
additional timepoint. 
 
Luminex multiplex assay for cytokine/chemokine concentrations in supernatants and 
serum. Supernatants from stimulated and unstimulated 24 hr cultures (see above) were later 
assayed for the following cytokines and chemokines: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-
12p40, IL-13, IL-15, TNF-α, IFN-γ, IP-10, GM-CSF, CCL3, CCL4 and CCL5. These assays 
were performed in 96-well filter plates on the Bio-Plex platform (Bio-Rad Laboratories, 
Hercules, CA, USA) using customized MilliplexTM kits (Millipore, St Charles, Missouri, 
USA) according to manufacturer’s instructions. Assays were performed in 29 participants (12 
placebo-treated and 17 prednisone-treated). The change in concentrations subtracting 
background from stimulated was used for comparisons. 
 
Serum was stored at -80°C and using the same protocols the following cytokines/chemokines 
were assayed in serum samples at a later time point: IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p40, 
TNF-α, IFN-γ, IP-10, GM-CSF, CCL3 and CCL4. Assays were performed in 58 participants 
(27 placebo-treated and 31 prednisone-treated). In all Luminex multiplex experiments 
samples from the same patient were included on the same 96-well plate. 
 
IL-8 sandwich ELISA. Human IL-8 ELISA Core Kit (Koma Biotechnology, Seoul, Korea) 
was used and the assay performed according to manufacturer’s instructions. 
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Statistical analysis. Medians are presented with interquartile range (IQR) and means ± 
standard deviation (SD). For clinical data, categorical variables were compared using Chi-
square or Fisher’s exact test and continuous variables with the Wilcoxon signed-rank test. 
Unpaired and paired normally distributed variables were compared using Student’s unpaired 
and paired t-tests as appropriate. Paired non-parametric variables were analysed by paired 
Wilcoxon signed-rank test.  To factor multiple comparisons p values were multiplied by n-1 
(Bonferroni correction) where n = number of comparisons. STATA 10.1 (Stata Corporation, 
USA) and GraphPad Prism® Version 5.0a Software (USA) were used for statistical tests. 
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Results 
 
Serial samples were available from 58 participants (27 placebo-treated and 31 prednisone-
treated). Among these 58 participants, 33 were female (57%) and the median age was 31 
years (IQR 26 - 35). The median CD4+ lymphocyte count prior to ART was 56 cells/µl (IQR 
29 - 94) and at study enrollment median CD4 count was 116 cells/µl (IQR 60 - 234). There 
were no significant differences between the placebo- and prednisone-treated participants in 
terms of demographics, TB and HIV disease characteristics (Table 1). ELISpot was 
performed in 41 participants, RT-PCR in 25 participants, Luminex multiplex on supernatants 
of cultures stimulated with hkH37Rv MTB of 29 participants and Luminex multiplex on 
serum of 58 participants.  
 
ELISpot 
There were no significant differences in median number of spot forming cells comparing 
placebo- and prednisone-treated participants at each of the three time points (week 0, 2 and 4 
weeks) for any of the 6 antigenic stimuli (Figure 1). Longitudinal within group analysis using 
paired Wilcoxon signed-rank test to compare week 0 with 2, week 0 with 4 and week 2 with 
week 4 revealed a difference only in the PPD stimulated wells: there was an increase in the 
median number of spot forming cells (SFC) from 449 SFC/106 PBMC (IQR 197 – 1368) at 
week 2 to 800 (IQR 188 – 2078) at week 4 (p = 0.03) in prednisone-treated participants. 
 
Next, delta values (∆ = week 4 ELISpot value – week 0 ELISpot value) were calculated and 
delta values for each antigenic stimulus were compared for placebo and prednisone-treated 
participants. The only significant difference was for the PPD-stimulated samples: between 
week 0 and 4 in placebo-treated participants median ELISpot value decreased by 496 
SFC/106 PBMC (IQR – 1623 to +217) and in prednisone-treated participants the median 
ELISpot value increased by 455 SFC/106 PBMC (IQR -140 to +807) (p = 0.007) (Figure 2). 
 
To assess the relationship between ELISpot responses and change in symptoms over time, the 
median ELISpot value at week 0 and at week 2 were compared for those who did, or did not, 
experience improvement by week 2 irrespective of whether they were randomized to 
prednisone or placebo. Thereafter, within group analyses comparing 0 and 2 week values 
were performed. No significant differences were shown apart from borderline significant 
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difference for 38 kDa comparing the values of those who improved to those who did not 
improve at week 2. In improvers the median was 580 SFC/106 PBMC (IQR 30 – 1435) and in 
non-improvers 10 SFC/106 PBMC (IQR 0 - 678) (p = 0.049) (Figure 3).  
 
RT-PCR for cytokine/chemokine gene upregulation in response to MTB stimulation 
There were significant reductions in mean log fold-induction in placebo-treated participants 
at week 4 (compared with week 0) for IL-1β, IL-6, IL-13, GM-CSF and CCL3 (Table 2). 
There was a significant increase in mean log fold-induction for IL-22 at week 4 in placebo-
treated participants and decrease in prednisone-treated participants at week 4 for IL-4 and IL-
10 genes (all compared with week 0). After Bonferroni correction the only change that 
remained significant was the decrease in mean log fold induction from 0.32 (±0.42) at week 0 
to -0.26 (±0.29) for IL-4 at week 4 in prednisone-treated participants (p corr = 0.03). 
 
Luminex multiplex analysis of tissue culture supernatants 
For placebo-treated participants in relation to week 0 there were increases in concentrations 
of IFNγ at week 2, decreased IL-13 at week 2, and decreased IL-1β, IL-6, IL-10, TNFα, GM-
CSF, CCL3 and CCL4 at week 4 (Table 3). In prednisone-treated participants GM-CSF and 
CCL3 decreased at week 2 and IL-1β and IL-6 decreased at both week 2 and week 4 in 
relation to week 0 value. After Bonferroni correction, none of these differences remained 
significant. 
 
Luminex multiplex analysis of serum 
Luminex multiplex analysis of serum from prednisone-treated participants showed significant 
declines from week 0 to week 2 and week 0 to week 4, after correcting for multiple 
comparisons, for IL-6, IL-10, IL-12p40, IP-10 and TNFα concentrations (Table 4, Figure 4). 
For IFNγ there was a significant decrease from week 0 to week 4, but not at week 2. There 
was no significant decrease in IL-8, CCL3 or CCL4 in prednisone-treated participants after 
correction for multiple comparisons. In placebo-treated participants none of these cytokines 
or chemokines declined significantly at the week 2 nor at week 4 timepoints compared with 
week 0 after correction for multiple comparisons.  Concentrations of IL-1β, IL-2 and GM-
CSF were undetectable in most samples and there was no significant change in values over 4 
weeks in either treatment group.  
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Figure1 
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Legend for Figure 1: ELISpot results in response to overnight restimulation of PBMC 
with six different antigen stimuli at 0, 2 and 4 weeks comparing placebo and 
prednisone-treated participants.  
 
Antigen stimuli used were: 5 µg/mL of early secreted antigen target-6 (ESAT‐6), 10 µg/mL 
of α-crystallin 1, 20 µg/mL of α-crystallin 2 and 2.5 µg/mL of 38kDa antigen. PPD was used 
at 200 IU/mL (4.6 µg/mL) and heat-killed H37Rv Mycobacterium tuberculosis at a 
multiplicity of infection (MOI) of 1:1 (200 000 H37Rv: 200 000 PBMC). 
 
Statistical comparisons of median values for each time point comparing placebo and 
prednisone-treated participants showed no significant differences. Within group paired 
comparisons between time points (0 vs 2 weeks, 0 vs 4 weeks and 2 vs 4 weeks) revealed 
only one significant difference (p < 0.05): a rise in the number SFC to PPD in the prednisone-
treated participants from 2 to 4 weeks (from 449 SFC/106 PBMC (IQR 197 – 1368) at week 2 
to 800 (IQR 188 – 2078) at week 4 (p = 0.03)). 
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Figure 2 
 
Figure 1 
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Legend for Figure 2: Changes in ELISpot responses between week 0 and week 4 
comparing placebo and prednisone-treated patients. 
 
These results relate to the same experiments as Figure 1, but show the change (delta) in 
responses over four weeks in placebo and prednisone-treated participants. The only 
siginificant difference (p < 0.05) was PPD: between week 0 and 4 in placebo-treated 
participants median ELISpot value decreased by 496 SFC/106 PBMC (IQR – 1623 to +217) 
and in prednisone-treated participants the median ELISpot value increased by 455 SFC/106 
PBMC (IQR -140 to +807) (p=0.007).
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Figure 3 
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Legend for Figure 3: ELISpot responses at week 0 and week 2 comparing participants 
who had no improvement in symptoms during this time with patients who reported 
symptom improvement, regardless of treatment allocation. 
 
Statistical comparisons were made between non-improvers and improvers at each time point 
and within group paired analyses comparing 0 and 2 week time points. There was a 
significant difference (p < 0.05) for 38 kDa comparing values of responders to non-
responders at week 2. In improvers the median was 580 SFC/106 PBMC (IQR 30 – 1435) and 
in non-improvers 10 SFC/106 PBMC (IQR 0 - 678) (p = 0.049).
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
150
c: 
o 
jg 
~ () 
400
1 
350 
300 
250 
200 
150 
150 
100 
50 
150 
100 
IL-6 
p(corr) = 0.002 
p(corr) < 0.001 
.. 
I·· • 
~ :. 
TNF alpha 
p(corr) < 0.001 
I I 
f (corr) < 0.001 
.. 
.. 
-:.-. 
50 ~ 
• 
i 
0 
~ 
~ 
'-' 
~ 
0 
~ 
1l 
8 
:. 
.. 
~ 
100001 
5000 
100 
80 
50 
40 
20 
'00'1 800 500 
400 
200 
150 
100 
50 
IL-l0 
p(corr) = 0.001 
1-------1 
p(corr) = 0.01 
· 
.. 
. .. 
.~. 
..: .. ~
..... : ~ 
IFNgamma 
p(corr) = 0.008 
· .. 
':.- ... 
· 
.. 
• !,,!~. .:::: 
... . . ..~ .. 
-,,'>co, i' 
· .. . :~ 
.. 
· 
. 
· . ... 
· 
. 
· -.,:-:-
-"~ 
0"· ",J>"'~ 0"· q<..J><:::-~ 0"· ",J>"'~ 
IL-12p40 
p(corr) = 0.002 
I 
I-l 
'~l f (corr) = 0.001 200 
-' 
150 
~ 100 g> 
100 
c: 
0 
80 jg .. 
~ 60 . · ... .. () 40 
· · 
20 
· · 
.:. 
~ ., .... . . 
IP-l0 
p(corr) = 0.006 
I 
I-f 
20000
1 
p(corr) = 0.001 
15000 
10000 
· 
.. 
-::-- ...... 
i .. 6000 
--4-0 g 
· ~ . . .. · .:: 4000 · · 
· 
-::- .. 
'-' 
· 
----.-e::_ •• •• . ... ... 
2000 : . . .. , .. 
. .. . . 
· 
-,,'>co, i' -"~ o~~o<::-!Q 0"· ". q,J><:::-~ ",0 q'. q,J>" 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
Legend for Figure 4: Serum Luminex multiplex assay showing results for IL-6, IL-10, 
IL-12p40, TNF-α , IFN-γ  and IP-10 concentrations in prednisone-treated participants at 
week 0, 2 and 4.  
 
Statistical comparisons were performed using the matched pairs Wilcoxon test and corrected 
for multiple comparisons with the Bonferroni correction. There were significant reduction 
(pcorr < 0.05) between week 0 and 2 for all these cytokines/chemokine apart from IFN-γ. 
There were significant reductions for all between week 0 and 4. Full results of these 
experiments are shown in Table 4. 
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Table 1: Clinical and demographic characteristics of participants included in immunological analyses 
 
Variable Placebo-treated 
N=27 
Prednisone-treated 
N=31 
p-value 
Gender   
    Male 
    Female 
 
13 (48%) 
14 (52%) 
 
12 (39%) 
19 (61%) 
 
 
0.8 
Age 31 (27 - 36) 31 (26 - 35) 0.6 
Previous TB 6 (22%) 10 (32%) 0.6 
Basis of TB diagnosis 
    Cultured Mycobacterium tuberculosis  
    Acid-fast bacilli smear positive 
    Clinico-radiological diagnosis 
 
20 (74%) 
5 (19%) 
2 (7%) 
 
17 (55%) 
4 (13%) 
10 (32%) 
 
 
 
0.07 
Extrapulmonary TB at TB diagnosis  15 (56%) 16 (52%) 0.8 
CD4 count prior to ART (cells/µl) 58 (20 – 95) 55 (31 – 94) 0.6 
CD4 count at enrollment (cells/µl) A 107 (49 – 202) 117 (73 - 278) 0.2 
C-reactive protein at enrollment (mg/l) 100 (80 -143) 94 (42 -150) 0.6 
Duration TB treatment to ART (days) 43 (26 - 79) 69 (35 - 96) 0.09 
Duration ART to TB-IRIS symptom onset (days) 10 (7 - 17) 14 (7 - 22) 0.1 
TB-IRIS clinical manifestations B 
    New or enlarging lymph node(s) 
    New or expanding pulmonary infiltrate(s) 
    New enlarging serous effusion(s) 
    Recurrent symptoms and infiltrate(s) on CXR but 
without baseline CXR available for comparison 
 
11 (41%) 
6 (22%) 
3 (11%) 
10 (37%) 
 
9 (29%) 
9 (29%) 
2 (6%) 
14 (45%) 
 
0.4 
0.8 
0.7 
0.6 
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Legend for Table 1 
 
Values shown are numbers (percentage) or median (interquartile range). P-values 
compare placebo and prednisone-treated participants. 
CXR = Chest radiograph 
A CD4 count at enrollment available for 24 placebo-treated and 27 prednisone-treated 
participants 
B Participants may have had more than 1 TB-IRIS manifestation, thus manifestations sum 
to more than 100%
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Table 2: Log fold gene induction after 24 hrs restimulation of PBMC with heat-killed H37Rv Mycobacterium tuberculosis at weeks 0, 2 
and 4 on clinical trial for placebo-treated and prednisone-treated participants 
 
 
                   PLACEBO-TREATED 
 
PREDNISONE-TREATED 
Cytokine/ 
chemokine 
 
Week 0 
 
N = 9 
Week 2 
 
N = 8 
Week 4 
 
N = 6 
p-value 
(0 vs 2) 
p-value 
(0 vs 4) 
 
Week 0 
 
N = 16 
Week 2 
 
N = 14 
Week 4 
 
N = 15 
p-value 
(0 vs 2) 
p-value 
(0 vs 4) 
IL-1β  
 
 
2.25 (0.80) 
 
2.35 (0.41) 
 
1.95 (0.76) 
 
0.46 
 
0.03 * 
 
2.29 (1.11) 
 
2.28 (0.94) 
 
2.14 (0.74) 
 
0.89 
 
0.34 
IL-2 
 
 
0.97 (0.68) 
 
0.99 (0.43) 
 
0.97 (0.81) 
 
0.57 
 
0.76 
 
0.78 (0.74) 
 
0.97 (0.55) 
 
0.68 (0.67) 
 
0.45 
 
0.61 
IL-4 
 
 
-0.13 (0.49) 
 
-0.09 (0.34) 
 
0.04 (0.30) 
 
0.75 
 
0.79 
 
0.32 (0.42) 
 
0.12 (0.52) 
 
-0.26 (0.29) 
 
0.43 
 
0.002 * 
IL-6 
 
 
2.63 (1.37) 
 
2.48 (1.10) 
 
2.46 (1.15) 
 
0.94 
 
0.01 * 
 
2.75 (1.56) 
 
2.69 (1.19) 
 
2.26 (1.11) 
 
0.68 
 
0.18 
IL-8 
 
 
1.29 (0.54) 
 
1.15 (0.45) 
 
1.14 (0.52) 
 
0.91 
 
0.26 
 
1.52 (0.83) 
 
1.33 (0.62) 
 
1.12 (0.66) 
 
0.34 
 
0.09 
IL-10 
 
 
0.24 (0.84) 
 
-0.04 (0.82) 
 
0.41 (1.05) 
 
0.23 
 
0.93 
 
0.38 (0.80) 
 
0.13 (0.69) 
 
-0.72 (1.08) 
 
0.46 
 
0.006 * 
IL-12p40 
 
 
2.02 (0.80) 
 
2.24 (0.62) 
 
2.47 (0.44) 
 
0.41 
 
0.62 
 
2.40 (0.82) 
 
2.04 (1.11) 
 
 
2.21 (1.23) 
 
0.45 
 
0.84 
IL-13 
 
 
2.24 (1.06) 
 
2.17 (0.96) 
 
1.94 (0.96) 
 
0.98 
 
0.004 * 
 
2.29 (0.86) 
 
1.89 (0.90) 
 
1.97 (0.75) 
 
0.31 
 
0.22 
IL-15 
 
 
 
0.43 (0.36) 
 
0.24 (0.54) 
 
0.63 (0.44) 
 
0.17 
 
0.38 
 
0.67 (0.53) 
 
0.73 (0.40) 
 
0.50 (0.49)  
 
 
0.51 
 
 
0.33 
IL-17A 
 
 
1.53 (0.64) 
 
1.46 (0.75) 
 
1.52 (0.83) 
 
0.79 
 
0.27 
 
1.28 (1.07) 
 
1.11 (0.65) 
 
1.10 (0.93) 
 
0.63 
 
0.65 
IL-22 
 
 
1.98 (0.89) 
 
1.98 (0.66) 
 
2.27 (0.80) 
 
0.68 
 
0.02 * 
 
1.90 (1.11) 
 
1.76 (0.77) 
 
1.83 (0.82) 
 
0.67 
 
0.80 
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IL-27 
 
 
1.42 (0.62) 
 
1.28 (0.49) 
 
2.00 (0.73) 
 
0.95 
 
 
0.37 
 
1.39 (0.79) 
 
1.52 (0.66) 
 
1.34 (1.21) 
 
0.82 
 
0.72 
TNFα  
 
 
1.60 (0.30) 
 
1.27 (0.80) 
 
1.47 (0.42) 
 
0.33 
 
0.26 
 
1.45 (0.65) 
 
1.45 (0.32) 
 
1.31 (0.64) 
 
0.74 
 
0.42 
IFNγ  
 
 
1.50 (0.78) 
 
1.82 (0.53) 
 
1.78 (0.42) 
 
0.09 
 
0.35 
 
1.45 (0.88) 
 
1.43 (0.70) 
 
1.25 (0.71) 
 
0.73 
 
0.44 
GM-CSF 
 
 
2.55 (1.43) 
 
2.62 (1.09) 
 
2.00 (1.10) 
 
0.88 
 
0.049 * 
 
3.01 (1.45) 
 
2.74 (1.19) 
 
2.48 (0.91) 
 
0.32 
 
0.15 
CCL3 
 
 
1.46 (0.51) 
 
 
1.41 (0.30) 
 
1.09 (0.68) 
 
0.74 
 
0.04 * 
 
1.50 (0.73) 
 
1.40 (0.54) 
 
1.33 (0.58) 
 
0.48 
 
0.29 
CCL4 
 
 
1.11 (0.32) 
 
0.93 (0.22) 
 
0.82 (0.35) 
 
0.31 
 
 
0.09 
 
1.17 (0.59) 
 
1.02 (0.45) 
 
0.95 (0.54) 
 
0.41 
 
0.26 
CCL5 
 
 
-0.09 (0.16) 
 
-0.21 (0.26) 
 
-0.11 (0.15) 
 
0.21 
 
0.73 
 
-0.02 (0.27) 
 
0.00 (0.30) 
 
-0.17 (0.39) 
 
0.61 
 
0.24 
 
 
Legend for Table 2 
 
Mean log fold-induction (+/- standard deviation) in gene expression of 18 cytokines and chemokines after 24 hrs restimulation of PBMC with 
heat-killed H37Rv Mycobacterium tuberculosis are shown for placebo and prednisone-treated patients at weeks 0, 2 and 4 on the clinical trial. P-
values were calculated for comparisons between 0 and 2 weeks values and 0 and 4 week values for each treatment group separately using 
Student’s paired t-tests. Two patients in the placebo-treated arm switched to open label prednisone at week 2 and their week 4 samples were thus 
excluded from analysis. 
 
Significant differences are indicated with *. After Bonferroni correction for multiple comparisons (pcorr = p x 18-1 = p x 17) only the change in 
IL-4 in prednisone-treated patients between week 0 and 4 remained significant (pcorr = 0.03).
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Table 3: Changes in concentrations of cytokines and chemokines in supernatants of cell cultures after restimulation of PBMC with heat-
killed H37Rv Mycobacterium tuberculosis for 24 hrs assessesed by Luminex multiplex assay 
 
 
                   PLACEBO-TREATED 
 
PREDNISONE-TREATED 
Cytokine/ 
chemokine 
 
Week 0 
 
N = 12 
Week 2 
 
N = 11 
Week 4 
 
N = 9 
p-value 
(0 vs 2) 
p-value 
(0 vs 4) 
 
Week 0 
 
N = 17 
Week 2 
 
N = 15 
Week 4 
 
N = 15 
p-value 
(0 vs 2) 
p-value 
(0 vs 4) 
IL-1β  
 
1556 
 
298.1 - 5182 
495 
 
226.4 - 2915 
184.6 
 
65 - 1788 
0.70 0.01 * 2375 
 
112.2 - 3623 
112.4 
 
0 – 699.4 
235.8 
 
98 – 456.8 
0.01 * 0.03 * 
IL-2 
 
94.6 
 
9.1 – 491.3 
101.8 
 
51.7 – 295.5 
215.9 
 
69.8 – 529.8 
0.28 0.82 55.1 
 
9.9 - 291 
64.8 
 
13.7 – 206.3 
65.2 
 
5.1 - 126 
0.45 0.71 
IL-4 
 
0 
 
0 – 0 
0 
 
0 - 0 
0 
 
0 - 0 
0.75 0.50 0 
 
0 – 1.6 
0 
 
0 - 0 
0 
 
0 - 0 
0.63 0.13 
IL-5 
 
0 
 
0 – 0 
0 
 
0 - 0 
0 
 
0 - 0 
0.50 1.0 0 
 
0 - 0 
0 
 
0 - 0 
0 
 
0 - 0 
1.0 1.0 
IL-6 
 
17957 
 
5088 - 29776 
13026 
 
2954 - 24499 
6884 
 
1119 - 15462 
0.64 0.01 * 17084 
 
3805 - 33389 
3213 
 
868.2 - 16139 
6496 
 
3411 - 12239 
0.02 * 0.04 * 
IL-10 
 
249.1 
 
139.3 - 2082 
465.9 
 
130.5 - 1297 
190.4 
 
77.1 - 1617 
1.0 0.02 * 751.1 
 
160.9 - 1591 
124.3 
 
55.4 – 963.7 
311.5 
 
187 – 638.8 
0.14 0.06 
IL-12p40 
 
41.3 
 
27.2 - 207.4 
54.2 
 
1.0 – 103.3 
29.0 
 
4.3 - 59.4 
0.83 0.73 7.4 
 
0 – 327.7 
7.1 
 
0 - 76.4 
3.2 
 
0 – 85.1 
0.08 0.91 
IL-13 
 
10.1 
 
0.2 - 62 
9.4 
 
2.8 – 67.9 
3.5 
 
-5.1 – 13.8 
0.03 * 0.20 3.8 
 
2 – 14.3 
5.4 
 
2.1 – 7.1 
5.3 
 
0.6 - 14 
0.49 0.98 
IL-15 
 
0 
 
0 – 2.6 
0 
 
0 – 3.8 
0 
 
0 – 0.3 
1.0 0.81 0 
 
0 – 0.4 
0 
 
0 - 0 
0 
 
0 - 0 
0.20 0.84 
TNFα  
 
3799 
 
1010 - 16035 
4749 
 
947 - 13480 
1372 
 
875.6 - 11891 
0.90 
 
 
0.01 * 6375 
 
1017 - 11679 
2727 
 
598.3 - 3712 
2627 
 
1448 - 5406 
0.06 0.07 
GM-CSF 
 
214.7 
 
76.5 - 2584 
314.8 
 
175 – 492.2 
116.8 
 
48.9 - 2747 
1.0 0.02 * 486.9 
 
152.5 - 1516 
147.2 
 
42 – 427.2 
245.8 
 
175 – 595.5 
0.03 * 0.06 
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IFNγ  
 
257.0 
 
37.6 - 5157 
835.8 
 
266.9 - 5830 
467.3 
 
219.6 – 983.8 
0.02 * 0.65 233.4 
 
28.5 - 2524 
133.9 
 
49.1 - 983 
416.4 
 
29 – 807.8 
0.06 0.39 
IP-10 
 
1430 
 
157.4 - 36114 
11596 
 
398.1 - 18355 
1201 
 
315.6 - 25330 
0.17 0.43 1282 
 
-30.8 - 17084 
20133 
 
4289 - 36155 
9222 
 
3964 - 18476 
0.23 0.76 
CCL3 
 
29972 
 
8888 - 95230 
29608 
 
12920 -65686 
13635 
 
3968 - 24054 
0.52 0.03 * 27820 
 
5995 - 49179 
9218 
 
4119 – 33611 
20029 
 
10720 - 26486  
0.03 * 0.08 
CCL4 
 
14046 
 
3428 - 20732 
8279 
 
4556 - 11353 
5293 
 
2165 - 8015 
0.64 0.01 * 8037 
 
2947 - 16094 
6860 
 
3128 - 11886 
6993 
 
4756 - 11283 
0.45 0.25 
CCL5 
 
2179 
 
486.2 - 7919 
3210 
 
1719 - 7681 
2580 
 
1486 - 3616 
0.28 0.20 4122 
 
871.8 - 7449 
2288 
 
636.5 - 14529 
4443 
 
1981 - 16442 
0.76 0.42 
IL-8 
(Elisa) 
ng/ml 
54 
 
13 - 63 
54.5 
 
0 – 64.3 
47 
 
0 – 59.8 
0.77 0.69 57 
 
39 – 65.5 
52 
 
34 - 62 
50 
 
39 - 62 
0.43 0.55 
 
 
Legend for Table 3 
 
Results shown are cytokine/chemokine concentrations assayed with Luminex multiplex subtracting concentration in unstimulated PBMC 
cultures from concentration in cultures of PBMC stimulated with heat-killed H37Rv for 24 hrs. Median and interquartile range values are 
presented and units are pg/ml. The exception was IL-8 which was assayed using ELISA and units are in ng/ml. P-values were calculated for 
comparisons between 0 and 2 weeks values and 0 and 4 week values for each treatment group separately using Wilcoxon matched pairs test. 
Two patients in the placebo-treated arm switched to open label prednisone at week 2 and thus their week 4 sample was excluded from analysis. 
 
Significant differences are indicated with *. After Bonferroni correction for multiple comparisons (pcorr = p x 17-1 = p x 16) none of the 
differences remained significant. 
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Table 4: Luminex multiplex assay of cytokine and chemokine concentrations in serum comparing participants treated with placebo vs 
patients treated with prednisone at weeks 0, 2 and 4 on the trial 
 
 
 
PLACEBO-TREATED PREDNISONE-TREATED 
 
 
Wk 0 
N=27 
Wk 2 
N=24 
Wk 4 
N=18 
P 
0-2 
Pcorr 
0-2 
P 
0-4 
Pcorr 
0-4 
Wk 0 
N=31 
Wk 2 
N=31 
Wk 4 
N=29 
P 
0-2 
Pcorr 
0-2 
P 
0-4 
Pcorr 
0-4 
IL-1β  
 
0 
 
0-0 
0 
 
0-0 
0 
 
0-0 
1.0  1.0  0 
 
0-0 
0 
 
0-0 
0 
 
0-0 
1.0  0.5  
IL-2 
 
0 
 
0-0 
0 
 
0-0 
0 
 
0-0 
1.0  1.0  0 
 
0-0 
0 
 
0-0 
0 
 
0-0 
0.55  0.53  
IL-6 
 
35.5 
 
20.4- 
57.1 
17.2 
 
6.8- 
30.2 
17.2 
 
5.0- 
37.0 
0.005 * 0.05  0.03 * 0.36 21.7 
 
11.8- 
42.7 
9.0 
 
0- 
11.5 
7.7 
 
0- 
16.3 
<0.0001 
* 
<0.001  
* 
0.0002 * 0.002 * 
IL-8 
 
70.6 
 
40.7- 
146.0 
72.7 
 
31.0- 
132.9 
66.9 
 
26.2- 
150.9 
0.25  0.26  50.6 
 
35.2- 
117.1 
49.9 
 
20.7- 
72.5 
50.8 
 
26.6- 
85.6 
0.008 * 0.09 0.12  
IL-10 
 
8.8 
 
4.6- 
25.7 
10.1 
 
4.1- 
22.4 
8.5 
 
3.6- 
17.9 
0.16  0.56  15.0 
 
7.0- 
22.5 
8.8 
 
4.6- 
17.2 
9.5 
 
2.5- 
14.4 
0.001 * 0.01 * 0.0001 * 0.001 * 
IL-12p40 
 
25.0 
 
11.9- 
55.8 
13.0 
 
0- 
32.8 
25.5 
 
4.4- 
219.9 
0.13  0.94  11.9 
 
0- 
56.1 
0 
 
0- 
10.2 
0 
 
0- 
16.5 
0.0001 * 0.001 * 0.0002 * 0.002 * 
TNFα  
 
51.1 
 
34.4-
105.1 
47.3 
 
22.0- 
95.6 
41.3 
 
24.4- 
102.9 
0.08  0.24  52.4 
 
33.1-
106.2 
26.9 
 
21.1- 
44.3 
25.9 
 
17.7- 
50.2 
<0.0001 
* 
<0.001 * <0.0001 
* 
<0.001 * 
IFNγ  
 
27.4 
 
12.8- 
68.9 
24.6 
 
8.2- 
71.9 
29.9 
 
15.7- 
52.9 
0.10  0.54  27.2 
 
18.2-
57.8 
15.9 
 
4.1- 
45.9 
12.4 
 
2.5- 
49.6 
0.10  0.0007 * 0.008 * 
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IP-10 
 
3801 
 
2299- 
9840 
3330 
 
1972- 
4229 
2736 
 
1943- 
3648 
0.07  0.008 * 0.09 5487 
 
2798- 
9998 
3728 
 
2309- 
5162 
3126 
 
2068- 
4896 
0.0001 * 0.001 * 0.0005 * 0.006 * 
GMCSF 
 
0 
 
0-0 
0 
 
0-0 
0 
 
0-0 
0.50  1.0  0 
 
0-0 
0 
 
0-0 
0 
 
0-0 
0.94  0.38  
CCL3 
 
29.8 
 
0- 
78.6 
 
23.3 
 
0- 
66.8 
35.2 
 
3.3- 
169.6 
0.79  0.04 * 0.45 26.6 
 
0- 
50.4 
15.5 
 
0- 
47.2 
24.3 
 
0- 
85.1 
0.66  0.63  
CCL4 
 
71.6 
 
40.8-
100.4 
53.0 
 
37.4- 
78.8 
69.1 
 
56.1- 
132.1 
0.03 * 0.37 0.19  78.3 
 
55.0- 
110.7 
81.9 
 
44.6- 
100.1 
81.8 
 
53.4- 
115.5 
0.02 * 0.26 0.73  
 
 
 
Legend for Table 4 
 
Results shown are cytokine/chemokine concentrations assayed with Luminex multiplex in serum. Median and interquartile range values are 
presented and units are pg/ml. P-values were calculated for comparisons between 0 and 2 weeks values and 0 and 4 week values for each 
treatment group separately using Wilcoxon matched pairs test. Four patients in the placebo-treated arm switched to open label prednisone at 
week 2 and thus their week 4 sample was excluded from analysis. 
 
Significant differences are indicated with *. Uncorrected p-values are shown and where the uncorrected p-value was < 0.05 a corrected p-value 
is also shown. The Bonferroni correction for multiple comparisons (p corr = p x 12 - 1 = p x 11) was used. 
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Discussion 
 
We have previously demonstrated in a randomized clinical trial that corticosteroid therapy 
results in clinical benefit in patients with paradoxical TB-IRIS (11). We have also previously 
demonstrated that TB-IRIS is associated with hypercytokinaemia (15) with the most 
consistently elevated cytokines being IL-6, TNFα and IFNγ.  In the current study we sought 
to identify the immune mechanism of action of prednisone in TB-IRIS and thus potentially 
gain insight into the pathogenesis of TB-IRIS.  
 
Corticosteroids are known to exert anti-inflammatory effects on immune cells through direct 
effects on transcription of inflammatory mediators via the Glucorticoid Responsive Element, 
indirect genomic effects via interference with other transcriptional factors such as NF-κB and 
AP-1, and non-genomic effects on anti-inflammatory proteins (23). These effects result in 
increased transcription of a number of anti-inflammatory mediators and decreased 
transcription of pro-inflammatory cytokines, chemokines, enzymes, receptors and adhesion 
molecules. In addition corticosteroids have been shown to reduce T cell survival by 
enhancing apoptosis (24).  
 
Our most important finding was that serum concentrations of IL-6, IL-10, IL-12p40, IP-10 
and TNFα were reduced in prednisone-treated participants at 2 and 4 weeks on the trial 
compared with baseline after correcting for multiple comparisons. The decrease in IFNγ 
occurred later at the week 4 time point. Similar decreases were not seen in placebo-treated 
participants. Many of these cytokines are of myeloid origin (IL-10, IL-12p40, IP-10) or of 
combined myeloid and lymphoid origin (TNFα and IL-6). These findings concur with reports 
that suggest myeloid cells may play an important role in TB-IRIS pathogenesis (25, 26).  
 
We have previously reported that among patients treated with prednisone in this trial the CRP 
fell from a median 104 mg/l at week 0 to 35 mg/l at week 2. In placebo-treated patients the 
decrease was more gradual (11). This corresponds with our finding here that there is a 
significant fall in IL-6 in prednisone, but not placebo treated patients, as IL-6 is the major 
stimulus of CRP production (27). The reduction in the regulatory cytokine IL-10 may have 
been a direct corticosteroid effect or as a consequence of decreased inflammatory activity. 
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We have previously reported highly dynamic and heterogenous expansions and contractions 
of tuberculosis-specific IFNγ secreting T cells in both TB –IRIS cases and controls who do 
not develop IRIS (14). Similar ELISpot patterns were noted during the 4 weeks course of 
treatment among patients on this trial and these were largely unaffected by prednisone 
therapy. The only significant finding was the difference in PPD-specific cells with an 
increase in prednisone-treated participants and a decrease in placebo-treated participants from 
week 0 to 4. A plausible explanation for this was that the anti-inflammatory effect of 
prednisone at tissue sites of IRIS resulted in recirculation of these effector cells into 
peripheral blood and reduced recruitment. We thus found no evidence that the effect of 
prednisone in TB-IRIS was mediated via a reduction in numbers of antigen-specific effector 
T cells in peripheral blood, although it did reduce IFNγ production at week 4. It is possible 
that this effect was mediated at a transcriptional level although we did not demonstrate this in 
ex vivo restimulation assays. 
 
The findings of the 24 hr stimulation experiments, which assessed changes in 
cytokine/chemokine gene expression by RT-PCR and protein concentration by Luminex 
multiplex in response to MTB stimulation, showed few differences and only a reduction in 
gene expression of IL-4 at week 4 in prednisone-treated participants remained significant 
after correcting for multiple comparisons. We interpret this to indicate that prednisone 
administered to patients does not have a significant effect that persists in tissue culture 
experiments during 24 hr ex vivo restimulation. 
  
A clinical trial conducted by Thwaites and colleagues in Vietnam demonstrated that 
adjunctive dexamethasone for TB meningitis reduced mortality (10). In their trial, as was the 
case in our study, there was no significant effect of corticosteroid therapy on ELISpot 
responses to ESAT-6 (and in their study no effect on PPD responses either) and there were no 
effects of corticosteroid therapy on monocyte-derived cytokine concentrations after ex vivo 
restimulation of whole blood with mycobacterial antigens (28). In contrast to our findings, 
dexamethasone did not significantly alter concentrations of a number of cytokines and 
chemokines assayed. However, in their study concentrations were assayed in cerebrospinal 
fluid (CSF) rather than serum. Similarly, in children with TBM, prednisone did not 
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significantly alter TNFα, IL-1β and IFNγ concentrations in CSF (29). The difference in our 
findings could be that we analysed blood. TB-IRIS frequently causes a systemic 
inflammatory syndrome characterized by fever, tachycardia and weight loss and this is 
reflected in high pro-inflammatory cytokine concentrations in blood (15) which are 
beneficially modulated by corticosteroids. A previous study of high dose prednisolone in 
patients with HIV-associated smear positive pulmonary TB and CD4 counts ≥ 200 cells/µl 
demonstrated a reduction in serum TNFα in patients taking prednisolone (30). 
 
Strengths of our study were that treatment allocation was randomized reducing potential 
biases, there were no significant differences in demographic and disease characteristics 
between treatment groups and the patients were extensively investigated to exclude 
alternative causes for deterioration and confirm the diagnosis of paradoxical TB-IRIS. An 
important limitation was the small sample size in the 24 hr stimulation assays because of 
insufficient serial samples being available. This may have limited power to detect significant 
differences. 
 
Our findings suggest that the mechanism of corticosteroid action in TB-IRIS is at least 
partially mediated by a reduction in concentrations of pro-inflammatory cytokines. It raises 
the question as to whether more targeted anti-inflammatory therapy with TNFα blockers 
(etanercept, infliximab, adalumimab, certolizumab or golimumab) or an IL-6 blocker 
(tocilizumab) (31) may be effective in TB-IRIS for severe cases such as enlarging 
intracerebral tuberculomas that are potentially life threatening and may respond poorly to 
corticosteroids (32). In addition, our findings may shed light on the mechanisms of action of 
corticosteroids in reducing pathological inflammation in mycobacterial infections in general.  
 
162
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
Acknowledgements 
 
This study was funded by the Medical Research Council of South Africa, the Wellcome Trust 
(081667, 084323, 088316, 084670) and EDCTP (060613). Graeme Meintjes and Dominique 
J Pepper received SATBAT research training that was Fogarty International Center and NIH-
funded (NIH/FIC 1U2RTW007373-01A1 and U2RTW007370). Gary Maartens was 
supported in part by Grant Number U2RTW007370 from the Fogarty International Center. 
Dominique J Pepper was supported by funding from the United States Agency for 
International Development and PEPFAR via the Perinatal HIV Research Unit. The content is 
solely the responsibility of the authors and does not necessarily represent the official views of 
the Fogarty International Center, the National Institutes of Health, USAID or the United 
States Government. The Gulf Drug Company (Durban, South Africa) donated the prednisone 
and placebo tablets.  
 
We are indebted to Priscilla Mouton, the study nurse, for her hard work. We also 
acknowledge the assistance of Tolu Oni with patient recruitment. 
 
 
 
 
 
163
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
References 
 
1. Hawkey, C.R., Yap, T., Pereira, J., Moore, D.A., Davidson, R.N., Pasvol, G., Kon, 
O.M., Wall, R.A., and Wilkinson, R.J. 2005. Characterization and management of 
paradoxical upgrading reactions in HIV-uninfected patients with lymph node 
tuberculosis. Clin Infect Dis 40:1368-1371. 
2. Cheng, V.C., Yam, W.C., Woo, P.C., Lau, S.K., Hung, I.F., Wong, S.P., Cheung, 
W.C., and Yuen, K.Y. 2003. Risk factors for development of paradoxical response 
during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect 
Dis 22:597-602. 
3. Meintjes, G., Lawn, S.D., Scano, F., Maartens, G., French, M.A., Worodria, W., 
Elliott, J.H., Murdoch, D., Wilkinson, R.J., Seyler, C., et al. 2008. Tuberculosis-
associated immune reconstitution inflammatory syndrome: case definitions for use in 
resource-limited settings. Lancet Infect Dis 8:516-523. 
4. Meintjes, G., Rabie, H., Wilkinson, R.J., and Cotton, M.F. 2009. Tuberculosis-
associated immune reconstitution inflammatory syndrome and unmasking of 
tuberculosis by antiretroviral therapy. Clin Chest Med 30:797-810, x. 
5. Phillips, P., Bonner, S., Gataric, N., Bai, T., Wilcox, P., Hogg, R., O'Shaughnessy, 
M., and Montaner, J. 2005. Nontuberculous mycobacterial immune reconstitution 
syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. 
Clin Infect Dis 41:1483-1497. 
6. Walker, S.L., and Lockwood, D.N. 2008. Leprosy type 1 (reversal) reactions and their 
management. Lepr Rev 79:372-386. 
7. Girdhar, B.K., Girdhar, A., and Chakma, J.K. 2007. Advances in the treatment of 
reactions in leprosy. Indian J Lepr 79:121-134. 
8. Hakim, J.G., Ternouth, I., Mushangi, E., Siziya, S., Robertson, V., and Malin, A. 
2000. Double blind randomised placebo controlled trial of adjunctive prednisolone in 
the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 
84:183-188. 
9. Strang, J.I., Kakaza, H.H., Gibson, D.G., Allen, B.W., Mitchison, D.A., Evans, D.J., 
Girling, D.J., Nunn, A.J., and Fox, W. 1988. Controlled clinical trial of complete open 
surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion 
in Transkei. Lancet 2:759-764. 
10. Thwaites, G.E., Nguyen, D.B., Nguyen, H.D., Hoang, T.Q., Do, T.T., Nguyen, T.C., 
Nguyen, Q.H., Nguyen, T.T., Nguyen, N.H., Nguyen, T.N., et al. 2004. 
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. 
N Engl J Med 351:1741-1751. 
11. Meintjes, G., Wilkinson, R.J., Morroni, C., Pepper, D.J., Rebe, K., Rangaka, M.X., 
Oni, T., and Maartens, G. 2010. Randomized placebo-controlled trial of prednisone 
for paradoxical tuberculosis-associated immune reconstitution inflammatory 
syndrome. AIDS 24:2381-2390. 
12. Bourgarit, A., Carcelain, G., Martinez, V., Lascoux, C., Delcey, V., Gicquel, B., 
Vicaut, E., Lagrange, P.H., Sereni, D., and Autran, B. 2006. Explosion of tuberculin-
specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV 
co-infected patients. AIDS 20:F1-7. 
13. Elliott, J.H., Vohith, K., Saramony, S., Savuth, C., Dara, C., Sarim, C., Huffam, S., 
Oelrichs, R., Sophea, P., Saphonn, V., et al. 2009. Immunopathogenesis and diagnosis 
of tuberculosis and tuberculosis-associated immune reconstitution inflammatory 
syndrome during early antiretroviral therapy. J Infect Dis 200:1736-1745. 
164
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
14. Meintjes, G., Wilkinson, K.A., Rangaka, M.X., Skolimowska, K., van Veen, K., 
Abrahams, M., Seldon, R., Pepper, D.J., Rebe, K., Mouton, P., et al. 2008. Type 1 
helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune 
reconstitution inflammatory syndrome. Am J Respir Crit Care Med 178:1083-1089. 
15. Tadokera, R., Meintjes, G., Skolimowska, K.H., Wilkinson, K.A., Matthews, K., 
Seldon, R., Chegou, N.N., Maartens, G., Rangaka, M.X., Rebe, K., et al. 2010 Epub 
ahead of print. Hypercytokinaemia accompanies HIV-tuberculosis immune 
reconstitution inflammatory syndrome. Eur Respir J. 
16. Lim, A., D'Orsogna, L., Price, P., and French, M.A. 2008. Imbalanced effector and 
regulatory cytokine responses may underlie mycobacterial immune restoration 
disease. AIDS Res Ther 5:9. 
17. Seddiki, N., Sasson, S.C., Santner-Nanan, B., Munier, M., van Bockel, D., Ip, S., 
Marriott, D., Pett, S., Nanan, R., Cooper, D.A., et al. 2009. Proliferation of weakly 
suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell 
responses in HIV-positive patients with mycobacterial immune restoration disease. 
Eur J Immunol 39:391-403. 
18. Wilson, D., Nachega, J., Morroni, C., Chaisson, R., and Maartens, G. 2006. 
Diagnosing smear-negative tuberculosis using case definitions and treatment response 
in HIV-infected adults. Int J Tuberc Lung Dis 10:31-38. 
19. Saranchuk, P., Boulle, A., Hilderbrand, K., Coetzee, D., Bedelu, M., van Cutsem, G., 
and Meintjes, G. 2007. Evaluation of a diagnostic algorithm for smear-negative 
pulmonary tuberculosis in HIV-infected adults. S Afr Med J 97:517-523. 
20. Wilkinson, K.A., Kon, O.M., Newton, S.M., Meintjes, G., Davidson, R.N., Pasvol, 
G., and Wilkinson, R.J. 2006. Effect of treatment of latent tuberculosis infection on 
the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 193:354-359. 
21. Wilkinson, K.A., Simsova, M., Scholvinck, E., Sebo, P., Leclerc, C., Vordermeier, 
H.M., Dickson, S.J., Brown, J.R., Davidson, R.N., Pasvol, G., et al. 2005. Efficient Ex 
vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically 
detoxified Bordetella pertussis adenylate cyclase antigen toxoids. Infect Immun 
73:2991-2998. 
22. Wilkinson, K.A., Wilkinson, R.J., Pathan, A., Ewer, K., Prakash, M., Klenerman, P., 
Maskell, N., Davies, R., Pasvol, G., and Lalvani, A. 2005. Ex vivo characterization of 
early secretory antigenic target 6-specific T cells at sites of active disease in pleural 
tuberculosis. Clin Infect Dis 40:184-187. 
23. Rhen, T., and Cidlowski, J.A. 2005. Antiinflammatory action of glucocorticoids--new 
mechanisms for old drugs. N Engl J Med 353:1711-1723. 
24. Payne, D.N., and Adcock, I.M. 2001. Molecular mechanisms of corticosteroid 
actions. Paediatr Respir Rev 2:145-150. 
25. Lawn, S.D., Wainwright, H., and Orrell, C. 2009. Fatal unmasking tuberculosis 
immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: 
the role of macrophages. AIDS 23:143-145. 
26. Oliver, B.G., Elliott, J.H., Price, P., Phillips, M., Saphonn, V., Vun, M.C., Kaldor, 
J.M., Cooper, D.A., and French, M.A. 2010. Mediators of innate and adaptive 
immune responses differentially affect immune restoration disease associated with 
Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. The 
Journal of infectious diseases 202:1728-1737. 
27. Pepys, M.B., and Hirschfield, G.M. 2003. C-reactive protein: a critical update. J Clin 
Invest 111:1805-1812. 
28. Simmons, C.P., Thwaites, G.E., Quyen, N.T., Chau, T.T., Mai, P.P., Dung, N.T., 
Stepniewska, K., White, N.J., Hien, T.T., and Farrar, J. 2005. The clinical benefit of 
165
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
adjunctive dexamethasone in tuberculous meningitis is not associated with 
measurable attenuation of peripheral or local immune responses. J Immunol 175:579-
590. 
29. Donald, P.R., Schoeman, J.F., Beyers, N., Nel, E.D., Carlini, S.M., Olsen, K.D., and 
McCracken, G.H. 1995. Concentrations of interferon gamma, tumor necrosis factor 
alpha, and interleukin-1 beta in the cerebrospinal fluid of children treated for 
tuberculous meningitis. Clin Infect Dis 21:924-929. 
30. Mayanja-Kizza, H., Jones-Lopez, E., Okwera, A., Wallis, R.S., Ellner, J.J., Mugerwa, 
R.D., and Whalen, C.C. 2005. Immunoadjuvant prednisolone therapy for HIV-
associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 191:856-865. 
31. Hennigan, S., and Kavanaugh, A. 2008. Interleukin-6 inhibitors in the treatment of 
rheumatoid arthritis. Ther Clin Risk Manag 4:767-775. 
32. Blackmore, T.K., Manning, L., Taylor, W.J., and Wallis, R.S. 2008. Therapeutic use 
of infliximab in tuberculosis to control severe paradoxical reaction of the brain and 
lymph nodes. Clin Infect Dis 47:e83-85. 
 
 
 
 
166
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 8 
 
Conclusions 
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Paradoxical TB-IRIS has rapidly emerged in the last decade in South Africa, and many other 
sub-Saharan African countries, as a common medical condition as a result of the convergence 
of the epidemics of HIV and TB together with the massive scale up of ART for HIV-infected 
people. In South Africa, a major contributing factor is that many patients (up to 42% in some 
clinics (1)) start ART while on treatment for active TB. The clinical services in Cape Town, 
given the historically high rates of TB in the city together with the rapid and successful scale-
up of the public sector ART programme in the Western Cape, provided an ideal setting for 
the conduct of these studies that investigated paradoxical TB-IRIS. 
 
This thesis reports studies that investigated distinct clinical and immunological aspects of 
paradoxical TB-IRIS. In Chapter 3, the consensus case definitions for TB-IRIS developed at 
a meeting of the International Network for the Study of HIV-associated IRIS (INSHI) are 
presented. Chapter 4 reports a study on the clinical diagnosis and features of TB-IRIS, 
Chapter 5 reports on two studies which aimed to define the role of Th1 and regulatory T cells 
in pathogenesis, Chapter 6 reports the randomized clinical trial that assessed a 4-week course 
of prednisone for the treatment of TB-IRIS, and Chapter 7 examines the effect that 
prednisone has on mediators of the immune response in paradoxical TB-IRIS.  
 
The study reported in Chapter 4 involved screening consecutive patients referred or 
presenting to GF Jooste Hospital with suspected paradoxical TB-IRIS. These were patients 
who had recently started ART while on treatment for active TB and subsequently deteriorated 
with clinical features compatible with worsening TB. Standardised case definitions for 
paradoxical TB-IRIS were used when screening patients. The case definitions we developed 
formed the framework for the INSHI consensus case definitions presented in Chapter 3. 
During screening patients were investigated for alternative causes of clinical deterioration 
(these investigations were directed by the organ system affected) and TB culture and drug 
susceptibility testing was requested on clinical specimens (sputum and other body fluids). Of 
the 100 patients, 7 were found to have alternative opportunistic diseases, 4 were known to 
have rifampicin-resistant TB and a further 9 were found to have previously undiagnosed 
rifampicin resistance (7 of whom also had isoniazid resistance and thus had multi-drug 
resistant TB). Thus undiagnosed rifampicin-resistant TB was present in 10.1% of patients 
with suspected TB-IRIS once known rifampicin resistance and patients with alternative 
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diagnoses were excluded.  Importantly there were no clinical or radiological features (apart 
from more frequent lymphadenopathy on chest radiograph) that differentiated these patients 
from those who presented with TB-IRIS without rifampicin-resistant TB. Based on these 
observations we proposed that paradoxical TB-IRIS and drug-resistant TB are not mutually 
exclusive diagnoses and that in patients with undiagnosed drug-resistant TB-IRIS may occur 
and accelerate clinical deterioration. These findings have important implications for clinical 
practice in our setting: in all patients presenting with suspected TB-IRIS drug susceptibility 
testing should be performed. This should preferably be done using a rapid rifampicin 
resistance assay. The FASTplaque assay we used in our studies performed poorly on fresh 
specimens, however newer PCR-based rapid tests such as the Genotype MTBDRplus and 
GeneXpert assays have shown more promising results (2, 3). In terms of clinical features, 
important findings of this study were that new or expanding lymph nodes were the most 
frequent TB-IRIS manifestation (present in 44%) and 56% of patients had hepatomegaly, 
many with cholestatic liver function derangement, suggesting that TB-IRIS frequently 
involves the liver. 
 
The first substantial immunological study of paradoxical TB-IRIS was conducted by 
investigators in France, a longitudinal study of 19 patients with HIV-associated TB starting 
ART, 7 of whom developed TB-IRIS (4). They demonstrated expansions of PPD-specific 
IFNγ-producing T cells using ELISpot in TB-IRIS cases that were not seen in controls. Only 
low ESAT-6-specific expansions were seen in 3 TB-IRIS cases and no antigen 85B-specific 
expansions were observed. There were higher Th1 and non-specific inflammatory 
cytokine/chemokine concentrations in cases than controls after PPD stimulation. The authors 
concluded that Th1 T cell expansions were the cause of IRIS. However, association does not 
mean causation. Important limitations of their study were that comparisons between cases 
and controls were performed at 0, 3 and 6 months on ART whereas most IRIS cases occur 
within the first 4 weeks of ART, and the relatively small sample size. We thus set out to 
investigate antigen-specific T lymphocyte populations in a larger cohort that compared TB-
IRIS cases with controls at earlier time points. We also wished to assess the role of regulatory 
T cells in pathogenesis, the hypothesis being that deficiencies in regulatory T cell numbers 
may contribute to the development of TB-IRIS. In Chapter 5 two studies that investigated 
the immunopathogenesis of paradoxical TB-IRIS are described: one was a cross-sectional 
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study that included 35 TB-IRIS cases and two control groups and the other a longitudinal 
study over the first 8 weeks of ART in patients with HIV-associated TB. In the cross-
sectional study patients with TB-IRIS sampled after 2 weeks on ART were found to have 
higher median ELISpot responses to a broad range of mycobacterial antigens including 
ESAT-6 (in contrast to Bourgarit’s findings (4)) when compared to the two controls groups. 
However, the responses were heterogenous in both cases and controls: some cases showed no 
expansions and some controls (who did not develop TB-IRIS on ART) showed high levels of 
IFNγ-producing T cells in response to mycobacterial antigens. Thus, even though 
mycobacterial-specific T cells likely play a role in the development of TB-IRIS, we 
questioned whether they were truly causal as our data suggested they were neither a sufficient 
nor necessary factor in the development of the condition. This conclusion was reinforced by 
the findings of the longitudinal study in which dynamic expansions and contractions of 
mycobacterial-specific IFNγ-producing T cells were seen over the first 8 weeks of ART in 
both cases and controls with few significant differences between the groups. With respect to 
T regulatory cells, we found that TB-IRIS cases in fact had higher numbers than controls in 
flow cytometry experiments (although this difference was non-significant). Since the 
publication of these findings another study showed no association between T cell expansions 
and IRIS (5) and other studies have confirmed our finding that TB-IRIS is not associated with 
reduced numbers of T regulatory cells (6, 7). 
 
In Chapter 6 a randomized placebo-controlled trial of prednisone for the treatment of 
paradoxical TB-IRIS is reported. Prior to this clinical trial there were anecdotal reports in the 
literature of patients with paradoxical TB-IRIS experiencing symptomatic benefit from 
corticosteroid treatment (8). There was also an extensive body of literature on the use of 
corticosteroids as adjunctive treatment for TB as described in Chapter 2, but substantial 
clinical benefit has only been conclusively demonstrated for TB meningitis (9, 10). Studies 
had shown that adjunctive corticosteroids for TB in HIV-negative patients were generally 
safe (11), but there are concerns regarding the safety profile in HIV-infected patients (12-15). 
Thus there was equipoise to justify a clinical trial of corticosteroids in paradoxical TB-IRIS. 
However, the decision was taken during the trial design phase to exclude patients with 
immediately life-threatening TB-IRIS, mainly those with neurological manifestations, from 
the trial and these patients were treated within the clinical service with corticosteroids. We 
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reasoned that for patients with immediately life-threatening TB-IRIS there was sufficient 
indirect evidence (as described in Chapter 2) to support the potential benefit of 
corticosteroids, and that potential harms were likely to be outweighed by the benefits. The 
main hypothesis of the clinical trial was that prednisone would reduce morbidity related to 
paradoxical TB-IRIS without an excess of corticosteroid side effects or infections. Mortality 
was not chosen as the primary endpoint of the trial because mortality due to paradoxical TB-
IRIS is infrequent (as discussed in Chapter 2) and patients with immediately life-threatening 
disease, including all those with neurological TB-IRIS, were excluded from the trial. The 
predetermined primary endpoint chosen for the clinical trial was a composite endpoint of 
total number of days hospitalized plus outpatient therapeutic procedures (for example 
therapeutic aspirations of suppurative lymph nodes), which were counted as one additional 
day. This primary endpoint was chosen because it allowed quantification of morbidity across 
a range of TB-IRIS presentations. Given the heterogeneity of TB-IRIS it was difficult to 
identify another endpoint that would adequately capture morbidity across the spectrum of 
potential manifestations. 
 
110 participants were enrolled in the trial (55 in each arm). The primary endpoint was 
significantly more frequent in the placebo arm than the prednisone arm (median 3 hospital 
days (IQR = 0-9) versus 0 hospital days (IQR = 0-3) respectively, p = 0.04). Patients on 
prednisone experienced significantly more rapid improvement in symptoms, quality of life, 
performance status, and a chest radiology score. There was also rapid reduction in C-reactive 
protein concentration observed in those treated with prednisone: the median C-reactive 
protein concentration fell from 104 mg/l to 34 mg/l within one week in those on prednisone. 
It took 12 weeks for the C-reactive protein to decline to similar concentrations in those in the 
placebo arm. There was no significant excess of steroid metabolic side effects or severe 
infections (defined as invasive bacterial infections and new World Health Organisation stage 
4 conditions) in the prednisone arm. There were more mild infections in those who received 
prednisone, such as oral or vaginal candidiasis and uncomplicated herpes simplex. A 
subgroup of participants required a prolonged course of open-label prednisone to control 
symptoms for a median of 84 days (IQR = 60-126) (the study design allowed for crossover to 
open label prednisone in patients deteriorating despite study drug and those who relapsed 
after completing the 4-week course).  
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Corticosteroids thus provide clinical benefit in paradoxical TB-IRIS reducing morbidity and 
improving symptoms. An understanding of their mechanism of action could therefore 
contribute to our understanding of the pathogenesis of paradoxical TB-IRIS. This question 
was addressed in the study reported in Chapter 7. Prior to this study our group had 
demonstrated that TB-IRIS is associated with higher gene expression levels and serum 
concentrations of a broad range of cytokines and chemokines, but most consistently IL-6, 
TNFα and IFNγ (16). Many of the cytokines we observed to be elevated in TB-IRIS are 
predominantly of myeloid origin. In the study described in Chapter 7, we analysed samples 
taken from 31 prednisone-treated and 27 placebo-treated participants at weeks 0, 2 and 4 on 
the clinical trial. The experiments performed were: ELISpot using a range of mycobacterial 
antigens, RT-PCR for gene expression levels following stimulation with heat-killed 
Mycobacterium tuberculosis and multiplex for cytokine/chemokine concentrations in the 
corresponding tissue culture supernatants and in unstimulated serum. The most important 
finding was that prednisone, but not placebo, suppressed concentrations of IL-6, IL-10, 
IL12p40, TNFα, IFNγ and IP-10 in unstimulated serum. Prednisone did not significantly 
decrease numbers of IFNγ-producing T cells in ELISpot experiments, suggesting that the 
mechanism of action of prednisone in TB-IRIS is mediated through suppression of the pro-
inflammatory cytokine responses that we had shown characterized TB-IRIS in the earlier 
study (16).  
 
Impact of the studies on the field  
 
Until 2004, the literature on TB-IRIS comprised of case reports and case series as well as 
cohort studies which reported the incidence and risk factors for the condition. There were 
anecdotal reports of treatments used and response. Standard case definitions were not used 
across studies making comparison difficult. 
 
Our clinical trial reported in Chapter 6 was the first clinical trial to assess a treatment strategy 
in any form of IRIS and showed that there was clinical benefit from a 4-week course of 
corticosteroids without an excess risk of severe infections or metabolic side effects. These 
findings have influenced clinical guidelines and practice. An important caveat based on 
173
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
findings presented in Chapter 4 is that patients with undiagnosed rifampicin-resistant TB may 
present with paradoxical TB-IRIS indistinguishable from patients without rifampicin-
resistant TB. If corticosteroids are prescribed to patients with undiagnosed rifampicin-
resistant TB, who are not on optimal TB treatment, they may potentially do harm. Hence our 
recommendation is that drug susceptibility testing be performed on paradoxical TB-IRIS 
suspects wherever feasible. 
 
Our group made a major contribution to the development of consensus case definitions for 
TB-IRIS under the auspices of INSHI. I (Graeme Meintjes) was the head of the writing 
committee and first author on the publication of these case definitions presented in Chapter 3. 
The main rationale for these case definitions was to promote standardization and 
comparability of studies investigating TB-IRIS. Since publication, they have been widely 
implemented in clinical and immunological studies of TB-IRIS. Four publications have 
specifically validated the performance of these case definitions in different settings using 
either expert opinion or other case definitions as the com arator (17-20). 
 
Over the last 5 years several groups across the world have investigated the 
immunopathogenesis of TB-IRIS (reviewed in Chapter 2). Our immunology studies 
presented in Chapter 4 raised questions regarding the causal role of mycobacterial-specific 
IFNγ-producing T cells in the pathogenesis of TB-IRIS and others have cited this study as 
one of the reasons for the exploring the role of the innate immune system in pathogenesis 
(21). Our findings, together with those of others (6, 7), have shown that there is no deficiency 
of regulatory T cell numbers in TB-IRIS suggesting that if defects in regulatory components 
of the immune system do play a role it is rather functional. The study presented in Chapter 7 
is yet to be published. 
 
Research priorities in TB-IRIS 
 
Ongoing research in the field of paradoxical TB-IRIS includes studies of 
immunopathogenesis, predictive markers, diagnosis, prevention and treatment. 
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Much research is being undertaken to define biomarkers for TB-IRIS that could be used in 
prediction and diagnosis and also contribute to understanding pathogenesis (22). Candidate 
biomarkers include serum cytokine and chemokine concentrations and combinations or ratios 
of these, ELISpot assays, concentrations of other inflammatory proteins such as C-reactive 
protein and gene expression profiles using microarrays. Although these biomarkers may help 
in understanding the immunopathogenesis of TB-IRIS and may help in predicting those at 
risk, they are likely to be perform poorly as a diagnostic test because the specificity in 
differentiating paradoxical TB-IRIS from the important clinical differential diagnoses (most 
importantly bacterial infections, opportunistic diseases and drug resistant TB) is likely to be 
low. The reason for this is that most TB-IRIS clinical mimics are also characterized by 
inflammatory responses. In addition, even if diagnostic biomarkers were discovered they may 
be difficult to implement in resource limited settings for cost and feasibility reasons, but 
could potentially be used in research.  
 
It is thus likely that paradoxical TB-IRIS will remain a clinical diagnosis of exclusion and 
research regarding the most clinically and cost-effective diagnostic work-up algorithms of 
patients with suspected TB-IRIS is a priority. Such algorithms would vary according to the 
organ system involved. For example, the work-up of a patient with a pulmonary presentation 
will be different to that of a patient with meningitis. Clinical prediction rules for the diagnosis 
of paradoxical TB-IRIS taking into account baseline data prior to ART, presenting features 
and diagnostic tests done at the time of presentation with suspected paradoxical TB-IRIS 
would assist clinicians in busy operational settings provided they are kept simple and usable. 
Given that drug-resistant TB is the most important diagnosis to exclude in patients presenting 
with suspected paradoxical TB-IRIS in our setting (as described in Chapter 4), rapid 
diagnostic tests to ascertain drug susceptibility results would assist in appropriate 
management of these patients. The novel GeneXpert test has shown promising results in 
facilitating rapid initial diagnosis of rifampicin-resistant TB in fresh clinical specimens and 
the assay takes 2 hours to perform (3). Studies to assess its performance in patients presenting 
with suspected TB-IRIS in a range of clinical specimens, including sputum and pus from 
tuberculous abscesses, are required. 
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While clinical trials have demonstrated that delaying ART to prevent paradoxical TB-IRIS in 
patients with CD4 counts < 50 cells/mm3 is not appropriate because this results in a higher 
incidence of AIDS progression and mortality (23-25), delaying ART to two months may be 
appropriate in patients with CD4 counts > 50 cells/mm3. Other preventive strategies that need 
to be studied include the role of immunomodulatory agents. It has been hypothesized that 
vitamin D deficiency may predispose to paradoxical TB-IRIS and that Vitamin D 
supplementation in deficient patients may thereby prevent TB-IRIS (26). Further studies to 
confirm this underlying hypothesis are required before taking investigations of vitamin D 
supplementation further. Maraviroc, doxycycline and statins have also been shown to have 
immunomodulatory properties and may be candidates for study (27-30). Our clinical trial 
demonstrated that corticosteroids provide symptomatic benefit and reduce morbidity in the 
treatment of paradoxical TB-IRIS, and it may be that they could have a role in the prevention 
of TB-IRIS among high-risk patients. We have, however, documented cases of TB-IRIS 
occurring in patients with TB meningitis despite patients being on high dose corticosteroids 
when ART is started (31). But even if corticosteroids do not prevent TB-IRIS they may 
decrease its severity or delay its onset (32). The role of corticosteroids in the prevention of 
TB-IRIS needs to be tested in a clinical trial. The risk-benefit equation for their role in 
prevention may be different to that of treatment as this would involve treating far more 
patients with corticosteroids, many of whom would not develop TB-IRIS. 
 
While we showed that prednisone provides clinical benefit in TB-IRIS, research into more 
targeted approaches to treatment is needed. In Chapter 7 we showed that the effect of 
corticosteroids was mediated at least in part through reduction in the concentrations of pro-
inflammatory cytokines including TNFα and IL-6. We suggested that there may be a role for 
specific blockers of these cytokines (for example the TNFα blocker infliximab or the IL-6 
blocker tocilizumab) in the treatment for TB-IRIS. Given the cost of these agents and the 
potential for TNFα blockers to precipitate fungal, bacterial, non-tuberculous mycobacterial 
and viral infections (33-35) it is likely that their use would only be warranted in life 
threatening cases, such as severe neurological TB-IRIS. The prevention and treatment of 
neurological TB-IRIS is the major clinical research priority given that it is relatively common 
and is the most life threatening form of TB-IRIS (36, 37) as discussed in Chapter 2. 
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A central issue in the treatment of TB-IRIS is that most of treatments that have been used 
(including corticosteroids) or suggested (such as TNFα blockers) are immunosuppressive 
with the risk of causing other infections and Kaposi’s sarcoma (13-15). The exception is non-
steroidal anti-inflammatory drugs that, however, have their own potential toxicities. The 
discovery of immunomodulatory agents that are not immunosuppressive that could be used to 
prevent and treat TB-IRIS would overcome this problem. 
  
In certain patients paradoxical TB-IRIS has a prolonged course of several months and long 
duration of corticosteroids are required to control symptoms, as described in the clinical trial 
(Chapter 6). Predicting which patients are likely to have prolonged TB-IRIS and the optimal 
treatment for such patients, including duration of corticosteroids and the role of other 
treatment modalities, requires research. Prediction of prolonged TB-IRIS may be possible 
based on baseline markers such as C-reactive protein, the extent of TB-IRIS in terms of 
number of organs involved or organ sites of TB-IRIS.  
 
In terms of the immunopathogenesis of TB-IRIS, the role of cells of the innate immune 
system has been relatively underexplored in research to date. While preliminary studies have 
suggested a role for monocytes and macrophages and cytokines produced by these cells 
(outlined in Chapter 2) these need to be confirmed and further defined in larger prospective 
studies. Our group’s findings that high neutrophil counts in cerebrospinal fluid both predict 
and characterize TB meningitis IRIS (31), warrant further study to explore the role of 
neutrophils in pathogenesis particularly at sites of disease using tissue and body fluid 
specimens. 
 
Looking ahead 
 
Recent clinical trial data presented in Chapter 2 supports starting ART within 2 weeks of TB 
treatment in patients with HIV-associated TB and a CD4 count < 50 cells/mm3. This will 
impact on guidelines and clinician practice and will result in patients starting ART sooner 
after TB diagnosis where operationally feasible. In such patients with low CD4 counts 
starting ART 2 weeks after TB treatment the risk of TB-IRIS was increased 2-3 fold in these 
clinical trials (23-25). For this reason paradoxical TB-IRIS is likely to become more common 
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in the immediate future. However, if broader public health policies are successful in 
achieving wider uptake of HIV testing and thereby earlier diagnosis of HIV and earlier 
initiation of ART prior to advanced immunosuppression and prevention of TB disease 
through scale-up of isoniazid preventive therapy (IPT), improved infection control practices, 
intensified case finding and ART, it could be anticipated that in the longer term the incidence 
of paradoxical TB-IRIS may decline. Improved diagnostics for TB in HIV-infected people 
(3) that allow TB diagnosis prior to dissemination of TB may reduce the incidence of TB-
IRIS, as disseminated TB and extrapulmonary TB have shown to be risk factor for TB-IRIS 
presumably related to antigen burden (38-41). 
 
However, there are over 20 million people living with HIV globally who have not yet 
accessed ART. There is a global effort to make ART accessible to these people when it is 
required. Many of these people live in regions of the world where TB is both prevalent and 
the most common cause of morbidity and mortality among HIV-infected people. Despite 
public health efforts to promote earlier HIV diagnosis and prevention of TB many people in 
these regions will continue to access health care late in the course of their HIV disease when 
they have active TB, partly due to health system access issues. They will thus need treatment 
of TB followed by ART while on TB treatment putting them at risk of paradoxical TB-IRIS. 
It is therefore predicted that paradoxical TB-IRIS will remain an important cause of 
morbidity in ART treatment programmes for decades to come particularly in resource limited 
settings. While important in its lf, the study of paradoxical TB-IRIS also provides an 
important window into the immune pathways and effector mechanisms involved in 
immunopathological responses to TB and mycobacterial diseases in general. 
 
  
178
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
References 
1. Boulle, A., Van Cutsem, G., Hilderbrand, K., Cragg, C., Abrahams, M., Mathee, S., 
Ford, N., Knight, L., Osler, M., Myers, J., et al. 2010. Seven-year experience of a 
primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 
24:563-572. 
2. Barnard, M., Albert, H., Coetzee, G., O'Brien, R., and Bosman, M.E. 2008. Rapid 
molecular screening for multidrug-resistant tuberculosis in a high-volume public 
health laboratory in South Africa. American Journal of Respiratory and Critical Care 
Medicine 177:787-792. 
3. Boehme, C.C., Nabeta, P., Hillemann, D., Nicol, M.P., Shenai, S., Krapp, F., Allen, 
J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. 2010. Rapid molecular detection 
of tuberculosis and rifampin resistance. The New England Journal of Medicine 
363:1005-1015. 
4. Bourgarit, A., Carcelain, G., Martinez, V., Lascoux, C., Delcey, V., Gicquel, B., 
Vicaut, E., Lagrange, P.H., Sereni, D., and Autran, B. 2006. Explosion of tuberculin-
specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV 
co-infected patients. AIDS 20:F1-7. 
5. Tieu, H.V., Ananworanich, J., Avihingsanon, A., Apateerapong, W., Sirivichayakul, 
S., Siangphoe, U., Klongugkara, S., Boonchokchai, B., Hammer, S.M., and 
Manosuthi, W. 2009. Immunologic markers as predictors of tuberculosis-associated 
immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected 
persons in Thailand. AIDS Res Hum Retroviruses 25:1083-1089. 
6. Seddiki, N., Sasson, S.C., Santner-Nanan, B., Munier, M., van Bockel, D., Ip, S., 
Marriott, D., Pett, S., Nanan, R., Cooper, D.A., et al. 2009. Proliferation of weakly 
suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell 
responses in HIV-positive patients with mycobacterial immune restoration disease. 
Eur J Immunol 39:391-403. 
7. Tan, D.B., Yong, Y.K., Tan, H.Y., Kamarulzaman, A., Tan, L.H., Lim, A., James, I., 
French, M., and Price, P. 2008. Immunological profiles of immune restoration disease 
presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med 
9:307-316. 
179
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
8. Breen, R.A., Smith, C.J., Bettinson, H., Dart, S., Bannister, B., Johnson, M.A., and 
Lipman, M.C. 2004. Paradoxical reactions during tuberculosis treatment in patients 
with and without HIV co-infection. Thorax 59:704-707. 
9. Prasad, K., and Singh, M.B. 2008. Corticosteroids for managing tuberculous 
meningitis. Cochrane database of systematic reviews:CD002244. 
10. Thwaites, G.E., Nguyen, D.B., Nguyen, H.D., Hoang, T.Q., Do, T.T., Nguyen, T.C., 
Nguyen, Q.H., Nguyen, T.T., Nguyen, N.H., Nguyen, T.N., et al. 2004. 
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. 
The New England Journal of Medicine 351:1741-1751. 
11. Smego, R.A., and Ahmed, N. 2003. A systematic review of the adjunctive use of 
systemic corticosteroids for pulmonary tuberculosis. The International Journal of 
Tuberculosis and Lung Disease  7:208-213. 
12. Mayanja-Kizza, H., Jones-Lopez, E., Okwera, A., Wallis, R.S., Ellner, J.J., Mugerwa, 
R.D., and Whalen, C.C. 2005. Immunoadjuvant prednisolone therapy for HIV-
associated tuberculosis: a phase 2 clinical trial in Uganda. The Journal of Infectious 
Diseases 191:856-865. 
13. Elliott, A.M., Luzze, H., Quigley, M.A., Nakiyingi, J.S., Kyaligonza, S., Namujju, 
P.B., Ducar, C., Ellner, J.J., Whitworth, J.A., Mugerwa, R., et al. 2004. A 
randomized, double-blind, placebo-controlled trial of the use of prednisolone as an 
adjunct to treatment in HIV-1-associated pleural tuberculosis. The Journal of 
Infectious Diseases 190:869-878. 
14. Elliott, A.M., Halwiindi, B., Bagshawe, A., Hayes, R.J., Luo, N., Pobee, J.O., and 
McAdam, K.P. 1992. Use of prednisolone in the treatment of HIV-positive 
tuberculosis patients. The Quarterly Journal of Medicine 85:855-860. 
15. Volkow, P.F., Cornejo, P., Zinser, J.W., Ormsby, C.E., and Reyes-Teran, G. 2008. 
Life-threatening exacerbation of Kaposi's sarcoma after prednisone treatment for 
immune reconstitution inflammatory syndrome. AIDS 22:663-665. 
16. Tadokera, R., Meintjes, G., Skolimowska, K.H., Wilkinson, K.A., Matthews, K., 
Seldon, R., Chegou, N.N., Maartens, G., Rangaka, M.X., Rebe, K., et al. 2011. 
Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution 
inflammatory syndrome. The European Respiratory Journal 37:1248-1259. 
180
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
17. Eshun-Wilson, I., Havers, F., Nachega, J.B., Prozesky, H.W., Taljaard, J.J., Zeier, 
M.D., Cotton, M., Simon, G., and Soentjens, P. 2010. Evaluation of paradoxical TB-
associated IRIS with the use of standardized case definitions for resource-limited 
settings. Journal of the International Association of Physicians in AIDS Care 9:104-
108. 
18. Haddow, L.J., Moosa, M.Y., and Easterbrook, P.J. 2010. Validation of a published 
case definition for tuberculosis-associated immune reconstitution inflammatory 
syndrome. AIDS 24:103-108. 
19. Manosuthi, W., Van Tieu, H., Mankatitham, W., Lueangniyomkul, A., 
Ananworanich, J., Avihingsanon, A., Siangphoe, U., Klongugkara, S., Likanonsakul, 
S., Thawornwan, U., et al. 2009. Clinical case definition and manifestations of 
paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. 
AIDS 23:2467-2471. 
20. Sharma, S.K., Dhooria, S., Barwad, P., Kadhiravan, T., Ranjan, S., Miglani, S., and 
Gupta, D. 2010. A study of TB-associated immune reconstitution inflammatory 
syndrome using the consensus case-definition. The Indian Journal of Medical 
Research 131:804-808. 
21. Oliver, B.G., Elliott, J.H., Price, P., Phillips, M., Saphonn, V., Vun, M.C., Kaldor, 
J.M., Cooper, D.A., and French, M.A. 2010. Mediators of innate and adaptive 
immune responses differentially affect immune restoration disease associated with 
Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. The 
Journal of Infectious Diseases 202:1728-1737. 
22. Sereti, I., Rodger, A.J., and French, M.A. 2010. Biomarkers in immune reconstitution 
inflammatory syndrome: signals from pathogenesis. Current opinion in HIV and 
AIDS 5:504-510. 
23. Abdool Karim S, Naidoo K, Padayatchi N, Grobler A, Baxter C, Gengiah S, El-Sadr 
W, Friedland G, Abdool Karim Q. Optimal Timing of ART during TB Therapy: 
Findings of the SAPiT Trial. Abstract 39LB. In 18th Conference on Retroviruses and 
Opportunistic Infections. Boston, US. February 2011. 
24. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, 
Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin SI, Sun S, Guillard B, 
Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE. The CAMELIA 
181
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
trial: Cambodian Early vs Late Introduction of Antiretrovirals. Abstract THLBB106. 
In 18th International AIDS Society Conference, Vienna 2010. 
25. Havlir D, Ive P, Kendall M, Luetkemeyer A, Swindells S, Kumwenda J, Qasba S, 
Hogg E, Anderson J, Sanne I and A5221 Team. International Randomized Trial of 
Immediate vs Early ART in HIV+ Patients Treated for TB: ACTG 5221 STRIDE 
Study. Abstract 38. In 18th Conference on Retroviruses and Opportunistic Infections. 
Boston, US. February 2011. 
26. Conesa-Botella, A., Mathieu, C., Colebunders, R., Moreno-Reyes, R., van Etten, E., 
Lynen, L., and Kestens, L. 2009. Is vitamin D deficiency involved in the immune 
reconstitution inflammatory syndrome? AIDS Research and Therapy 6:4. 
27. Funderburg, N., Kalinowska, M., Eason, J., Goodrich, J., Heera, J., Mayer, H., 
Rajicic, N., Valdez, H., and Lederman, M.M. 2010. Effects of maraviroc and 
efavirenz on markers of immune activation and inflammation and associations with 
CD4+ cell rises in HIV-infected patients. PloS One 5:e13188. 
28. Turner, J.E., Steinmetz, O.M., Stahl, R.A., and Panzer, U. 2007. Targeting of Th1-
associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for 
inflammatory diseases. Mini Reviews in Medicinal Chemistry 7:1089-1096. 
29. Elkington, P.T., Ugarte-Gil, C.A., and Friedland, J.S. 2011. Matrix metalloproteinases 
in tuberculosis. The European Respiratory Journal 38:456-464. 
30. Sun, H.Y., and Singh, N. 2011. Potential role of statins for the management of 
immune reconstitution syndrome. Medical Hypotheses 76:307-310. 
31. Marais S, Meintjes G, Pepper D, Schutz C, Ismail Z, Wilkinson K, Wilkinson R. 
Findings in Patients with Tuberculous Meningitis IRIS. 18th Conference on 
Retroviruses and Opportunistic Infections. Abstract 856. Boston, 2011. 
32. Luzzati, R., Cavinato, S., and Giacomazzi, D. 2010. Do corticosteroids prevent the 
paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome? 
The International Journal of Tuberculosis and Lung Disease 14:930. 
33. Crum, N.F., Lederman, E.R., and Wallace, M.R. 2005. Infections associated with 
tumor necrosis factor-alpha antagonists. Medicine 84:291-302. 
34. Wallis, R.S. 2009. Infectious complications of tumor necrosis factor blockade. 
Current opinion in Infectious Diseases 22:403-409. 
182
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
35. Kim, S.Y., and Solomon, D.H. 2010. Tumor necrosis factor blockade and the risk of 
viral infection. Nature Reviews. Rheumatology 6:165-174. 
36. Pepper, D.J., Marais, S., Maartens, G., Rebe, K., Morroni, C., Rangaka, M.X., Oni, 
T., Wilkinson, R.J., and Meintjes, G. 2009. Neurologic manifestations of paradoxical 
tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. 
Clin Infect Dis 48:e96-107. 
37. Asselman, V., Thienemann, F., Pepper, D.J., Boulle, A., Wilkinson, R.J., Meintjes, 
G., and Marais, S. 2010. Central nervous system disorders after starting antiretroviral 
therapy in South Africa. AIDS 24:2871-2876. 
38. Breton, G., Duval, X., Estellat, C., Poaletti, X., Bonnet, D., Mvondo Mvondo, D., 
Longuet, P., Leport, C., and Vilde, J.L. 2004. Determinants of immune reconstitution 
inflammatory syndrome in HIV type 1-infected patients with tuberculosis after 
initiation of antiretroviral therapy. Clin Infect Dis 39:1709-1712. 
39. Burman, W., Weis, S., Vernon, A., Khan, A., Benator, D., Jones, B., Silva, C., King, 
B., LaHart, C., Mangura, B., et al. 2007. Frequency, severity and duration of immune 
reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 11:1282-
1289. 
40. Manosuthi, W., Kiertiburanakul, S., Phoorisri, T., and Sungkanuparph, S. 2006. 
Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected 
patients receiving antituberculous and antiretroviral therapy. J Infect 53:357-363. 
41. Michailidis, C., Pozniak, A.L., Mandalia, S., Basnayake, S., Nelson, M.R., and 
Gazzard, B.G. 2005. Clinical characteristics of IRIS syndrome in patients with HIV 
and tuberculosis. Antivir Ther 10:417-422. 
 
 
183
